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DNA damage by reactive oxygen species (ROS) is a cause of many chronic diseases. 
This work examines the ability of sulfur and selenium antioxidants to prevent oxidative 
DNA damage and the mechanisms for this activity.  Although iron- and copper-generated 
hydroxyl radical are primary causes of damage under oxidative stress conditions, studies 
typically focus on ROS scavenging rather than antioxidant-metal binding as a mechanism 
for sulfur and selenium antioxidant behavior.  
Mass spectrometry studies of sulfur and selenoamino acids (Chapter 2) show that 
most form CuI and FeII complexes, regardless of their metal-mediated DNA damage 
prevention abilities. Because their electrochemical properties do not correlate to 
antioxidant activity, metal binding rather than ROS scavenging is the major mechanism 
for these sulfur and selenium antioxidants.  
DNA damage assays with N,N’-dimethylimazole thione (dmit) and selone (dmise) 
determined that both prevent CuI-mediated DNA damage (IC50 = 1550 and ~240 µM, 
respectively; Chapter 3). Surprisingly, dmit and dmise more effectively inhibit FeII-
mediated DNA damage (IC50 = 89.1 and 3.2 µM, respectively), an ability not previously 
observed for this class of antioxidants. Dmise and dmit coordinate CuI and FeII and 
prevent DNA damage by peroxynitrite (IC50 = 171.4 and 155.2, respectively). Studies 
with similar thiones, selones, and their derivatives (Chapter 4) showed that these 
compounds are also multifunctional antioxidants, preventing DNA damage by CuI (IC50 
= 22-1023 µM), FeII (IC50 = 2.3-1000 µM) and peroxynitrite (IC50 = 57.4-594 µM). Many 
ii 
of these compounds readily undergo oxidation and reduction, and mass spectrometry 
studies show CuI or FeII coordination, regardless of antioxidant activity. These are the 
first sulfur and selenium compounds with multifunctional antioxidant activity, and the 
structure-activity relationships established in this work will allow development of more 
potent antioxidants for disease treatment and prevention. 
Studies in Chapter 5 focus on how metal binding alters drug properties. 
Clotrimazole-metal complexes kill cancer cells, yet their cytotoxic mechanisms are not 
understood. Similarly, studies have not examined the effects of metal coordination on the 
biological properties of pseudoephedrine-derived compounds.  DNA damage studies with 
copper complexes of both compounds found that they significantly damage DNA (EC50 = 
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SULFUR AND SELENIUM ANTIOXIDANTS: CHALLENGING RADICAL 
SCAVENGING MECHANISMS AND DEVELOPING STRUCTURE-ACTIVITY 
RELATIONSHIPS BASED ON METAL BINDING 
 
1.1. Introduction 
Reactive oxygen species (ROS) such as superoxide (O2•-), hydrogen peroxide 
(H2O2), hydroxyl radical (•OH), peroxynitrite (ONOO-), and singlet oxygen (1O2) are 
natural byproducts of cellular respiration that can cause cellular oxidative damage but 
also serve as cell signaling agents.1-3 Hydroxyl radical is the most damaging ROS,4-7 
although peroxynitrite also directly damages lipids, proteins, and DNA. In contrast, H2O2 
and superoxide are only indirect contributors to oxidative DNA damage.3,8-11 This DNA 
damage is linked to development of cancer, inflammation, neurodegenerative diseases, 
and cardiovascular diseases.12-16   
Cellular generation of •OH typically occurs by iron- or copper-mediated hydrogen 
peroxide (H2O2) reduction (Reactions 1 and 2, respectively). In fact, metal-mediated •OH 
generation is the major cause of DNA damage and cell death in E. coli and human 
cells.17-19  
FeII + H2O2 → FeIII + -OH + •OH (1) 
CuI + H2O2 → CuII + -OH + •OH (2) 
Hydroxyl radical generation is catalytic in the presence of cellular reductants such as 
ascorbic acid or nicotinamide adenine dinucleotide (NADH) that can reduce the oxidized 
metal ions back to their •OH-generating reduced states.20,21 Cells typically control labile 
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(non-protein-bound) metal ions, but under conditions of oxidative stress, mis-regulation 
of iron and copper can lead to a significant increase in labile metal ion concentrations and 
•OH generation.22-24 Labile (non-protein-bound) iron levels are typically 1-30 μM in 
human cells, with concentrations up to 210 μM in the mitochondria.25-27 Similarly, 
reports show labile copper pools in mouse mitochondria and human brain tissue from 1 to 
~1300 µM.28,29 Sulfur and selenium antioxidants may promote cellular survival by 
scavenging radicals;30-32 however, due to hydroxyl radical’s short half-life (~1 ns),33,34 
scavenging of this radical is unlikely.  In contrast to focusing exclusively on the 
damaging radical species (a process that can be compared to trying to catch bullets after 
they are fired from a gun), we have instead focused on exploring the ability of sulfur and 
selenium antioxidants to bind iron and copper and prevent radical formation or release (a 
process analogous to removing the gun). Our studies over the past decade have proven 
that metal coordination is the primary mechanism by which sulfur and selenium 
antioxidants prevent DNA damage.18,35-37  
Numerous studies have demonstrated the beneficial health effects of sulfur and 
selenium compounds:38,39 garlic extracts protect against the toxic effects of arsenic,40 
selenomethionine (Figure 1.1) has been used to treat sepsis,41 and selenium 
supplementation can reduce oxidative damage in pulmonary tuberculosis patients.42 In 
the past ten years, interest in selenium-containing antioxidants has significantly increased 
due to studies focused on the disease prevention and chemopreventative activity of 
selenium supplementation.43-46 However, the Nutritional Prevention of Cancer (NPC) 
clinical trial and the Selenium and Vitamin E Cancer Prevention Trial (SELECT), 
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reported conflicting cancer-preventative abilities for selenium supplementation. In both 
double-blind trials, patients were given selenium supplements (200 µg/day).  The 8-year 
NPC trial reported a 37 % decrease in cancer incidence, a total that included a 63 % 
reduction in prostate cancer.47 In contrast, the SELECT trial determined that selenium 
supplementation did not consistently prevent prostate cancer, and this trial was canceled 
in 2008, the fifth year of the study.18,48-50  
In 2009, El-Bayoumy discussed the difference in the selenium supplement 
between these trials as the possible source of discrepancy in these trial results.51 
Selenium-enriched yeast, the selenium supplement in the NPC trial, is comprised of 54-
62 % selenomethionine, < 1 % selenite, and 36-46 % unidentified selenium species,50 
whereas the SELECT study used only selenomethionine. In a separate report, El-
Bayoumy and Sinha reported that methyl-selenocysteine (Figure 1.1), another selenium 
species in selenium-enriched yeast is a more effective anticancer agent than 
selenomethionine,52 and Menter et al. observed that selenomethionine inhibits growth of 
malignant prostate cells only at extremely high levels.53  As these conflicting results 
demonstrate, a comprehensive understanding of sulfur and selenium antioxidant activity 
at the mechanistic level is critical for the success of future animal and clinical trials for 
disease prevention. 
In addition to their ROS scavenging abilities, small-molecule selenium 
compounds are also extensively investigated as mimics of the selenoenzyme glutathione 
peroxidase.54 However, many of these in vitro studies are not reliably reproducible, are 
typically conducted using non-physiological conditions, such as in organic solvents or 
3 
acidic solution, and most have not led to significant promising results in cellular and 
animal trials.18,55-59   In a recent notable exception, selenium-containing glutathione 
peroxidase mimics improved glucose-stimulated insulin secretion in GPX1 knockout 
mice.60 
Figure 1.1. Selected sulfur and selenium compounds studied for their antioxidant activities. 
Interest in thione (C=S) and selone (C=Se) antioxidants can be attributed to 
naturally occurring ergothioneine and selenoneine (Figure 1.1). Ergothioneine has been 
studied for its anti-inflammation effects, oxidative DNA damage prevention, and the 
scavenging of peroxynitrite and hydrogen peroxide.61-66 Ergothioneine concentration in 
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human blood serum from 0.4-308 µM,68 and intracellular ergothioneine levels are 
reported to be 2 to 9 times higher than plasma levels in the same patient.69 Akanmu et al. 
reported that ergothioneine addition (1000 µM) resulted in 100 % inhibition of CuI-
mediated deoxyribose degradation.61 Similarly, Zhu et. al  reported that ergothioneine 
inhibits CuI-mediated DNA damage between 100-1000 µM, with complete damage 
prevention by 1000 µM.66  
Selenoneine was recently discovered in the blood of bluefin tuna (0.46 µM),70 and 
effectively scavenges 1-diphenyl-2-picrylhydrazyl (DPPH) radical.70,71 A recent study 
measured selenoneine blood concentrations up to 9 nM in a Japanese population with 
high bluefin tuna consumption.72  
Traditionally, ROS scavenging is investigated as the primary mechanism for 
sulfur and selenium antioxidant activity; however, due to our work and others’,3,58,73,74 
metal coordination has recently started to gain consideration as an independent 
antioxidant mechanism. This review discusses our investigations into the mechanisms by 
which various sulfur and selenium compounds prevent metal-mediated DNA damage and 
how copper and iron coordination contributes to this activity. Figure 1.2 compares the 
traditional ROS scavenging antioxidant mechanisms (top) with two potential metal-
binding mechanisms for DNA damage prevention (bottom). Metal binding to sulfur and 
selenium antioxidants could either prevent copper and iron redox cycling and hydroxyl 
radical generation (redox control mechanism) or allow targeted scavenging of hydrogen 
peroxide or hydroxyl radical by the metal-bound antioxidant, preventing oxidative 
damage (targeted scavenging mechanism). Because no stability constants have been  
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Figure 1.2. Proposed mechanisms for sulfur and selenium DNA damage prevention. A) Currently accepted 
reactive oxygen species (ROS) scavenging mechanisms involve no metal ions. B) Metal-binding 
mechanisms include sulfur or selenium binding to shift redox potentials of the metal ion outside of the 
biological window for hydroxyl radical formation (redox control), and/or  metal-bound sulfur or selenium 
antioxidants preferentially reacting with hydrogen peroxide to prevent metal oxidation and hydroxyl radical 
formation (targeted scavenging). 
measured for sulfur or selenium antioxidant binding to CuI or FeII, it is unknown whether 
the metal ion can remain on the DNA after binding and oxidation.  Oxidation studies with 
N,N’-dimethylimidazole thione (dmit) and selone (dmise) indicate that these oxidized 
sulfur and selenium species do not remain bound to the metal (see section 1.6), but 
similar studies have not been conducted with other sulfur and selenium species to 
determine metal binding after oxidation. From this improved mechanistic understanding 
we have determined the chemical properties necessary for DNA damage prevention and 
developed predictive models for sulfur and selenium antioxidant activity based on metal 
binding. 
 The work presented in this chapter was conducted in collaboration with Professor 
Craig Bayse (Old Dominion University), who provided the DFT calculation results, and 
Professor Ria Ramoutar (Georgia Southern University), who conducted experiments with 
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the oxosulfur and oxoselenium compounds and obtained mass spectrometry data with the 
sulfur-containing amino acids. 
 
1.2. Sulfur and Selenium Compounds Prevent Metal-Mediated DNA Damage 
1.2.1 Quantifying DNA damage prevention by selenium antioxidants. The sulfur 
and selenium compounds selected for investigation were chosen due to their presence in 
biological systems (such as methionine, selenocystine, or glutathione), or because of their 
similarity to biologically relevant compounds (N,N’-dimethylimidazole thione (dmit) is 
an analog of ergothioneine). Guttormsen et al.75 reported human plasma levels of cysteine 
and methionine around 256 µM and 23 µM, respectively, and cellular levels of these two 
amino acids are reported in the 100-200 µM range in skeletal muscle.76  The intracellular 
concentration of glutathione is much higher, between 10,000-15,000 µM,11,77 due to its 
critical role as a cellular antioxidant. Methimazole, a thione structurally similar to dmit 
but without one methyl group, is the primary drug used to treat hyperthyroidism in the 
United States.  Blood concentrations of methimizole are reported to be in the range of 4-
13 µM in hyperthyroid patients.78,79 
Biological selenium concentrations are significantly lower than for analogous 
sulfur compounds.  In the United States, human plasma Se concentrations average 1.5-1.6 
µM, with more than 90% of this selenium present in selenoproteins or as non-specifically 
protein-incorporated selenomethionine, leaving less than 0.16 µM of non-protein-bound 
selenium.80 Long-term human supplementation with selenomethionine or selenium-
enriched yeast (up to 600 µg) raises plasma concentrations by 26% after 16 weeks, with 
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most of the selenium present as protein-incorporated selenomethionine.80 Although 
selenium toxicity levels are currently debated, Reid et al. reported no toxic symptoms in 
prostate cancer patients supplemented with high doses of selenium-enriched yeast (1600 
µg for 12 months), resulting in a selenium plasma concentration of ~10  µM.81 Although 
many selenium supplementation studies use oral supplements of selenium-enriched yeast, 
selenomethionine, or inorganic selenite and selenate, treatment of acute oxidative stress 
using intravenously administered high-dose selenium also may reduce mortality in 
critically ill patients.82  Human studies with selone compounds as the selenium source 
have not been conducted.   
Most studies of sulfur and selenium antioxidant behavior focus on ROS 
scavenging, with little, if any, mention of metal coordination.83 Many of these studies are 
not performed under expected biological conditions, including acidic or basic pH, the use 
of organic solvents such as dimethyl sulfoxide, or with oversimplified assumptions about 
the complex biological reactions that produce damaging ROS.30,57,58,84  In contrast, our 
studies examine sulfur and selenium antioxidant behavior using copper- or iron-generated 
•OH radical to damage DNA, the primary mechanism for DNA oxidation and cell death 
under oxidative stress conditions.85-89   
 Studies with the selenium compounds in Figure 1.1 were performed to determine 
their ability to prevent CuI-mediated oxidative damage (single-strand nicking) to plasmid 
DNA (in MOPS buffer at pH 7 with 130 mM NaCl); all Fenton and Fenton-like reactions 
were quenched with ethylenediaminetetraacetic acid (EDTA) after 30 min. In the 
example DNA damage gel shown in Figure 1.3A, it is clear that H2O2 alone (50 µM, lane  
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Figure 1.3. A) Gel electrophoresis image of CuI-mediated oxidative DNA damage prevention by 
selenomethionine (SeMet). Lane MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + 
H2O2 (50 µM); lane 3: p + SeMet + H2O2; lane 4: p + ascorbate (7.5 µM) + CuSO4 (6 µM) + H2O2 (50 
µM); lanes 5-9: p + CuSO4 + ascorbate + increasing concentrations of SeMet: 0.1, 1, 10, 100, and 1000 
µM, respectively. B) The best-fit dose-response curve for prevention of CuI-mediated oxidative DNA 
damage by selenomethionine. 
2) or with selenomethionine (lane 3) does not damage DNA. However, combining CuI (6 
µM/7.5 µM ascorbic acid) and H2O2 generates •OH and results in 98 % DNA damage 
(lane 4). Addition of selenomethionine in increasing concentrations decreases DNA 
damage (lanes 5-9), with 100 % DNA damage inhibition at 1000 µM. Quantification of 
band intensities, plotting the log of selenomethionine concentration versus percent DNA 
damage inhibition, and fitting the resultant sigmoidal dose-response curve allows 
calculation of an IC50 value, the antioxidant concentration necessary to inhibit 50 % of 
DNA damage (Figure 1.3B).36 Since 6 µM CuI was used in these studies, coordination is 
expected to occur between 6-24 µM (1:1 to 1:4 metal-to-ligand molar ratio), and 
selenomethionine exhibits an IC50 value slightly higher than a 1:4 molar ratio (25.10 ± 
0.01 µM). Of the nine selenium compounds examined, seven prevented copper-mediated 
damage (IC50 values in Table 1.1). Selenocystamine promoted DNA damage from 1-500  
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Table 1.1. DNA damage inhibition by sulfur and selenium antioxidants with H2O2 (50 µM) and CuI (6 µM) 
or FeII (2 µM) compared to mass spectrometry results showing coordination ratios of the compounds (1 
equiv = 75 µM in 1:3 methanol:water solution). 
 aIC50 value is the concentration required to inhibit 50% of DNA damage; bMALDI mass spectrometry 
samples prepared in water with 1 equiv = 300 µM. cCoordination observed in both MADLI and ESI. 
dCoordination with H2O: [FeII(dmise)3(H2O)]2+ and [FeII(dmise)5(H2O)]2+. 
 
µM, but even this compound was an antioxidant at 1000 µM, preventing 59 % DNA 
damage.18,36  
 Similar DNA damage studies were conducted with these selenium compounds to 
determine their ability to prevent iron-mediated oxidative DNA damage (in MES buffer 
at pH 6 to prevent iron precipitation). Of the nine tested, selenocystamine and methyl-
selenocysteine were the only two amino acid compounds to inhibit FeII-mediated DNA 
damage (Table 1.1).18  This striking difference between prevention of copper- and iron-
mediated DNA damage emphasizes the importance of metal interactions for selenium 




FeII IC50 (µM)a FeII:Se/S 
Ligand 
Ref. 
Selenocystine 3.34 ± 0.08 1:1, 1:2 No activity 1:1, 1:2, 1:3 18, 36 
Selenomethionine 25.10 ± 0.01 1:1, 1:2, 1:3 No activity 1:2, 1:3 18, 36 
Methyl-selenocysteine 8.64 ± 0.02 1:1, 1:2, 1:3 378.4 ± 0.1 1:1, 1:2, 1:3 18, 36 
Selenocystamine 59 ± 3% 
(1000 µM) 
None 121.4 ± 0.3 1:3 18, 36 
2-Aminophenyl diselenide No activity None No activity 1:1 18 
2-Carboxyphenyl 
diselenide 
No activity 1:1 No activity 1:1 18 
Sodium selenite 1479 ± 2 None 84.5 ± 0.2 None 90 
Selenium dioxide 3802 ± 5 None 859 ± 2 1:1, 1:2 90 
N,N’-Dimethylimidazoleb 
selone (dmise)  
~240 1:1 3.2 ± 0.9 1:3, 1:5d 97 
Sulfur Compound      
Cystine 3.34 ± 0.07 1:1 No activity 1:1 37 
Methionine 11.02 ± 0.02 1:1 No activity None 37 
Methyl-cysteine 10.02 ± 0.02 1:1 No activity 1:1, 1:2 37 
Cystamine No activity None No activity None 37 
2-Aminophenyl disulfide No activity None No activity None 37 
2,2’-Dithiosalicylic acid No activity None No activity 1:1 37 
Methionine sulfoxide 18 ± 1 1:1 No activity 1:1 35 
Methylcysteine sulfoxide 8.1 ± 0.5 1:1, 1:2 DNA damage 1:1, 1:2 35 
Reduced glutathione 12.98 ± 0.01 1:2 23 ± 8% (10,000 μM) 1:1 37 
Oxidized glutathione 6.82 ± 0.03 1:1, 1:2 10,372 ± 2 1:1 37 
N,N’-Dimethylimidazoleb  
thione (dmit)  
1550 ± 3 1:2c 89.1 ± 0.2 1:3, 1:4c 97 
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antioxidant activity. 
 Sodium selenite (SeO3-) and sodium selenate (SeO42-) are inorganic selenium 
compounds used as selenium supplements in multivitamins, animal feed, and infant 
formula, and have been extensively examined for their antioxidant and anticancer 
properties.74,90,91  In a small clinical study, Mantovani et al. observed that selenium 
dioxide treatment inhibits progression of stage IV cancer tumors in the head, neck, lung, 
prostate, and biliary tract.92 Davis et al. reported that selenite or selenate supplementation 
significantly reduces formation of the 3,2’-dimethyl-4-aminobiphenyl-DNA adduct (a 
mimic for various mutagens in cooked fish and meat) in rats.93  Additionally, Ip and 
Hayes94 found that selenite is more active than selenomethionine in reducing 
dimethylbenz[a]anthracene-induced tumors in rats.  In cellular studies, Spyrou et al.95 
determined that both selenate and selenite inhibit human lymphocyte growth, and that 
selenite-induced effects are reversible if selenate is removed.   
In our studies, sodium selenite treatment prevented 50 % of the copper-mediated 
DNA damage inhibition at 1479 µM, and selenium dioxide had a much higher IC50 value 
of 3802 µM.96 Sodium selenite was significantly better at inhibiting FeII-mediated DNA 
damage (IC50 = 84.5 µM), whereas selenium dioxide showed prooxidant activity at lower 
concentrations (0.5-50 µM), but had an overall IC50 value of 859 µM.96 As was observed 
for the organoselenium compounds, selenium speciation, rather than just the presence of 
the element itself is critical to DNA damage prevention.  
In contrast to other selenium antioxidants tested, the selone compound dmise does 
not show a simple sigmoidal dose-response curve. Instead, initial dmise DNA damage 
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prevention increases between 1-10 µM before leveling off around 45 % and then 
increasing to 100 % between 300 and 3000 µM.97  Thus, dmise effectively prevents CuI-
mediated oxidative DNA damage, with an IC50 value around 240 µM (Table 1.1) but an 
IC40 of approximately 7.5 µM. Since CuI coordination should occur within the range of 6-
24 µM, this initial increase in activity is likely due to copper binding. The second 
increase in activity is well above the expected dmise-CuI coordination range, and is likely 
due to ROS scavenging.  
Surprisingly, dmise also prevented significantly more FeII-mediated DNA damage 
(IC50 = 3.2 µM; Table 1.1) than CuI-mediated DNA damage,97 the first selenium 
compound to show such activity.18,35-37,96  Notably, this activity with FeII occurs within 
the possible metal coordination window of 1:1 to 1:6 molar ratio (2 to 12 µM), since 2 
µM FeII was used in these studies, a value at the low end of labile iron in human cells.25-27  
Although human selenium concentrations are in the low micromolar range even 
upon high-dose supplementation (0.1-10 µM), selenocystine, methyl-selenocystine, and 
dmise prevent significant copper-mediated DNA damage within these concentrations. 
Notably, selenomethioneine, a major component of selenium-enriched yeast and an often-
used selenium supplement, shows very little activity within this range. Of all the tested 
selenium compounds, only dmise prevents significant iron-mediated DNA damage at 
biological selenium concentrations. These results not only demonstrate the 
multifunctional antioxidant potential of selone compounds, but also illustrate the 
dramatic effects different selenium-containing functional groups have on antioxidant 
activity.  
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1.2.3 Quantifying DNA damage prevention by sulfur antioxidants. To compare 
sulfur and selenium antioxidant prevention of DNA damage, we also conducted CuI DNA 
damage assays with sulfur analogs of the selenium antioxidants in Figure 1.1.  Cystine, 
methionine, and methyl-cysteine exhibited activity similar to their selenium-containing 
counterparts, with IC50 values from 3.3 to 11 µM (Table 1.1). In contrast, cystamine 
exhibited no ability to inhibit CuI-mediated DNA damage. Both of the oxo-sulfur 
compounds, methionine sulfoxide and methyl-cysteine sulfoxide prevented CuI-mediated 
DNA damage with similar IC50 values compared to their non-oxidized amino acid 
analogs.35,37 Additionally, the endogenous cellular antioxidant glutathione, in both 
oxidized and reduced forms, effectively inhibited CuI-mediated oxidative DNA damage 
well within its biological concentration range (1-15 mM).11,37,98 The thione-containing 
dmit (Figure 1.1) also inhibited CuI-mediated oxidative DNA damage, although at 
substantially higher concentrations than its selone analog, dmise, and outside of the 
concentration window for potential metal coordination.97  
  As with the selenium compounds, FeII-mediated DNA damage prevention by 
sulfur antioxidants (Figure 1.1), revealed completely different results from the CuI 
studies. Seven of the eleven sulfur compounds tested inhibited no FeII-mediated DNA 
damage. In fact, methyl-cysteine sulfoxide promoted a small amount (17 ± 3 %) of FeII-
mediated DNA damage at high concentrations (1000 µM).35  Both oxidized and reduced 
glutathione prevented approximately 50 % and 23 % FeII-mediated DNA damage, 
respectively, at 10,000 μM,37 the only sulfur-amino-acid compounds to inhibit both CuI- 
and FeII-mediated oxidative DNA damage. Dmit showed substantially stronger inhibition 
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of FeII-mediated DNA damage than CuI-mediated DNA damage, with an IC50 value of 
89.1 µM.97 Except for dmit, DNA damage prevention effects for these sulfur-containing 
antioxidants are well within the biological concentrations measured for these or similar 
compounds.  The diverse abilities of these sulfur compounds to inhibit DNA damage by 
CuI and FeII illustrate that the metal ion generating •OH, as well as the chemical 
environment of the sulfur, can radically alter antioxidant behavior.  
The antioxidant activity of sulfur and selenium amino acids and related 
compounds are primarily examined using ROS scavenging investigations.99,100  Kim et 
al.57 determined that S-allyl-L-cysteine sulfoxide and S-allyl-L-cysteine were the only 
two compounds capable of scavenging •OH in vitro and preventing neuronal cells from 
ischemic damage. Similarly, Yildiz and Demiryurek30 used chemiluminescence studies to 
determine that methionine scavenges •OH. Ergothioneine (Figure 1.1) scavenges harmful 
ROS such as ONOO- and •OH, and may act as a possible trigger for immune system 
responses.63,65,66 Ergothioneine also inhibits CuI-mediated deoxyribose degradation at 
high concentrations (1 mM).61  
Our studies established that, with the exception of selones and thiones, sulfur- and 
selenium-containing amino acid compounds showed strong inhibition of CuI-mediated 
DNA damage, yet were generally ineffective at preventing FeII-mediated DNA damage. 
Clearly, the presence of a sulfur or selenium atom alone is not sufficient for antioxidant 
activity.  If ROS scavenging were the major antioxidant mechanism, then similar DNA 
damage inhibition would be expected for both FeII and CuI studies. Because this was 
decidedly not the case, and because the tested sulfur and selenium antioxidants exhibited 
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activity close to expected coordination ratios for copper and iron, our DNA damage 
prevention results strongly supported metal coordination as a significant antioxidant 
mechanism.   
 
1.3. Establishing metal coordination as a primary mechanism for sulfur and 
selenium antioxidant activity 
 Current research into metal binding for the sulfur and selenium complexes in 
Figure 1.1 is limited, with the majority of publications focused on structural 
determination rather than potential biological activity. McAuliffe et al.101 and Sze et al.102 
investigated metal-methionine complexes with CrIII, MnII, FeIII, CoII, NiII, CuII, ZnII, AgI, 
CdII, HgII, and RhIII. Similarly, complexes of cysteinate and methyl-cysteinate have been 
synthesized and characterized for CdII, PbII, HgII, and ZnII,102,103 and methyl-cysteine 
complexes with MnII, CoII, NiII, CuII, ZnII, CdII, HgII, PdII, and PtII have also been 
reported.103,104  
 Due to the incorporation of selenium into metalloenzymes, such as 
selenocysteine-molybdenum coordination in formate dehydrogenase H and 
selenocysteine-nickel coordination in [NiFeSe] hydrogenase,105,106 seleno-amino acid-
metal complexes also have been examined.58 Zainal et al.107 characterized (SeMet)2Cu 
and (SeMet)2Zn complexes using IR and Raman spectroscopic studies and determined 
that selenomethionine binds to CuII and ZnII through the nitrogen and oxygen atoms of 
the amine and carboxylic acid groups, and that the selenium does not participate in metal 
coordination.  
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 To prove our observed DNA damage prevention was a result of metal 
coordination, DNA damage assays (similar conditions as in Section 1.2) were performed 
using 50 µM [Cu(bipy)2]+ (bipy = 2,2’-bipyridine) or 400 µM [Fe(EDTA)]2- (EDTA = 
ethylenediaminetetraacetic acid) in place of unchelated CuI or FeII. Both [Cu(bipy)2]+ and 
[Fe(EDTA)]2- react with H2O2 to yield •OH, but fully chelate CuI  and FeII to inhibit 
subsequent sulfur or selenium antioxidant binding. UV-vis spectroscopy and mass 
spectrometry studies were also conducted to determine whether metal complexes of the 
sulfur and selenium antioxidants could form in aqueous solutions at pH 6-7.  
 With [Cu(bipy)2]+ as the CuI source, no DNA damage prevention was observed 
for the sulfur and selenium-containing amino acids and related compounds in Figure 
1.1,18,37 proving that copper-antioxidant interactions are critical to DNA damage 
prevention. Methionine sulfoxide and methylcysteine sulfoxide prevented DNA damage 
only at concentrations 20 times higher than required for inhibition of CuI-mediated DNA 
damage: 43 ± 3 % and 88 ± 4 % inhibition at 1000 µM, respectively.35 Similarly, dmise 
and dmit prevent DNA damage caused by [Cu(bipy)2]+ and H2O2 at much higher 
concentrations than CuI alone.97  
Gel electrophoresis studies were also conducted with [Fe(EDTA)]2- in place of 
FeII to determine whether iron binding is required for the observed antioxidant behavior. 
Since the binding affinity of FeII-EDTA is 2 × 1014,108 it is unlikely that the selenium and 
sulfur compounds investigated compete with EDTA for FeII binding. Methyl-
selenocysteine at 1000 µM inhibited 27 % of DNA damage caused by [Fe(EDTA)]2- and 
H2O2; the same concentration of methyl-selenocysteine inhibited 60 % of FeII-mediated 
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DNA damage. Selenocystamine studies showed similar results, preventing 60 % of DNA 
damage with [Fe(EDTA)]2- at 1000 µM, significantly less than the 100 % inhibition 
observed with FeII at the same concentration.18 Similarly, methylcysteine sulfoxide 
prevented no DNA damage in the presence of chelated FeII.35  This limited activity 
observed only at very high antioxidant concentrations with chelated copper or iron as the 
hydroxyl radical generator is likely due to ROS scavenging, and suggests that this is only 
a secondary antioxidant mechanism for these compounds. 
Oxidized and reduced glutathione (10,000 μM) prevent 68 % and 76 % DNA 
damage caused by [Fe(EDTA)]2-, respectively, 18 % and 43 % more, respectively, than 
inhibition of non-chelated FeII-mediated DNA damage at the same concentrations.37 This 
unique activity for glutathione indicates that it may prevent DNA damage by both ROS 
scavenging and iron coordination, a useful trait for the primary sulfur-containing cellular 
antioxidant.109,110 
 To establish copper and iron coordination and stoichiometry with sulfur and 
selenium antioxidants, UV-vis studies were conducted on all compounds, regardless of 
their ability to prevent metal-mediated DNA damage. UV-vis studies (in 10 mM MOPS 
buffer at pH 7) conducted with the selenium compounds that prevented CuI-mediated 
DNA damage revealed absorption bands around 226 nm,18 the range expected for copper-
selenium charge transfer bands,111 whereas the selenium compounds that did not prevent 
DNA damage had no such bands. Although FeII coordination (in 10 mM MES buffer at 
pH 6) results in absorption bands of 316-340 nm for iron-thiolate clusters and 311-389 
nm for iron-selenolate clusters,112-115 UV-vis studies of all the sulfur and selenium 
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compounds with FeII revealed no absorption bands indicative of metal coordination, 
indicating that selenium- or sulfur-iron binding is weak, or that iron coordination may not 
occur through the selenium or sulfur atoms.18,37 
 Electrospray ionization mass spectrometry (ESI-MS) studies were also conducted 
with the antioxidants in Figure 1.1 with FeII or CuI to directly investigate their metal 
coordination. A majority of the compounds coordinated CuI in a 1:1 or 1:2 molar ratio of 
metal to ligand; only 2-aminophenyl diselenide, selenocystamine, sodium selenite, 
selenium dioxide, cystamine, 2-aminophenyl disulfide, and 2,2’-dithiosalicylic acid 
showed no copper coordination (Table 1.1).18 Since many of the compounds investigated 
could coordinate CuI through the oxygen and/or nitrogen of the amino acid in addition to 
potential sulfur/selenium coordination, 1:1 or 1:2 metal-to-ligand molar ratios were 
expected.96,116,117  
Similar mass spectrometry studies with FeII revealed that all of the tested 
organoselenium compounds formed FeII complexes with 1:1 and/or 1:2 metal-to-ligand 
ratios (Table 1.1), regardless of their ability to prevent iron-mediated DNA damage. Most 
of the organosulfur compounds also formed FeII complexes with the same ratios, with the 
exceptions of methionine, cystamine, and 2-aminophenyl disulfide. FeII has up to six 
possible binding sites, so expected metal-to-ligand ratios are 1:1 to 1:3 for potentially 
bidentate amino acids.118,119 Although most of the compounds coordinated CuI or FeII, not 
all of them prevented metal-mediated DNA damage. Thus, metal coordination is 
necessary but not sufficient for DNA damage inhibition.18 To result in DNA damage 
prevention, binding of the sulfur or selenium compound would  have to significantly alter 
18 
the metal redox potential to prevent CuI or FeII oxidation by H2O2 (Figure 1.2, redox 
control mechanism). Alternatively, direct metal-sulfur or –selenium coordination may be 
required to efficiently scavenge H2O2 before DNA damage occurs (Figure 1.2, targeted 
oxidation mechanism). 
 
1.4. Investigating the electrochemistry of sulfur and selenium antioxidants 
 Since generation of •OH from H2O2 is a one-electron redox reaction, we focused 
on electrochemical studies to determine the oxidation ability of the tested sulfur and 
selenium compounds since this property should be directly related to •OH scavenging 
ability. Researchers commonly study selenium compounds using a gold or mercury 
electrode, both of which readily coordinate sulfur and selenium.12,120,121 Thus, redox 
potentials observed using metallic electrodes are most likely of a metal-selenium 
complex. To better mimic biological conditions, we used a glassy carbon electrode and 
samples in in 10 mM MOPS buffer at pH 7 for our cyclic and differential pulse 
voltammetry experiments to determine correlations between antioxidant ability and redox 
activity.18 All of the selenium compounds in Table 1.1 were readily oxidized (Table 1.3), 
except the oxo-selenium compounds and methyl-selenocysteine, suggesting that most 
could be effective ROS scavengers. Only three compounds were found to undergo both 
oxidation and reduction: selenocystamine, 2-aminophenyl diselenide, and 2-
carboxyphenyl diselenide.18 Two of the most active selenium antioxidants for copper-
mediated DNA damage prevention, selenomethionine and selenocystine, showed 
irreversible oxidation, but the electrochemically inactive methyl-selenocysteine prevented  
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Table 1.2. Electrochemical results vs. normal hydrogen electrode for selected CuI complexes (1 
mM) in acetonitrile with tetra-n-butylammonium hexafluorophosphate (100 mM) as the 
supporting electrolyte.  
 CuII/I  
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) Ref. 
[TpmiPrCu(NCCH3)][BF4] 1.254 -0.340 1.594 0.457 122 
[TpmMeCu(NCCH3)][BF4] 1.158 -0.620 1.778 0.269 122 
[TpmCu(NCCH3)][BF4] 0.203 -0.641 0.844 -0.219 122 
Dmise  0.039 -0.773 0.812 -0.367 122 
[TpmiPrCu(dmise)][BF4] -0.049 -0.729 0.680 -0.390 122 
[TpmMeCu(dmise)][BF4] -0.088 -0.644 0.556 -0.366 122 
[TpmCu(dmise)][BF4] -0.030 -0.536 0.506 -0.283 122 
[Cu(dmise)4][OTf] -0.191 -0.555 0.364 -0.373 123 
Dmit  0.424 -0.761 1.158 -0.167 122 
[TpmiPrCu(dmit)][BF4]  0.187 -0.507 0.694 -0.160 122 
[TpmMeCu(dmit)][BF4]  0.307 -0.518 0.825 -0.105 122 
[TpmCu(dmit)][BF4]  0.392 -0.252 0.644  0.070 122 
[Cu(dmit)3][OTf]  0.000 -0.434 0.434 -0.217 124 
both copper- and iron-mediated DNA damage. Similarly, for the sulfur antioxidants, only 
methionine and cysteine exhibited oxidation waves (Table 1.3). Because the oxidation 
potentials of these sulfur and selenium antioxidants do not correlate with their antioxidant 
abilities, and because these compounds prevented little or no DNA damage with chelated 
[Cu(bipy)2]+ or [Fe(EDTA]2-,18,37 we established that ROS scavenging (Figure 1.2, top) is 
not a major mechanism for their activity.  
To directly compare the electrochemistry of a CuI-coordinated selones and 
thiones, we synthesized dmit and dmise copper complexes with tris(pyrazolyl)methane 
(TpmR) ligands (Table 1.2). These selone and thione ligands are similar in structure to the 
natural antioxidants ergothioneine,62,63,122 selenoneine,70 respectively (Figure 1.1), as well 
methimazole, a drug used to treat hyperthyroidism.123  The TpmR ligands were selected to 
mimic the guanine N7 binding typical for CuI- and FeII-DNA interactions,124,125  and 
coordination of these tridentate ligands to CuI permitted only one selone or thione ligand 
to bind, mimicking expected cellular ratios for copper and selenium antioxidants. 
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 Electrochemical studies of uncoordinated dmise and dmit in acetonitrile 
determined that the selone undergoes reduction more readily than the thione (E1/2 values 
of -167 and -367 mV, respectively).126 When coordinated to CuI in the [TpmRCu(dmise)]+ 
complexes, binding of a single dmise ligand shifted the E1/2 values for CuII/I reduction by 
an average of -234 mV compared to analogous dmit complexes (Table 1.2), indicating 
increased CuII stabilization.126,127 Increased stabilization of CuII upon dmise complexation 
is also observed for the homoleptic [Cu(dmise)4]+ and Cu(dmit)3]+ complexes (Table 1.2).  
If metal complex reduction potentials are more negative than the reduction potential of 
NADH (-324 mV), cellular CuII or FeIII reduction to the hydroxyl-radical-generating CuI 
and FeII is inhibited.128 Most of the Cu-dmise complexes in Table 1.2 have CuII/I 
reduction potentials more negative than -324 mV, but none of the Cu-dmit complexes 
have such low CuII/I potentials.126,127  Thus, if similar copper-selenium antioxidant 
complexes form in cells, they may prevent copper redox cycling and copper-mediated 
DNA damage significantly more efficiently than analogous sulfur antioxidant complexes 
(Figure 1.2, redox control mechanism).  These results are consistent with the trend of 
increased copper-mediated DNA damage prevention observed for selenium antioxidants 
compared to their sulfur analogs (Table 1.1) and highlight the importance of metal-
binding antioxidant mechanisms.  
Although our electrochemical studies demonstrated that dmit and dmise stabilize 
CuII over CuI, subsequent UV-vis studies indicated that dmise reduces CuII to CuI at a rate 
three times faster than dmit.129 This apparent contradiction of the electrochemical 
(thermodynamic) and UV-vis (kinetic) results underscores the complex redox behavior of 
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these ligands and their copper complexes and suggests that the biological antioxidant 
abilities of these two antioxidants may vary greatly, since copper redox cycling is critical 
to oxidative DNA damage.130,131  
 
1.5. Determining CuI coordination modes and predictive models for sulfur and 
selenium antioxidants 
 To obtain structural details of copper-seleno-amino acid coordination, we 
characterized the first such CuI complexes with selenomethionine and methyl-
selenocysteine. Upon adding 1 equiv [Cu(NCCH3)4]+ to an aqueous solution of methyl-
selenocysteine at pH 7, the 1H NMR resonances shifted significantly, suggesting that CuI 
bound through the selenium as well as a carboxylic acid oxygen or amine nitrogen.132 
Similar results were observed for selenomethionine-CuI interactions,132 and are consistent 
with methyl-cysteine and methionine coordination to AgI.133 Selenium-CuII interactions 
have also been reported for selenocysteine-containing copper proteins.134,135 X-ray 
absorption studies of these CuI-seleno-amino acid complexes confirmed trigonal planar 
CuI bound to methyl-selenocysteine and selenomethionine through the selenium atom in 
addition to two oxygen or nitrogen atoms.132   
Density functional theory (DFT) models of these trigonal planar [Cu(L)(OH2)]+ 
complexes (L = methyl-selenocysteine and selenomethionine), as well as their sulfur 
analogs (unpublished data), indicated that coordination through the chalcogen and the 
amine is slightly more favorable than through the carboxylate, and that trigonal planar 
coordination of the complex was completed with water.132 These studies revealed both 
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the ability of sulfur and selenium compounds to readily form CuI complexes and 
strengthened the link between antioxidant-metal coordination and DNA damage 
prevention. 
 Transition metal complexes with heterocyclic thione and thione-derived 
scorpionate ligands, are well known.136-139  Williams et al. have explored the metal 
complexes of N,N’-dimethylimidazole thione (dmit) and selone (dmise) with CdII,140 
ZnII,141,142 and CoII.143 Although many researchers have investigated copper coordination 
by various thione-containing ligands,144-148 only a few have reported copper coordination 
by selone ligands.139,149-151 To compare the reactivity of analogous CuI selone and thione 
complexes, the [TpmRCu(dmit/dmise)][BF4] complexes were obtained by treating 
[Cu(NCCH3)4][BF4] with one equivalent of dmise/dmit, followed by addition of an 
equimolar amount of the tris(pyrazolyl) ligand (Scheme 1.1A).126 We synthesized CuI 
complexes with the hydrotris(3,5-dimethylpyrazolyl)borate (Tp*) ligand, 
Tp*Cu(dmit/dmise) using similar methods.126  
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We also synthesized homoleptic CuI complexes of dmise and dmit (Scheme 1.1B 
and 1.1C) by treating Cu(OTf)2 with an excess of dmit or dmise in a mixture of 
acetonitrile and dichloromethane.127 Surprisingly, these reactions yielded sulfur and 
selenium complexes with different coordination numbers: a trigonal planar [Cu(dmit)3]+ 
complex and a distorted tetrahedral [Cu(dmise)4]+ complex, in addition to a disulfide 
dication and triselenide dication, respectively.127 These synthetic results highlight the 
significant differences between sulfur and selenium coordination chemistry, and reinforce 
the fact that both sulfur and selenium complexes must be fully characterized and 
compared to develop a complete understanding of their antioxidant activity. 
 DFT calculations of [TpmMeCu(L)]+ (L = CH3CN, dmit, dmise) showed that 
protection of the CuI center may be attributed to an important change in the HOMO of the 
complex upon  dmit/dmise coordination.152  Whereas the HOMO of the CH3CN complex 
is localized on the metal d orbitals, a p-type lone pair of dmit/dmise is the major 
contributor to the HOMO of these complexes (Figure 1.4). Metal coordination 
destabilizes the lone pair of the thiolate/selenolate resonance structure of dmit/dmise  
Figure 1.4. HOMOs for [TpmMeCu(dmit)]+ (left) and [TpmMeCu(NCCH3)]+ (right).  Reprinted with 
permission from Kimani, M. M.; Bayse, C. A.; Stadelman, B. S.; Brumaghim, J. L. Inorg. Chem. 2013, 52, 




Scheme 1.2. Molecular orbital diagram showing the destabilization of the thiolate lone pair upon CuI 
coordination. 
 
perpendicular to the Cu-S(Se) bond to make it more susceptible to oxidation (Scheme 
1.2). This effect may be of general importance to the prevention of Fenton-type chemistry  
by S/Se compounds because for free, hydrated metal ions, the frontier MOs are metal-
based, so that electrons will be drawn from these MOs in an oxidation process. Because 
most S/Se ligands act as p-donors, electrons will be removed from the destabilized lone 
pair to protect the metal. 
 Therefore, instead of a one-electron oxidation of Cu(I) producing •OH, the 
chalcogen is targeted for a two-electron oxidation, fully reducing H2O2. The HOMO 
energy of a series of [Cu(L)(OH2)]+ complexes with a S/Se compound L correlates well 
with the ability of the compound to protect DNA against oxidative damage based upon 
the IC50 data (Figure 1.5 and Table 1.4 at the end of the Experimental Methods section).  
Note that there is no correlation with the HOMO of the free S/Se compounds, again 
indicating that metal coordination is central to the protection mechanism.  
25 
Figure 1.5. Correlations between the HOMO energies for a series of A) [Cu(L)(OH2)]+ complexes (R2 = 
0.90) and B) the free ligands (L; R2 = 0.07).  IC50 values are from references 18 and 35-37. 
 
This destabilization of the lone pairs may explain why S/Se compounds are more 
effective against CuI-mediated oxidative damage.  Because FeII is a borderline Lewis 
acid, it has less affinity for the soft S/Se ligands and prefers linkage isomers that bond 
through the N,O donors. Because no Fe-S/Se bond forms, the sulfur or selenium lone 
pairs are not activated for ROS scavenging and no protection from oxidative damage is 
observed except at very high concentrations. The main exception to this rule are 
dmit/dmise which are significantly more effective against FeII. These ligands can only 
form Fe-S/Se bonds with FeII and their greater effectiveness may be attributed to both the 
activation of the lone pairs and the delocalization of the spin density to the chalcogen.  















































mechanisms for antioxidant behavior can meaningful predictive models be developed for 
sulfur and selenium compounds. 
 
1.6. Establishing targeted scavenging as an antioxidant mechanism linked to metal 
binding 
Synthesis of the [TpmMeCu(dmit/dmise)]+ complexes also afforded us a system to 
examine whether these coordinated sulfur and selenium ligands protected CuI from 
oxidation.  First, unbound dmise and dmit were treated with up to three equivalents of 
H2O2, and the results were observed by 1H, 13C, and 77Se (for dmise) NMR spectroscopy 
in CD3CN.  Significant downfield shifts in the NMR resonances upon oxidation and 
indicated the formation of the N,N’-dimethylimidazolium cation and oxidized sulfur and 
selenium species, products that were confirmed by electrospray ionization mass 
spectrometry results (ESI-MS).152  In the 77Se NMR spectrum, this oxidation was 
unmistakable, since the selenium resonance shifted from  δ -29.5 for dmise to  an SeO2 
species at δ 1345.152 Bhabak et al. determined that both dmise and dmit are similarly 
oxidized when treated with peroxynitrite.99 As expected from the electrochemical results 
(Table 1.2), dmise is more sensitive to oxidation than dmit, requiring addition of only two 
equivalents of H2O2 for complete oxidation compared to the three equivalents required 
for complete oxidation of dmit.152  
 Similar oxidation studies with [TpmMeCu(dmise)]+ and [TpmMeCu(dmit)]+ were 
also performed to determine if dmise or dmit coordination could prevent CuI oxidation by 
H2O2.  1H and 13C NMR studies with the CuI-selone complex in acetonitrile treated with 
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0.5, 1, and 2 equivalents of H2O2 showed sharp peaks, indicative of CuI, with shifts in the 
bound dmise resonances the same as those seen for unbound oxidized dmise.152 These 
results were again corroborated by ESI-MS, and the [TpmMeCu(NCCH3)]+ complex was 
also isolated from the oxidized reaction mixture, confirming the presence of CuI.  
Treatment of [TpmMeCu(NCCH3)]+ with H2O2 resulted in only CuII formation.152  
Similarly, treatment of [TpmMeCu(NCCH3)]+ with O2 resulted in immediate oxidation of 
CuI to CuII and formation of [{TpmMe(Cu(OH)}2]2+.129 Thus, dmise binding protects CuI 
from H2O2 oxidation (Figure 1.6). Similar results were observed when the thione 
complex was treated with up to three equivalents of H2O2, confirming that dmise is a 
more effective H2O2 scavenger than dmit.152  
 Dmise and dmit are extremely versatile antioxidants, preventing oxidative DNA 
damage from oxidation by both copper or iron coordination and ROS scavenging.  Their 
ability to protect bound CuI is the first example of metal-antioxidant binding leading to 
targeted ROS scavenging (Figure 1.2, bottom) and proves that metal coordination 
mechanisms are required to fully understand sulfur and selenium antioxidant activity. 
Figure 1.6. Reaction of [TpmMeCu(L)]+ (L = dmise or dmit) with H2O2.  Reprinted with permission from 
Kimani, M. M.; Bayse, C. A.; Stadelman, B. S.; Brumaghim, J. L. Inorg. Chem. 2013, 52, 11685-11687 































1.7. Conclusions and future directions 
 1.7.1 Conclusions. Sulfur and selenium antioxidants prevent metal-mediated 
oxidative DNA damage by coordinating CuI or FeII at biologically relevant 
concentrations.  Whereas previous studies have almost exclusively focused on ROS 
scavenging as a primary antioxidant mechanism, our work has established the importance 
of metal interactions in antioxidant mechanisms. Three of the nine tested selenium 
compounds and seven of the eleven tested sulfur compounds more efficiently inhibited 
CuI-mediated DNA damage compared to FeII-mediated DNA damage. Our studies have 
also revealed that merely the presence of a sulfur or selenium atom is not sufficient for 
the prevention of DNA damage, and that functional groups with the ability to interact 
with metal ions substantially affect antioxidant behavior. Mass spectrometry confirmed 
copper and iron coordination for all sulfur and selenium compounds, regardless of 
antioxidant ability, indicating that metal binding is necessary but not sufficient for sulfur 
and selenium prevention of DNA damage.  Because sulfur and selenium antioxidants can 
prevent DNA damage through multiple pathways, it is critical to fully understand the 
structural properties necessary for potent antioxidant activity for ROS scavenging and 
metal-binding mechanisms. 
 NMR and X-ray absorption spectroscopy studies of methyl-selenocysteine and 
selenomethionine with CuI confirmed that coordination occurs through the selenium or 
sulfur atoms in addition to the nitrogen and/or oxygen atoms. DFT calculations of CuI 
complexes with dmise and dmit revealed the destabilization of the selenium or sulfur lone 
pair upon coordination that makes dmise and dmit more susceptible to oxidation than CuI. 
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In addition, electrochemical studies showed that, upon dmise-CuI coordination, the CuII/I 
redox potential is shifted outside the biological window for hydroxyl radical generation. 
Our results not only identify the chemical properties that contribute to antioxidant activity 
and prove that metal coordination is the key to fully understanding sulfur and selenium 
antioxidant mechanisms, but have established the first predictive models for sulfur and 
selenium prevention of metal-mediated DNA damage.  
1.7.2. Future research directions. Future studies will focus on testing second-
generation sulfur and selenium antioxidants with different functionalities to determine the 
effects of coordination mode and denticity on antioxidant behavior. Additional studies 
will focus on determining the formation constants of sulfur and selenium compounds 
with copper and iron, to determine the correlation between complex stability and 
antioxidant behavior. Our work over the past ten years has challenged the traditional 
mindset that sulfur and selenium antioxidant activity is controlled only by ROS 
scavenging and continues to illuminate the importance of metal-binding antioxidant 
mechanisms.  
The research presented in this dissertation focuses on determining the DNA 
damage prevention mechanisms of sulfur and selenium compounds in vitro. The review 
in this introductory Chapter is submitted for publication in the Journal of Inorganic 
Biochemistry (Zimmerman, M. T.; Bayse, C. A.; Ramoutar, R. R.; Brumaghim, J. L. J. 
Inorg. Biochem., submitted) Currently, the general consensus in the field is that sulfur 
and selenium compounds prevent oxidative DNA damage through ROS scavenging, 
while the role of redox active metal ions has been relatively unexplored. Thus, the sulfur 
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and selenium compounds discussed in Chapters 3 and 4 have been shown to exhibit 
metal-coordinating abilities and prevent oxidative DNA damage caused by metal- and 
nonmetal-mediated pathways.   
The work presented in Chapter 2 examines the redox and metal coordinating 
properties of sulfur and selenium amino acids, and determines the correlation between 
these properties and DNA damage prevention capabilities. Furthermore, these studies 
show the significance of metal coordination in preventing DNA damage. Chapter 3 
discusses the DNA damage prevention abilities of N,N’-dimethylimidazole selone 
(dmise) and thione (dmit), the first sulfur and selenium compounds to inhibit DNA 
damage from FeII/H2O2, CuI/H2O2, and peroxynitrite in vitro. These results also confirm 
the first selenium and sulfur compounds that prevent oxidative DNA damage through 
both metal coordination and ROS scavenging. The research in Chapter 4 examines how 
secondary functional groups, S/Se species, and methylation of the imidazole nitrogens 
affect the DNA damage prevention abilities of various selenium and sulfur compounds in 
vitro. This chapter also compares the ability of the hyperthyroid drug, methimazole, and 
the natural thione, ergothioneine, to prevent oxidative DNA damage from FeII/H2O2, 
CuI/H2O2, and peroxynitrite for the first time. Since interest in selenium and sulfur 
antioxidants has dramatically grown over the past decade, knowing how they prevent 
oxidative damage, and which chemical properties are necessary for activity, will permit 
better development of selenium and sulfur antioxidants for animal and clinical trials; 
leading to more effective treatment of diseases linked to oxidative damage.       
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Chapter 5 explores the redox properties of clotrimazole and pseudoephedrine 
metal complexes. This work describes the significance of transition metals on the 
antifungal mechanisms of clotrimazole, and suggests that one mechanism may be the 
metal-mediated generation of ROS. DNA damage studies with a copper clotrimazole 
complex suggest that CuII-clotrimazole complexes produce the harmful •OH similar to 
Reaction 2.  
Pseudoephedrine is commonly used as an antitussive drug or nasal decongestant, 
but little is known about the effect metal interactions have on its function. The 
electrochemical studies in Chapter 5 indicate that the presence of redox-active metal ions 
greatly reduces the oxidation potential of pseudoephedrine derivatives. In addition, DNA 
damage studies with trinuclear copper pseudoephedrine-derivative complexes suggest 
that DNA damage is dose-dependent and similar to Reaction 2. Understanding the 
significance of metal binding interactions for endogenous and exogenous antioxidants 
and drugs is critical for the development and targeting of future therapies to treat a wide 




DFT density functional theory 
Dmise N,N’-dimethylimidazole selone 
Dmit N,N’-dimethylimidazole thione 
EDTA ethylenediaminetetraacetic acid 
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ESI-MS electrospray ionization mass spectrometry 
MALDI matrix-assisted laser-desorption ionization 
MES 2-(N-morpholino)ethanesulfonic acid 
MOPS 3-(N-morpholino)propanesulfonic acid 
NADH nicotinamide adenine dinucleotide 
NPC Nutritional Prevention of Cancer 
OTf trifluoromethane sulfonate 
ROS reactive oxygen species 





1.9 Experimental Methods 
Electrochemical measurements for sulfur compounds. Cyclic voltammetry 
samples were prepared by dissolving the sulfur compounds (300 µM) in MOPS buffer 
(10 mM, pH 7) with KNO3 (10 mM) as a supporting electrolyte.  Solutions were degassed 
for 5 min with N2 before each experiment.  All CV experiments were conducted at 100 
mV/s.  Differential pulse voltammetry experiments (pulse amplitude of 0.080 V, pulse 
width of 0.100, sample width of 0.045, and pulse period of 0.200) were also performed 
and showed similar results to the CV data.   Samples of each compound were cycled 
between -1000 mV and 1000 mV using a glassy carbon working electrode, a Pt counter-
electrode, and a Ag/AgCl (197 mV vs. NHE)153 reference electrode.  
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Theoretical methods.  The HOMO energies used for the graphs in Figure 1.5 were 
obtained from the minimum energy conformations of methionine, S-methylcysteine, 
cystine, methionine sulfoxide, S-methylcysteine sulfoxide, methyl methanethiosulfonate 
(MMTS), selenomethionine, Se-methylselenocysteine, selenocystine and glycine and 
their complexes with Cu(I) [Cu(OH2)L]+ (Table 1.3). Geometries were optimized using 
the BP86 xc functional,154,155 as implemented in PQS version 3.3,156 as previously 
reported in our study of Cu(I) with selenoamino acids.132 Copper and selenium were 
represented by the Hurley et al relativistic effective core potentials.157 The copper basis 
set was further modified by the 4p Couty-Hall contraction.158 Sulfur was represented by 
the Wadt-Hay basis set augmented with diffuse and polarization functions.159 Dunning 
split-valence triple-ζ basis sets,160 modified with polarization and diffuse (heavy atoms 
only) functions were used for nitrogen, oxygen and hydrogen atoms attached to non- 
carbon heavy atoms. Hydrocarbon fragments used Dunning double-ζ basis sets with 
 















aElectrochemical values from reference 18.  
Selenium Compounda Epa (mV) Epc (mV) ΔE(mV) E1/2 (mV) 
Selenocystine -115 — — — 
Selenomethionine 693 — — — 
Methyl-selenocysteine — — — — 
Selenocystamine -131 -526 394 -329 
2-Aminophenyl diselenide 593, 120 24, -978 569, 1099 308, -429 
2-Carboxyphenyl diselenide 501 569 67 535 
Sulfur Compound     
Cystine 458 617 159 538 
Methionine -244 — — — 
Methyl-cysteine — — — — 
Cystamine — — — — 
2,2’-Dithiosalicylic acid — — — — 
Reduced glutathione — — — — 
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polarization functions on carbon only.161  Structures were shown to be minima of the 
potential energy surface by frequency calculations.  
 Amino acids were modeled as bidentate ligands. [Cu(OH2)L]+ complexes 
preferred to coordinate through S/Se and the amine over the S/Se and the carboxylate or 
the amine and carboxylate (N,O).132  Glycine prefers to coordinate to the amino acid only 
(N,O-coordination). MMTS is a monodentate ligand through the sulfoxide oxygen.  
 
Table 1.4. IC50 data and DFT(BP86) HOMO energies for selected sulfur and selenium compounds (L), free 
and in complex with Cu(I) [Cu(OH2)L]+. 
Compound IC50 (µM)a HOMO L (a. u.) HOMO [Cu(OH2)L]+ (a. u.) 
Methionine 11.8 -0.20184 -0.31208 
S-methylcysteine 9.6 -0.18036 -0.30642 
cystine 3.4 -0.19924 -0.29899 
methionine sulfoxide 18.0 -0.21360 -0.33569 
S-methylcysteine sulfoxide 8.1 -0.20676 -0.30748 
MMTS 35.0 -0.21579 -0.36929 
selenomethionine 25.1 -0.19268 -0.32517 
Se-methylselenocysteine 8.64 -0.16986 -0.31314 
selenocystine 3.34 -0.21704 -0.29358 
glycine 22.04 -0.20716 -0.33668 
aIC50 values are from references 18 and 35-37. 
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THE RELATIONSHIP BETWEEN ELECTROCHEMICAL PROPERTIES AND 
METAL COORDINATION FOR SULFUR AND SELENIUM ANTIOXIDANTS  
 
2.1 Introduction 
Oxidative damage caused by reactive oxygen species (ROS) has been linked to 
cancer, neurodegenerative diseases, inflammation, and cardiovascular diseases.1-5 One of 
the most prevalent and damaging ROS is •OH,6-9 commonly generated from reduction of 
H2O2 by redox-active transition metals FeII and CuI (Reactions 1 and 2).10-12 
FeII + H2O2 → FeIII + -OH + •OH (1)  
CuI + H2O2 → CuII + -OH + •OH (2) 
Although cells maintain metal homeostasis through various mechanisms, mis-regulation 
of this homeostasis can occur, resulting in rapid increases in the concentrations of non-
protein bound FeII and CuI. Infact, one study has reported that neuronal cells can store 
between 100-1000 µM non-protein bound FeII and CuI in cellular compartments.13  These 
elevated metal concentrations can lead to a drastic increase in •OH generation,14-16 and 
cellular reductants make this reaction to be catalytic by reduction of FeIII and CuII back to 
FeII and CuI.17,18 To combat oxidative stress, cells incorporate antioxidant sulfur 
compounds such as cysteine, methionine, and glutathione to defend against oxidative 
damage.19,20 Dietary organosulfur compounds, such as those in garlic, have shown 
promise for preventing stomach, colorectal, and prostate cancers in clinical trials.20-23 
Methionine is an essential amino acid with ROS scavenging capabilities, and glutathione, 
one of the most abundant cellular antioxidants, is present in concentrations between 1 and 
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15,000 µM and is a critical component in the glutathione peroxidase (GPx) antioxidant 
cycle.24-26 Cell viability has been linked to the ROS scavenging capability of glutathione 
in GPx activity.26  
Measuring the ability of selenium compounds to scavenge H2O2 in a manner 
similar to  GPx is a standard method to assess their antioxidant efficacy.27-29 Ebselen, the 
most promising and thoroughly studied GPx mimic, clinical trials have shown that it can 
protect against ischemic brain damage, and it is studied for the treatment of Parkinson’s 
disease.30-33 However, measuring selenium antioxidant activity based on GPx-like 
behavior is not without flaws. The greatest difficulty is that GPx activity measurements 
typically use non-physiological conditions such as acidic solutions34-36 and that decreased 
activity can be observed due to unexpected thiol exchanges.28,37,38 Additionally, H2O2 is a 
longer-lived and less reactive ROS compared to •OH and is relatively harmless in metal-
free environments.11,12,39 Due to the extreme reactivity of hydroxyl radical, greater 
oxidative DNA damage prevention may occur from preventing metal-mediated •OH 
formation or by reducing DNA damage from metal-generated •OH rather than scavenging 
H2O2.40 This prevention of hydroxyl radical generation or release could be accomplished 
by direct metal coordination of the selenium or sulfur antioxidant. 
Interest in selenium antioxidant properties has also increased over the years due to 
the link between selenium deficiency and Keshan disease,41 Kashin-Beck disease,42,43 
cancer,44-48 and pulmonary tuberculosis.49 The anticancer properties of selenium were the 
primary interest in two clinical trials with conflicting results. The Nutritional Prevention 
of Cancer (NPC) reported a 63 % decrease in prostate cancer incidence upon selenium-
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enriched yeast supplementation (200 µg/day).50 In contrast, the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) reported no decrease in prostate cancer incidence 
upon administering the same amount of selenium supplement.51,52 The NPC trial used 
selenium-enriched yeast comprised of multiple selenium species, whereas the SELECT 
trial used only selenomethionine, the major selenium species in selenium-enriched 
yeast.53,54 The difference in the outcomes of these trials indicates that it is not sufficient to 
simply supplement with selenium; understanding selenium antioxidant mechanisms is 
critical to identify effective selenium supplements for successful clinical trials.   
 Studies have suggested that copper-glutathione binding may reduce the cellular 
toxicity of copper.55,56 In addition, gel electrophoresis studies by the Brumaghim group 
have shown the ability of several sulfur antioxidants (Figure 2.1) to effectively prevent 
CuI-mediated DNA damage from •OH under physiological conditions.20 None of these 
sulfur compounds, however, inhibit DNA damage when [Cu(bipy)2]I (bipy =  
 
Figure 2.1. Structures of sulfur and selenium compounds discussed in Chapter 2. 
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2,2’-bipyridine) is substituted for unchelated CuI. The presence of the bipy ligands 
effectively prevents sulfur antioxidant binding to CuI and subsequent DNA damage 
inhibition, suggesting that metal coordination is necessary for the antioxidant abilities of 
these sulfur compounds.20 These sulfur compounds much more effectively prevent 
copper-mediated DNA damage than that caused by iron; only oxidized glutathione, 
reduced glutathione, and 3-carboxypropyl disulfide prevent FeII-mediated DNA 
damage.20  
 Similar gel electrophoresis studies with the selenium compounds in Figure 2.1 
revealed that selenocystine, methyl-selenocysteine, selenomethionine, and 
selenocystamine prevent CuI-mediated DNA damage and that this activity is significantly 
different from their measured abilities for scavenging H2O2 in a GPx-like mechanism.11 
In contrast to their sulfur analogs, 3,3’-diselenobispropionic acid, selenocystamine, 
methyl-selenocysteine, and 3,3’-selenobispropionic acid also prevent FeII-mediated DNA 
damage, but 3,3-diselenobispropionic acid and 3,3’-selenobispropionic acid exhibit no 
GPx-like activity.11 Thus, H2O2 scavenging is not an accurate method for measuring 
selenium this antioxidant activity and is not a primary mechanism for metal-mediated 
DNA damage prevention. 
Metal coordination is a separate mechanism from the traditional ROS scavenging 
mechanisms, and it has recently been the focus of many studies on the antioxidant 
abilities of sulfur and selenium compounds. Figure 2.2 compares the two accepted 
scavenging mechanisms, GPx-like activity (A) and direct ROS scavenging (B). 
Alternatively, metal binding to sulfur and selenium antioxidants could prevent oxidative  
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Figure 2.2. Proposed ROS scavenging mechanisms of sulfur and selenium compounds without metal ions. 
A) Glutathione peroxidase (GPx)-like cycle for H2O2 scavenging by selenium compounds. B) The typical 
ROS scavenging mechanism assumed for sulfur and selenium compounds. 
damage by the targeted scavenging of H2O2 or •OH at the site of generation (Figure 2.3). 
Since •OH is a strong oxidizing agent, investigating the electrochemical properties of the 
compounds in Figure 2.1 will shed light on the ability of sulfur and selenium compounds 
to undergo oxidation, indicating possible ROS scavenging ability. Mass spectrometry 
studies with CuI and FeII will indicate metal coordination ability, and the capability to 
prevent oxidative damage through a targeted scavenging mechanism. The results of the 
studies with the selenium antioxidants (Figure 2.1) presented in this Chapter are 
published in Battin, E. E.; Zimmerman, M. T.; Ramoutar, R. R.; Quarles, C. E.; 
Brumaghim, J. L. Metallomics 2011, 3, 503-512 (reproduced by permission of The Royal  
 
Figure 2.3. Metal coordination mechanism for sulfur and selenium compounds targeting H2O2, preventing 
metal oxidation and the generation of •OH. 
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Society of Chemistry http://pubs.rsc.org/en/content/articlepdf/2011/mt/c0mt00063a; 
Appendix A) and results of the sulfur compound studies were obtained in collaboration 
with Dr. Carolyn E. Quarles and Prof. Ria R. Ramoutar. 
   
2.2 Results and Discussion 
2.2.1. Electrochemistry of selenium compounds.  To determine whether a 
correlation exists between selenium antioxidant activity and electrochemistry of the 
selenium compounds (Figure 2.1), cyclic voltammetry (CV; Figures 2.4 and 2.5) 
experiments were conducted in aqueous buffer at pH 7. Differential pulse voltammetry 
(DPV) experiments were also conducted to confirm the presence of any weak redox 
waves in the CV studies (Figures 2.8-2.11 in the Experimental Methods section).  
Because hydroxyl radical is a strong oxidant, one might expect to observe high 
oxidation potentials for the most effective selenium antioxidants if hydroxyl radical 
scavenging is a major antioxidant mechanism.  Only three of the ten selenium compounds 
have measureable E1/2 values using a glassy carbon working electrode: selenocystamine 
(-329 mV), 2-carboxyphenyl diselenide (535 mV), and 2-aminophenyl diselenide (with 
two redox potentials at 308 and -429 mV; Table 2.1). In contrast, selenomethionine, 2-
carboxyphenyl selenide, 3,3’-diselenobispropionic acid, and selenocystine show only a 
single oxidation wave,  whereas 3,3’-selenobispropionic acid, 4-carboxyphenyl 
diselenide, and methyl-selenocysteine exhibit no electrochemical activity between -1000 
mV and 1000 mV.  
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 In contrast, Bai et al.57 observed two anodic waves for selenocystine at 810 mV 
and ~1200 mV vs. Ag/AgCl as well as two anodic waves for selenomethionine at ~640 
mV and 1100 mV.  This discrepancy is likely due to the difference in both the pH and 
choice of working electrode; Bai and coworkers reported these potentials at pH 3.9 using 
a gold working electrode.  Many electrochemical studies of selenium antioxidants have 
been performed with either mercury or gold electrodes;57,58 however, both mercury59 and 
gold60 can form selenium complexes.  As a result, the observed electrochemical behavior 
may be of the metal complex between the selenium compound and the electrode rather 
than the selenium compound alone.   
 Selenocystine, an antioxidant containing both amine and carboxylate 
functionalities, has a single irreversible anodic wave at -115 mV, whereas the amine-
functionalized selenocystamine 
Table 2.1. Electrochemical properties of selenium compounds versus normal hydrogen electrode (NHE). 
Compound Epa (mV) Epc (mV) ΔE(mV) E1/2 (mV) 
Selenomethionine 693 — — — 
Selenocystine -115 — — — 
Methyl-selenocysteine — — — — 
Selenocystamine -131 -526 394 -329 
2-Aminophenyl diselenide 593, 120 24, -978 569, 1099 308, -429 
2-Carboxyphenyl diselenide 501 569 67 535 
2-Carboxyphenyl selenide 832 — — — 
4-Carboxyphenyl diselenide — — — — 
3,3’-Diselenobispropionic acid 907 — — — 




Figure 2.4. Cyclic voltammograms for A) selenomethionine, B) selenocystamine, C) methyl-selenocysteine, D) selenocystine, E) 2-aminophenyl diselenide, and 
F) 2-carboxyphenyl diselenide in MOPS buffer (10 mM, pH = 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Selenium compounds (300 µM) were 
cycled between -1000 mV and 1000 mV (2APSe2 was cycled between -1200 mV and 800 mV) vs. NHE at a scan rate of 100 mV/s.   
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Figure 2.5. Cyclic voltammograms for A) 2-carboxyphenyl selenide, B) 4-carboxyphenyl diselenide, C) 3,3’-
diselenobispropionic acid, and D) 3,3’-selenobispropionic acid in MOPS buffer (10 mM, pH =7.0) containing KNO3 
(10 mM) as a supporting electrolyte.  Selenium compounds (300 µM) were cycled between -1000 mV and 1000 mV 
vs. NHE at a scan rate of 100 mV/s. 
exhibits quasi-reversible behavior with a similar redox potential of -329 mV.  In contrast, the 
similar amino acids selenomethionine and methyl-selenocysteine show very different 
electrochemical behavior; selenocystine has a single anodic wave at 693 mV, and methyl-
selenocysteine exhibits no electrochemical behavior.  These electrochemical differences are 
surprising, since selenomethionine and methyl-selenocysteine differ only by one methylene 
group.    
 The results of our DNA damage assays (Tables 2.2 and 2.3) do not correlate with the 
observed electrochemistry of the selenium compounds (Table 2.1). Selenocystine, the most 
effective selenium compound for preventing CuI-mediated DNA damage, exhibits the ability to 
undergo oxidation but lacked any activity towards FeII-, [Fe(EDTA)]2-, and [Cu(bipy)2]+-  
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Table 2.2. IC50 values and mass spectrometry data for the tested selenium compounds with CuI, as well as GPx-like 
activity measurements. 
Compound CuI IC50 (μM)a m/z (Da) CuI : Se compound Relative GPx 
Activityb 
Selenocystine 3.34 ± 0.08c 397.8, 731.6 1:1, 1:2 4.5 
Methyl-selenocysteine 8.64 ± 0.02 247.8, 427.8, 598.1 1:1, 1:2, 1:3 0.7 
Selenomethionine 25.10 ± 0.01c 261.9, 456.9, 650.9 1:1, 1:2, 1:3 0.6 
Selenocystamine 59 ± 3 % (1000 µM)c  — — 8.8 
2-Aminophenyl diselenide — — — 6.4 
2-Carboxyphenyl diselenide — 466.9 1:1 ~ 0 
2-Carboxyphenyl selenide — 383.9 1:1d ~ 0 
4-Carboxyphenyl diselenide — 466.9 1:1 ~ 0 
3,3’-Diselenobis(propionic acid) — 370.6, 673.4 1:1, 1:2 ~ 0 
3,3’-Selenobis(propionic acid) — 290.7, 515.6 1:1, 1:2 ~ 0 
aIC50 is defined as the concentration at which the compound inhibits 50% of DNA damage. bGPx relative activity values are 
reported relative to ebselen in methanol. cValues from reference 61. dESI mass spectrometry voltage of 5500 V. 
 
Table 2.3. IC50 values, and mass spectrometry data for the tested selenium compounds with FeII. 
Compound FeII IC50 (µM)a m/z (Da) FeII : Se compound 
3,3’-Diselenobispropionic acid ~ 75b 360.6, 664.4 1:1, 1:2 
Selenocystamine 121.4 ± 0.3 415.1 1:3 
Methyl-selenocysteine 378.4 ± 0.1 239.1, 420.8, 601.8 1:1, 1:2, 1:3 
3,3’-Selenobispropionic acid 42 ± 8% inhibition (1000 µM) 288.7, 506.6 1:1, 1:2 
Selenocystine — 390.8, 724.7, 1058.2 1:1, 1:2, 1:3 
2-Aminophenyl diselenide — 404.8 1:1c 
2-Carboxyphenyl diselenide — 465.7 1:1c 
2-Carboxyphenyl selenide — 376.9, 696.7 1:1, 1:2c 
4-Carboxyphenyl diselenide — 455.1 1:1 
Selenomethionine — 448.9, 643.9 1:2, 1:3 
aIC50 is defined as the concentration at which the compound inhibited 50% of DNA damage. bEstimated value. cESI mass 
spectrometry voltage of 5500 V. 
mediated DNA damage.61 Similarly, selenomethionine inhibits CuI-mediated DNA damage61 and 
shows only an oxidation potential. Methyl-selenocysteine inhibits both CuI- and FeII-mediated 
DNA damage, but exhibits no electrochemical activity. 3,3’-Diselenobispropionic acid 
undergoes only oxidation and inhibits FeII-mediated DNA damage, whereas the analogous 
selenide 3,3’-selenobispropionic acid also inhibits FeII-mediated DNA damage, but has no 
observable electrochemical behavior.  Both 2-carboxyphenyl selenide and 2-carboxyphenyl 
diselenide also differ by a single selenium atom, but 2-carboxyphenyl diselenide undergoes both 
oxidation and reduction, whereas 2-carboxyphenyl selenide exhibits only an oxidation potential.  
Despite their high oxidation potentials, neither 2-carboxyphenyl diselenide or 2-carboxyphenyl 
selenide inhibit CuI- or FeII-mediated DNA damage.  Since no correlation is observed between 
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oxidation potential and DNA damage prevention, direct ROS scavenging is likely not a major 
mechanism for the observed antioxidant activity.   
2.2.2. Electrochemistry of sulfur compounds. Similar electrochemical studies, both CV 
and DPV, were conducted on all the sulfur compounds in Figure 2.1 (except oxidized glutathione 
and 2-aminophenyl disulfide) in aqueous buffer at pH 7. Of the eight compounds investigated, 
only methionine and cystine show redox activity; methionine exhibits only a single irreversible 
anodic wave at -244 mV, and cystine exhibits a quasi-reversible redox couple with an E1/2 value 
of 580 mV (Table 2.4).  All cyclic voltammograms are provided in Figures 2.6, and DPV scans 
for methionine and cysteine are provided in Figure 2.7.  
The electrochemical results for these sulfur compounds do not correlate with previous 
DNA damage prevention gel electrophoresis studies (Table 2.5). Cystine exhibited the lowest 
IC50 value for prevention of CuI-mediated DNA damage (3.4 µM), and undergoes both oxidation 
and reduction. In contrast, methyl-cysteine, reduced glutathione, and oxidized glutathione 
prevent CuI-mediated DNA damage (IC50 values of 9.6, 12.4, and 6.6  µM, respectively), but 
exhibit no redox activity under these conditions. In addition, cystamine, 2,2’-dithiosalicylic acid, 
and 3-carboxypropyl disulfide have no redox activity and did not prevent CuI-mediated DNA 
damage. Similarly, both reduced  
Table 2.4. Electrochemical properties of sulfur compounds versus normal hydrogen electrode (NHE). 
Compound Epa (mV) Epc (mV) ΔE(mV) E1/2 (mV) 
Methionine -244a — — — 
Cystine 428a 617a 75a 580a 
Cysteine — — — — 
Methyl-cysteine — — — — 
Reduced glutathione — — — — 
Cystamine — — — — 
3-Carboxypropyl disulfide — — — — 
2,2’-Dithiosalicylic acid — — — — 
    a Potentials from DPV scans. 
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Figure 2.6. Cyclic voltammograms for A) reduced glutathione, B) methionine, C) methyl-cysteine, D) cystine, E) cystamine, F) 22’-dithiosalicylic acid, and G) 
3-carboxypropyl disulfide in MOPS buffer (10 mM, pH = 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Sulfur compounds (300 µM) were cycled 
between -1000 mV and 1000 mV vs. NHE, and a scan rate of 100 mV/s. 
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Figure 2.7. Differential pulse voltammograms of A) negative scan of methionine, B) positive scan of methionine, C) 
negative scan of cystine, and D) positive scan of cysteine. in MOPS buffer (10 mM, pH = 7.0) containing KNO3 (10 
mM) as a supporting electrolyte.  Sulfur compounds (300 µM) were scanned between -1000 mV and 1000 mV vs. 
NHE.   
 
and oxidized glutathione prevented FeII-mediated DNA damage, but exhibited no redox activity. 
Since no correlation exists between metal-mediated DNA damage prevention and the redox 
activities of these sulfur compounds, direct ROS scavenging is likely not a major antioxidant 
mechanism. 
2.2.3. Mass spectrometry evidence for metal coordination to selenium antioxidants.  
Electrospray ionization mass spectroscopy (ESI-MS) was used to examine CuI and FeII 
coordination of the selenium compounds in Figure 2.1. Most selenium compounds form 1:1 and 
1:2 (Cu:ligand) complexes with CuI, except for 2-aminophenyl diselenide, which forms only a 
1:1 complex, and selenocystamine, which shows no coordination (Table 2.2).  Both 












Table 2.5. IC50 values and mass spectrometry data for the tested sulfur compounds with CuI and FeII. 
Compound CuI IC50 (μM)a m/z (Da)b CuI : S compound FeII IC50 (μM)a m/z (Da)b FeII : S compound 
Oxidized glutathione 6.82 ± 0.03c 674.0 1:1 10,372 ± 2c 667.0 1:1 
Reduced glutathione 12.98 ± 0.01c 369.0, 674.0 1:1, 1:2 23 ± 8 % (10,000 µM)c 362.0  1:1 
Cystine 3.34 ± 0.07c 302.9 1:1 — 294.9 1:1 
Cysteine 7.6 ± 1.2c 302.9 1:2 — 175.9, 296.9, 415.2 1:1, 1:2, 1:3 
Methyl-cysteine 10.02 ± 0.02c 198.0 1:1 — 190.0, 325.0 1:1, 1:2 
Methionine 11.02  ± 0.02c 212.0 1:1 — — — 
Cystamine — — — — — — 
3-Carboxypropyl disulfide — — — 22 ± 6 % (1000 µM)c — — 
2-Aminophenyl disulfide  — — — — — — 
2,2’-Dithiosalicylic acid — — — — 360.9 1:1 
aIC50 is defined as the concentration at which the compound inhibited 50% of DNA damage. bESI mass spectrometry voltage of 5500 V. cValues from reference 20.
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methyl-selenocysteine also form complexes with CuI in a 1:3 ratio. 
 Because CuI typically adopts tetrahedral coordination geometry, it is probable that many 
of these selenium compounds bind CuI through the selenium atom, as well as through the amine 
nitrogen and/or carboxylate oxygen atom(s), similar to the geometry found for CuI methyl-
selenocystine and selenomethionine complexes.62 Since the majority of selenium compounds 
show metal coordination regardless of antioxidant activity, these results indicate that metal 
coordination is necessary but not sufficient for prevention of copper-mediated DNA damage. 
 Similar mass spectrometry studies with FeII reveal iron binding to all of tested selenium 
compounds (Table 2.3).  Both 1:1 and 1:2 stoichiometries (Fe:ligand) are observed for all 
compounds except 4-carboxyphenyl diselenide, which binds in only a 1:1 ratio, and 
selenocystamine, which binds in only a 1:3 ratio.  A 1:3 coordination ratio was also observed for 
selenomethionine, selenocystine, and methyl-selenocysteine.  Again, all the selenium compounds 
coordinate FeII, regardless of antioxidant activity, indicating that iron coordination is necessary 
but not sufficient for the observed DNA damage prevention.  Metal-antioxidant binding may 
prevent DNA damage by either altering the redox potential of the metal ion and preventing H2O2 
reduction to •OH or preventing CuII and FeIII reduction by cellular reductants.63  Alternatively, 
the metal-bound selenium antioxidant may be poised to efficiently scavenge •OH immediately 
upon formation at the metal center before it is released (targeted scavenging mechanism in 
Figure 2.3).   
2.2.4. Mass spectrometry evidence for metal coordination to sulfur antioxidants. Similar 
mass spectrometry studies were conducted on the sulfur compounds to determine their ability to 
coordinate CuI and FeII. Of the ten compounds investigated, five formed either 1:1 or 1:2 (CuI : 
ligand) complexes, and five exhibited no metal coordination under the conditions investigated 
60 
(Table 2.5). Due to the similar chemical properties of sulfur and selenium, these sulfur amino 
acid compounds will likely bind through the sulfur atom, in addition to the amine nitrogen or 
carboxylate oxygen to adopt the stable tetrahedral geometry typical for CuI.  Similar coordination 
to AgI has previously been observed with methyl-cysteine and methionine.64 Since all of the 
compounds inhibit CuI-mediated DNA damage also coordinate CuI, metal coordination is 
required for this antioxidant activity. The necessity for CuI coordination is further supported by 
the lack of DNA damage prevention by the sulfur compounds when [Cu(bipy)2]+ is used in place 
of unchelated CuI to damage DNA.  
 Similar studies with FeII revealed the ability of most sulfur amino acid compounds to 
coordinate FeII regardless of antioxidant activity. Molar ratios of 1:1 (Fe:ligand) are observed for 
cysteine, cystine, methyl-cysteine, 2,2’-dithiosalicylic acid, reduced glutathione, and oxidize 
glutathione (Table 2.5); and the thiols cystine and reduced glutathione also form 1:2 complexes. 
Methionine, cystamine, 2-aminophenyl disulfide, and 3-carboxypropyl disulfide show no FeII 
coordination under our experimental conditions. Of the sulfur compounds investigated, only 
oxidized glutathione prevented FeII-mediated DNA damage and exhibited FeII coordination. 
Since the majority of the sulfur compounds coordinate FeII but do not prevent iron-mediated 
DNA damage, these studies suggest that metal coordination alone is not sufficient for antioxidant 
activity of both sulfur and selenium compounds. 
 
2.3. Conclusions 
 Sulfur and selenium compounds exhibit the ability to prevent metal-mediated oxidative 
DNA damage with IC50 values between 3.34-1000 µM with CuI, and 75-10,300 µM with FeII. 
This ability to prevent DNA damage does not correlate with electrochemical properties of these 
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compounds, suggesting that typical ROS scavenging (Figure 2.2) is not the primary mechanism 
for prevention of metal-mediated DNA damage. Similarly, mass spectrometry studies revealed 
that the majority of sulfur and selenium compounds coordinate to CuI and FeII, regardless of 
antioxidant activity. Thus, metal binding alone is not sufficient to prevent metal-mediated 
oxidative DNA damage. These results illustrate the complex nature of sulfur and selenium 
antioxidant mechanisms and that further investigations must be completed to understand the 
chemical properties required for effective antioxidant activity. This knowledge will be invaluable 
for the future development of effective sulfur and selenium compounds and their testing in 
animal and human trials to treat the wide array of diseases linked to oxidative stress. 
 
2.4. Experimental and Methods     
  Materials.  Water was deionized (diH2O) using a Nano Pure DIamond Ultrapure H2O 
system (Barnstead International).  CuSO4 was purchased from Fisher.  Selenocystamine, and 
selenocystine were purchased from Sigma-Aldrich; 3-(N-morpholino)propanesulfonic acid 
(MOPS), selenomethionine, 2-aminophenyl diselenide, and methyl-selenocysteine were obtained 
from Acros. FeSO4 was purchased from Alfa Aesar.  2-Carboxyphenyl selenide, 2-
carboxyphenyl diselenide, and 4-carboxyphenyl diselenide were purchased from Focus.  
Ascorbic acid was obtained from J. T. Baker.  
Mass spectroscopy measurements.  Electrospray ionization (ESI) mass spectra were 
obtained using the QSTAR XL Hybrid MS/MS System (Applied Biosystems), with direct 
injection of the sample (flow rate = 0.05 mL/min) into the Turbo Ionspray ionization source. 
Samples were run under positive mode, with an ionspray voltage of 3000 V (except as otherwise 
indicated) in time-of-flight scan mode (error ± 2 m/z).  Mass spectrometry samples for a 1:3 
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metal to ligand ratio were prepared by combining CuSO4 (75 µM) and ascorbic acid (94 µM) in 
methanol/water, and allowed to stand for 3 min at room temperature. The selenium or sulfur 
compounds (225 µM) were added to the solution to obtain a final volume of 1 mL, and allowed 
to stand for 5 min at room temperature. A similar procedure was followed for studies with FeII, 
combining FeSO4 (75 µM) and the selenium/sulfur compounds (225 µM), for a 1:3 metal to 
ligand ratio.  All concentrations indicated are the final concentrations in a 1 µL volume.  All 
reported m/z peak envelopes matched theoretical peak envelopes for the assigned complexes.   
Electrochemical measurements.  Electrochemical experiments were conducted on CH 
Electrochemical Analyzer (CH Instruments, Inc.).  Cyclic voltammetry samples were prepared 
by dissolving the selenium or sulfur compounds (300 µM) in MOPS buffer (10 mM, pH 7) with 
KNO3 (10 mM) as a supporting electrolyte.  Solutions were degassed for 5 min with N2 before 
each experiment.  All CV experiments were conducted at 100 mV/s.  For differential pulse 
voltammetry experiments (Figures 2.8-2.11), a pulse amplitude of 0.080 V, a pulse width of 
0.100, a sample width of 0.045, and a pulse period of 0.200 were used. Samples of each 
compound were cycled between -1000 mV and 1000 mV (2APSe2 was cycled between -1200 
mV and 800 mV) using a glassy carbon working electrode, a Pt counter electrode, and a 
Ag/AgCl (197 mV vs. NHE65) reference electrode.   
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Figure 2.8. Differential pulse voltammetry scans for A) positive scan of selenomethionine, B) negative scan of selenomethionine, C) positive scan of 
selenocystamine, D) negative scan of selenocystamine, E) negative scan of methyl-selenocysteine, and D) positive scan of methyl-selenocysteine in MOPS 
buffer (10 mM, pH 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Selenium compounds (300 µM) were cycled between -1000 mV and 1000 mV  
vs NHE, using a pulse width of 0.100, a sample width of 0.045, and a pulse period of 0.200.   
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Figure 2.9. Differential pulse voltammetry scans for A) positive scan of selenocystine, B) negative scan of selenocystine, C) positive scan of 2-aminophenyl 
diselenide, D) negative scan of 2-aminophenyl diselenide, E) negative scan of 2-carboxyphenyl diselenide, and D) positive scan of 2-carboxyphenyl diselenide  
in MOPS buffer (10 mM, pH 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Selenium compounds (300 µM) were cycled between -1000 mV and 
1000 mV vs. NHE, using a pulse width of 0.100, a sample width of 0.045, and a pulse period of 0.200.  
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Figure 2.10. Differential pulse voltammetry scans for A) positive scan of 2-carboxylphenyl selenide, B) negative 
scan of 2-carboxyphenyl selenide, C) positive scan of 4-carboxyphenyl diselenide, and D) negative scan of 4-
carboxyphenyl diselenide in MOPS buffer (10 mM, pH 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  
Selenium compounds (300 µM) were cycled between -1000 mV and 1000 mV vs. NHE, using a pulse width of 












Figure 2.11. Differential pulse voltammetry scans for A) positive scan of 3,3’-diselenobispropionic acid, B) 
negative scan of 3,3’-diselenobispropionic acid, C) positive scan of 3,3’-selenobispropionic acid, and D) negative 
scan of 3’3’-selenobispropionic acid in MOPS buffer (10 mM, pH 7.0) containing KNO3 (10 mM) as a supporting 
electrolyte.  Selenium compounds (300 µM) were cycled between -1000 mV and 1000 mV vs. NHE, a pulse width 
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MULTIFUNCTIONAL SELONE AND THIONE ANTIOXIDANTS PREVENT DNA 




Multifunctional antioxidants are compounds that prevent oxidative damage by 
multiple mechanisms, including (but not limited to) scavenging of reactive oxygen 
species (ROS), redox signaling interference,1-3 and metal coordination (either by 
inhibiting ROS production, or by targeted ROS scavenging). Due to the increase in 
diseases caused by cellular oxidative stress such as Alzheimer’s, age-related macular 
degeneration, and amyotrophic lateral sclerosis, as well as the pharmaceutical prospect of 
developing compounds that target multiple pathways in which a disease is induced, 
recent interest in multifunctional antioxidants has risen over the past decade.4-6  
A major source of cellular ROS, including superoxide (O2•-), hydrogen peroxide 
(H2O2), and hydroxyl radical (•OH) is the cytochrome P450 enzyme in mitochondria.7,8 
To maintain low concentrations of these damaging ROS, mitochondria also have high 
concentrations of antioxidant enzymes such as superoxide dismutase (SOD) and 
glutathione peroxidase (GPx) to actively scavenge O2•- and H2O2, respectively. However, 
the primary source of damage is from •OH generation in the Fenton (Fe) or Fenton-like 
(Cu) reactions with H2O2 (Reaction 1).9 
FeII/CuI + H2O2 → FeIII/CuII + -OH + •OH             (1) 
Under physiological conditions, this process is controlled by the relatively low 
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concentrations of non-protein-bound FeII, CuI, and H2O2, but during oxidative stress, 
H2O2 concentrations rise sufficiently to damage iron-sulfur clusters. H2O2 oxidizes the 
proteins containing these clusters, releasing FeII and leading to an increased concentration 
of non-protein-bound FeII, which can then react with excessive H2O2 to generate •OH.10 
Additionally, non-protein bound CuI can interact with excess H2O2 to generate •OH.11,12  
This process can be particularly acute in patients suffering from hemochromatosis (iron 
overload) and Wilson’s disease (copper overload).13-15 Thus, excessive concentrations of 
iron and copper leads to increased oxidative damage, resulting in cell death and disease. 
In the past decade, the most widely examined class of multifunctional 
antioxidants has been polyphenols. Various studies have shown the ability of polyphenol 
antioxidants to directly scavenge ROS such as •OH and ONOO- 16-19 in addition to 
coordinating redox-active metals such as Fe, Cu, Cr, Co, and V.20-23 Chelation of redox-
active metals promotes cellular survival by preventing metal-mediated oxidative 
stress.24,25 Furthermore, polyphenols have been shown to bind to various proteins and 
enzymes linked to inflammation. Joven et al.26 reported that polyphenols in the extract of 
Hibiscus sabdariffa were effective peroxyl radical scavengers, inhibited the radical 
generating enzyme xanthine oxidase, and reduced the production of cytokines during the 
misregulation of tumor necrosis factor α (TNF-α) in endothelial cells. Studies by Patel et 
al.27 revealed that polymeric black tea polyphenols decreased cell proliferation induced 
by 12-O-tetradecanoylphorbol-13-acetate (used to chemically promote skin cancer) in 
mice by reducing the activation of signaling kinases and the inflammatory protein 
cyclooxygenase 2.   
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The vast majority of antioxidant research with sulfur and selenium compounds 
over the years has focused on their ability to scavenge ROS, leaving the role of metal 
coordination relatively unexplored. However, our group discovered that some sulfur- and 
selenium-containing antioxidants effectively prevent oxidative copper-mediated DNA 
damage by binding copper, but were substantially less effective at preventing FeII-
mediated DNA damage.28-30  
 N,N’-dimethylimidazole selone (dmise) and thione (dmit; Figure 5.1) were 
selected for the investigation of their DNA damage inhibition properties due to their 
structural similarities to ergothioneine and selenoneine. Ergothioneine (ESH; Figure 5.1), 
is a natural thione found in animals and plants, and has been found to prevent oxidative 
DNA damage, scavenge ROS, and promote anti-inflammatory effects in cells.31-35 The 
concentration of ergothioneine varies in the human body, ranging from 100-2000 µM in 
tissue,36 to 0.4-308 µM in blood serum.37 Its selenium analog, selenoneine, was only 
recently discovered in bluefin tuna (0.46 µM in blood)38 and in humans (up to 9 nM in 
blood),39 and it can scavenge 1-diphenyl-2-picrylhydrazyl (DPPH) radical.38,40 Both 










E = Se, Selenoeine
E = S, Ergothioneine (ESH)
N N R
E
E = Se, R = CH3: N,N'-Dimethylimidazoleselone (Dmise)
E = S, R = CH3: N,N'-Dimethylimidazoleselone (Dmit)
E = S, R = H: Methimazole
 
Figure 3.1. Selones and thiones discussed in Chapter 3. 
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Previous antioxidant studies with dmit and related compounds have shown their 
ability to prevent the peroxynitrite nitration of tyrosine by ROS scavenging.43,44 In 
contrast, studies of sulfur- and selenium-containing amino acids have established the 
importance of metal coordination for their antioxidant activity.28,29 Coordination 
chemistry studies with dmise and dmit have shown their ability to readily bind 
copper(I),45 suggesting that these compounds may potentially prevent DNA damage 
through metal coordination similar to the sulfur- and selenoamino acids. Thus, these two 
compounds showed promise as multifunctional antioxidants.  In this work, dmise and 
dmit were tested for their ability to inhibit copper-, iron-, and peroxynitrite- mediated 
DNA damage using gel electrophoresis methods,28-30,46 and their ability to coordinate FeII 
and CuI in aqueous solution was determined using mass spectrometry.  
 
3.2. Results and Discussion    
3.2.1. Prevention of copper(I)-mediated DNA damage. Plasmid DNA damage 
assays were used to determine the ability of dmise and dmit to prevent DNA single-strand 
backbone nicking caused by CuI/H2O2 (Reaction 1). These studies observe a biological 
endpoint (DNA damage) rather than relying on traditional methods for determining 
radical scavenging that use non-aqueous solutions, aromatic radical species that do not 
have the very short lifetime of hydroxyl radical, or highly acidic or basic pH.47-50  For our 
experiments, 6 µM CuI is combined with H2O2 (50 µM) to generate •OH. This copper 
concentration is within the reported concentration in human neuronal tissue of 1-1300 
µM.51,52 Figure 3.2 shows the results of a gel electrophoresis experiment to measure  
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Figure 3.2. Gel electrophoresis image of CuI-mediated DNA damage inhibition by N,N’-dimethylimidazole 
selone (dmise) in MOPS buffer (10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: 
plasmid DNA (p); lane 2: p + H2O2; lane 3: p + dmise  (2000 μM) + H2O2; lane 4: p + ascorbate (7.5 μM) + 
CuSO4 (6 μM) + H2O2 (50 µM); lanes 5-24: p + CuSO4 + ascorbate + increasing concentrations of dmise: 
0.2, 0.5, 0.75, 0.9, 1, 2.5, 5, 7.5, 10, 50, 100, 200, 300, 400, 600, 800, 1000, 1200, 1500, and 2000 μM 
dmise, respectively. 
dmise inhibition of CuI-mediated DNA damage. Lane 2 shows that combining plasmid 
DNA with H2O2 does not result in DNA damage (single-strand DNA nicking), nor does 
combining the highest concentration of dmise (2000 µM, lane 3) with H2O2, although 
combining H2O2, CuSO4 (6 µM), and ascorbic acid (7.5 µM) results in 85% DNA 
damage (lane 4).  As the concentration of dmise increases (lanes 5-26), the percentage of 
DNA damage decreases.  
A plot of the percent DNA damage inhibition versus the log concentration of 
dmise is shown in Figure 3.3. From this plot, the concentration of dmise required to 
inhibit 50% oxidative DNA damage (IC50 value), of approximately 240 µM was 
determined. Surprisingly, the DNA damage prevention activity of dmise did not fit a 
typical dose-response curve; an initial increase in activity is observed between 1-10 µM, 
and a second increase occurs between 300-3000 µM. The appearance of a second 
increase in activity has not been observed in previous studies of sulfur and selenium 
antioxidants using similar methods, and suggests that dmise inhibits DNA damage 
through more than one mechanism. Since CuI typically coordinates four monodentate 
ligands in a tetrahedral geometry, the approximate concentration range for DNA damage 
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prevention for these studies with 6 µM CuI is expected to occur around dmise 
concentrations of 6-24 µM. Since dmise inhibits 40% of DNA damage at 7.5 µM, at low 
concentrations, dmise may inhibit oxidative DNA damage through copper coordination. 
To confirm that metal coordination is essential for this antioxidant activity of 
dmise, further gel electrophoresis experiments were conducted using [Cu(bipy)2]+ (bipy = 
2,2’-bipyridine) in place of CuI.  In these experiments, the CuI ions are fully coordinated 
prior to the addition of dmise, preventing copper-dmise binding (all gel figures are 
provided at the end of the Experimental Methods section in Figures 3.5-3.9). Although  
 
Figure 3.3. Dose-response curves for dmise prevention of DNA damage by A) CuI/H2O2, [Cu(bipy)2]+/ 
H2O2, and peroxynitrite; and B) FeII/ H2O2, [Fe(EDTA)]2-/ H2O2, and peroxynitrite (ONOO–). 
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the IC50 value calculated from the best-fit dose-response curve for dmise inhibition of  
[Cu(bipy)2]+-mediated DNA damage (205.5 ± 0.4 µM; Table 3.1) is about the same 
concentration as the IC50 value for prevention of copper-mediated DNA damage, dmise 
activity in the [Cu(bipy)2]+ studies exhibits a typical dose-response curve, without the 
increased DNA damage inhibition observed at low concentrations in the CuI studies 
(Figure 3.3A). Because copper binding is prevented by using [Cu(bipy)2]+, this marked 
difference supports the conclusion that primary mode of DNA damage inhibition is due 
to metal coordination at low concentrations and that ROS scavenging may be a secondary 
mechanism at significantly higher concentrations.  
Dmit also prevents copper-mediated DNA damage, but with a high IC50 value of 
1550 ± 1 µM (Table 3.1; IC50 plots are provided at the end of the Experimental Methods 
section in Figure 3.10) with no activity observed within the expected range for tetrahedral 
copper coordination (6-24 µM). When [Cu(bipy)2]+ is used to damage DNA instead of 
CuI, the  IC50 value increases by more than two-fold to 3470 ± 5 µM, suggesting that dmit 
inhibits DNA damage by different mechanisms for labile and chelated CuI-mediated 
DNA damage. From their IC50 values, dmise is at least six time more effective than dmit 
at inhibiting CuI-mediated DNA damage. 
Table 3.1. IC50 values for dmise and dmit prevention of DNA damage and MALDI mass spectrometry 
results with metal coordination. 
IC50 Value  Dmise (µM) M:L Ratio (m/z, Da) Dmit (μM) M:L Ratio (m/z, Da) 
CuI  ~240a 1:1 (242) 1550 ± 3 1:2 (320)c 
FeII  3.2 ± 0.9 1:3 (301; [FeII(dmise)3(H2O)]2+) 
1:5 (480; [FeII(dmise)5(H2O)]2+) 
89.1 ± 0.2 1:3 (220)c 
1:4 (284)b 
[Fe(EDTA)]2- 34.0 ± 0.1  353.2 ± 0.4  
[Cu(bipy)2]+ 205.5 ± 0.4  3470 ± 5  
ONOO- 155.2 ± 0.1  171.4 ± 0.2  
aEstimated value. bCoordination observed only by ESI mass spectrometry. cCoordination observed inboth 
ESI and MALDI studies. 
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3.2.2. Prevention of iron(II)-mediated DNA damage. Gel electrophoresis studies 
were also conducted on dmise and dmit to determine their ability to prevent iron-
mediated DNA damage.  All iron studies were conducted at pH 6.0 in to maintain FeII 
solubility.53 These FeII-mediated DNA damage prevention studies were conducted with 2 
µM FeSO4, a concentration at the low end of the intracellular labile iron concentration (1- 
30 µM).54-56 Figure 3.4 shows the results of a gel electrophoresis experiment with dmise 
under these conditions. Lane 2 shows that addition of H2O2 alone (50 µM) to plasmid  
DNA results in no DNA damage (nicking), nor does the highest concentration of dmise 
(6000 µM, lane 3) combined with H2O2, but combining H2O2 and FeSO4 (2 µM) results 
in 85 % DNA damage (lane 4).  As the concentration of dmise increases (lanes 5-26), the 
percentage of DNA damage decreases.  Fitting the dose-response curve for these data 
gives an IC50 value of 3.2 ± 0.9 μM for dmise inhibition of FeII-mediated DNA damage 
(Figure 3.3B).  This is especially significant, since dmise is the first selenium compound 
to show greater efficacy at preventing iron-mediated DNA damage than copper-mediated 
damage. 
 Once again, the iron-mediated DNA damage prevention ability of dmise did not 
fit a typical dose-response curve; an initial increase in activity is observed between 1-50 
 
Figure 3.4. Gel electrophoresis image of FeII-mediated DNA damage inhibition by N,N’-dimethylimidazole 
selone (Dmise) in MES buffer (10 mM, pH 6). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid 
DNA (p); lane 2: p + H2O2; lane 3: p + dmise  (6000 μM) + H2O2; lane 4: p + FeSO4 (2 μM) + H2O2 (50 
µM); lanes 5-24: p + FeSO4 + increasing concentrations of dmise: 0.01, 0.2, 0.5, 0.75, 1, 2.5, 5, 7.5, 10, 50, 
100, 200, 300, 400, 600, 800, 1000, 1200, 1500, 2000, 4000, and 6000 μM, respectively. 
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µM, with a second increase between 600-6000 µM. This second increase in activity again 
suggests that dmise inhibits DNA damage through two distinct mechanisms. The first 
increase is observed in the range expected for possible octahedral dmise-iron binding (up 
to 12 µM for 2 µM FeII with 63 % DNA damage inhibition at 10 µM dmise), indicating 
that dmise may inhibit oxidative DNA damage by iron coordination at low 
concentrations. In contrast, sulfur and selenoamino acids exhibit little or no ability to 
prevent FeII-mediated DNA damage. Only methyl-selenocysteine, selenocystamine, and 
reduced and oxidized glutathione inhibited FeII-mediated DNA damage with IC50 values 
ranging from 120-10,000 µM.28-30 Thus, dmise compounds is almost 40 times more 
effective at preventing FeII-mediated DNA damage than the most effective selenoamino 
acid, methylselenocysteine. 
To confirm that iron coordination is essential for the observed antioxidant activity 
of dmise, further gel electrophoresis experiments were conducted using [Fe(EDTA)]2- 
(EDTA = ethylenediaminetetraacetic acid) in place of FeII. In these experiments, FeII is 
fully chelated prior to dmise addition, thus preventing dmise-iron coordination. Dmise 
prevents 50 % DNA damage by [Fe(EDTA)]2-/H2O2 at 34.0 ± 0.1 µM, approximately 10 
times higher than dmise with unchelated FeII (Figure 3.3B). This difference suggests that 
the antioxidant activity at low concentrations of dmise is due to FeII coordination and 
ROS scavenging is a likely secondary mechanism at significantly higher concentrations.  
Using the same DNA damage assays, dmit prevents iron-mediated DNA damage 
with an IC50 value of 89.1 µM and [Fe(EDTA)]2--mediated DNA damage at four times 
this concentration (IC50 = 353 µM). In the unchelated FeII studies, 40 % of DNA damage 
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is prevented at 10 µM dmit, well within the 12 µM limit for octahedral FeII binding. 
Thus, these results suggest that dmit, while a less effective antioxidant than dmise, also 
prevents metal-mediated DNA damage through multiple antioxidant mechanisms. At 
more biologically relevant, lower concentrations, metal coordination is critical to activity, 
and at high concentrations ROS scavenging is more prevalent.  
 Akanmu et al. reported that ESH inhibits 100% of CuI-mediated deoxyribose 
degradation at a concentration of 1 mM,57 well within biological concentrations (1-3 
mM).58,59 Surprisingly, both dmise and dmit inhibit FeII-mediated DNA damage at 
substantially lower concentrations than CuI-mediated DNA damage, in contrast to other 
sulfur- and selenium-containing antioxidants.28-30 The effectiveness of these two 
compounds at preventing FeII-mediated DNA damage is unexpected, since CuI is a soft 
Lewis acid and should favor binding the soft sulfur and selenium atoms more than 
borderline FeII.   
3.2.3. Significance of metal coordination. Mass spectrometry studies in water 
were conducted to determine the FeII and CuI coordination ability of dmise and dmit 
(Table 3.1). Dmise coordinates FeII in both 1:3 and 1:5 Fe:dmise molar ratios, whereas 
dmit shows coordination only in a 1:3 Fe:dmit ratio. Similar studies with CuI revealed 
signals for a 1:1 complex with CuI and dmise and a 1:2 complex with dmit. Thus, both 
these antioxidants are capable of binding iron and copper in aqueous solution, with higher 
coordination numbers for the potentially octahedral FeII compared to the potentially 
tetrahedral CuI. In addition, Stadelman et al.60 have reported that dmise and dmit form 
isolable complexes with iron(II) in 1:2 and 1:4 molar ratios.  
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3.2.4. Prevention of peroxynitrite-mediated DNA damage. To determine the 
extent to which dmise and dmit prevent DNA damage by ROS scavenging, gel 
electrophoresis studies with peroxynitrite were performed. Peroxynitrite (ONOO-) anion 
is produced in vivo by the reaction of nitric oxide with superoxide61,62 and can directly 
damage DNA.63,64 Around pH 7, peroxynitrite is protonated to form peroxynitrous acid 
that decomposes into nitrogen dioxide (NO2•) and •OH with a half-life of about 1 s.65  
Thus, peroxynitrite causes hydroxyl radical damage to DNA without the presence of 
metal ions. Peroxynitrite DNA damage studies were performed similarly to the metal-
based studies, but with the addition of peroxynitrite (1450 µM) at pH 6.8 (10 mM MOPS 
buffer) for stability.   
Dmise and dmit effectively prevent peroxynitrite-mediated DNA damage with 
IC50 values of 155.2 and 171.4 µM, respectively. Since these studies with ONOO- are 
conducted in the absence of metals, the ability of dmise and dmit to prevent this oxidative 
DNA damage only at higher micromolar concentrations suggests that ROS scavenging is 
not the primary antioxidant mechanism at lower concentrations. Studies by Bhabak and 
Mugesh have reported that dmise has a low IC50 value (12.2 μM) for the prevention of 
tyrosine nitration by peroxynitrite, supporting the fact that these compounds possess the 
ability to act as ROS scavengers,43 but these IC50 values cannot be realistically compared 






These results demonstrate the first example of multifunctional sulfur and selenium 
compounds that prevent oxidative DNA damage through copper coordination, iron 
coordination, and ROS scavenging. Dmit DNA damage prevention activity falls within 
the concentration ranges found for the biological thiones ergothioneine (0.4-308 µM in 
human blood serum, and between 100-2000 µM in human tissue)36,66 and methimazole 
(4-13 µM in blood of hyperthyroid patients).67,68 Human plasma concentrations of 
selenium are typically about 1.5µM, and selenium supplementation studies have reported 
non-toxic concentrations up to ~10 µM,69,70 within the activity window for dmise 
prevention of iron-mediated DNA damage.  
These multifunctional antioxidants prevent DNA damage by two separate 
mechanisms. At low concentrations, copper or iron coordination is the primary 
mechanism at very low micromolar concentrations, whereas ROS scavenging occurs at 
concentrations above 100 µM, as confirmed by peroxynitrite-mediated DNA damage 
studies.  Surprisingly, both compounds exhibited more potent prevention of FeII-mediated 
than CuI-mediated DNA damage, an ability not previously reported for sulfur or selenium 
antioxidants. Thus, these results have opened the doors for the development of future 
selone- and thione-derived compounds that can be tuned for antioxidant activity by 
targeted coordination to specific redox-active metals and prevention of disease-causing 




3.4. Experimental Methods 
Materials. A NANOpure Diamond water deionization system (Barnstead 
International) was used to prepare deionized H2O. NaCl (99.999%) and FeSO4 · 7H2O 
were purchased from Alfa Aesar; CuSO4 · 5H2O, yeast extract, tryptone (peptone), and 
30% H2O2 were purchased from Fisher. MOPS and MES were obtained from Alfa Aesar. 
Ethanol (200 proof) and ascorbic acid were from Acros Organics. Dmise and dmit were 
prepared according to a previous report.71 Glucose and ampicillin were from EMD.  
Ethidium bromide and agar were from Lancaster.  TRIS hydrochloride and 
microcentrifuge tubes were from VWR.  Metal-free microcentrifuge tubes were prepared 
by washing the tubes in 1 M HCl for ~1 h, and then triple rinsing three times with 
deionized H2O.   
Plasmid transfection, amplification, and purification.  Plasmid DNA (pBSSK) 
was purified from DH1 E. coli competent cells using a 5 Prime PerfectPrepTM Spin Kit 
(Fisher).  Tris-EDTA buffer (pH 8.01) was used to elute the plasmid from the spin 
columns.  Plasmid DNA was dialyzed against 130 mM NaCl for 24 h at 4 °C to ensure all 
Tris-EDTA buffer and metal contaminates were removed, and its concentration was 
determined through the use of UV-vis spectroscopy at a wavelength of 260 nm.  
Absorbance ratios of A250/A260 ≤ 0.95 and A260/A280 ≥ 1.8 were determined via UV-vis 
for DNA used in all experiments.  Plasmid purity was determined through digestion of 
plasmid (0.1 pmol) with Sac 1 and KpN1 in a mixture of NEB buffer and bovine serum 
albumin was conducted at 37 °C for 90 minutes.  Comparison to an undigested plasmid 
sample and a 1 kb molecular weight marker was conducted by gel electrophoresis. 
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DNA damage gel electrophoresis experiments. Deionized H2O, MOPS buffer (10 
mM, pH 7.0), NaCl (130 mM), ethanol (10 mM), CuSO4 · 5H2O (6 µM), ascorbate (7.5 
µM), and the indicated concentrations of sulfur or selenium compounds were combined 
in a microcentrifuge tube and allowed to stand for 5 min at room temperature. Plasmid 
(pBSSK, 0.1 pmol in 130 mmol NaCl solution) was then added to the reaction mixture 
and allowed to stand for 5 min at room temperature. Hydrogen peroxide (50 μM) was 
then added and allowed to react at room temperature for 30 min.  EDTA (50 μM) was 
added after 30 min to quench the reaction.  For Fe2+ DNA damage experiments, FeSO4 ∙ 
7H2O (2 µM) and MES (10 mM, pH 6.0) were used in place of CuSO4, ascorbic acid, 
MOPS buffer. All concentrations are final concentrations in a 10 μL volume.  All 
samples were loaded into a 1% agarose gel in TAE running buffer; damaged and 
undamaged plasmid was separated by electrophoresis (140 V for 30 min).  Gels were 
then stained using ethidium bromide and imaged under UV light.  The amounts of nicked 
(damaged) and circular (undamaged) DNA were quantified using UViProMW (Jencons 
Scientific Inc., 2007).  The intensity of the circular plasmid band was multiplied by 1.24, 
due to the lesser binding ability of ethidium bromide to supercoiled plasmid.72,73 
Experiments using [Cu(bipy)2]2+ (50 µM) or [Fe(EDTA)]2- (400 µM) in the place of Cu2+ 
and Fe2+ were conducted using a similar procedure. For gels with [Cu(bipy)2]2+, 62.5 µM 
ascorbic acid was also added. Tabular data for all metal-containing gel experiments can 
be found at the end of this section in Tables 5.2-5.9. 
Calculating percent inhibition of DNA damage. The formula 1-[%N-%B]*100 
was used to calculate percent DNA damage inhibition; %N = percent of nicked DNA in 
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lanes 6 and higher, and %B = the percent of nicked DNA in the Cu+/H2O2 or Fe2+/H2O2 
control lane. All percentages were corrected for residual nicked DNA (lane 2) prior to 
calculation. Results were obtained from an average of three trials, with indicated standard 
deviations. 
Synthesis of peroxynitrite anion (ONOO-). Synthesis of peroxynitrite followed the 
method of Keith and Powell,74 resulting in the bright yellow-colored ONOO-. The 
concentration of ONOO- was calculated from its absorbance at 302 nm, using an 
extinction coefficient of 1670 cm-1 mol-1 dm3.75 Samples of ONOO- were stored at -80 °C 
for up to two weeks before use. 
Gel electrophoresis experiments with ONOO-. Selenium or sulfur compounds 
were combined with ethanol (10 mM 100%), NaCl (130 mM), MOPS buffer (10 mM, pH 
6.8), and plasmid DNA (pBSSK, 0.1 mmol in 130 mM NaCl) in an acid-washed 
microcentrifuge tube and allowed to stand for 5 min. Peroxynitrite (1450 µM) was added 
at 4°C, and the reaction was allowed to stand for an additional 5 min at room 
temperature. All concentrations indicated are the final concentrations in a 10 µL volume. 
After the 5 min incubation with ONOO-, loading dye was added to obtain a final volume 
of 12 µL. All samples were loaded into a 1% agarose gel in TAE running buffer, and gel 
electrophoresis was performed as previously stated. Data for all peroxynitrite gels are 
presented at the end of this section in Tables 5.10 and 5.11. 
Mass spectrometry studies. MALDI mass spectrometry experiments were 
performed using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-
tert-butylphenyl)-2-methyl-2-propenyldiene (250.34 m/z) as the matrix. Stock solutions 
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of FeSO4 (900 µM), CuSO4 (900 µM), ascorbic acid (900 µM), dmise (900, 3600, and 
5400 µM), and dmit (900, 3600, and 5400 µM) were prepared in deionized H2O. Mass 
spectrometry samples for 1:4 metal-to-ligand ratios were prepared by combining CuSO4 
(300 µL, 900 µM) and ascorbic acid (300 µL, 900 µM) solutions and allowing the 
samples to stand for 5 min at room temperature. Dmise or dmit (300 µL or 3600 µM) was 
then added to the solution, and allowed to stand for an additional 5 min. A similar 
procedure was followed for studies with FeII, by combining FeSO4 (300 µL, 900 µM in 
deionized H2O) and either dmise or dmit (300 µL, 5400 µM in deionized H2O) for 1:1 
and 1:6 metal-to-ligand ratios. ESI-MS studies were conducted on a Waters Alliance 
2695 LC / Waters Micromass ZQ Mass Spectrometer by Emily Kurfman and Prof. 
Sandra K. Wheeler (Furman University). Experiments were conducted in diH2O and at 
the same concentration as MALDI studies.  All concentrations indicated are final 
concentrations in 900 µL volumes. All reported m/z peak envelopes matched theoretical 
peak envelopes for the assigned complexes. 
 
 
Figure 3.5. Gel electrophoresis image of CuI-mediated DNA damage inhibition by N,N’-dimethylimidazole 
thione (dmit) in MOPS buffer (10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid 
DNA (p); lane 2: p + H2O2; lane 3: p + dmit (6000 μM) + H2O2; lane 4: p + ascorbate (AA, 7.5 μM) + 
CuSO4 (6 μM) + H2O2 (50 µM); lanes 5-16: p + CuSO4 + AA + increasing concentration of dmit: 0.1, 1, 




Figure 3.6. Gel electrophoresis images of [Cu(bipy)2]+-mediated DNA damage inhibition by A) N,N’-
dimethylimidazole selone (dmise) and B) N,N’-dimethylimidazole thione (dmit) in MOPS buffer (10 mM, 
pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + 
S/Se compound (dmise = 1200; dmit = 6000 μM) + H2O2; lane 4: p + ascorbate (63 µM) + [Cu(bipy)2]+ (50 
μM) + H2O2 (50 µM); lanes 5+: p + FeSO4 + increasing concentrations of compound: A) 1, 10, 50, 100, 
200, 500, 1200, 1500, and 2000 μM dmise, respectively, and B) 0.1, 1, 10, 100,  1000, 1500, 2000, 2500, 




Figure 3.7. Gel electrophoresis images of FeII-mediated DNA damage inhibition by N,N’-
dimethylimidazole thione (dmit) in MES buffer (10 mM, pH 6). Lane: MW = 1 kb molecular weight 
marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + dmit (6000 μM) + H2O2; lane 4: p + FeSO4 
(2 µM) + H2O2 (50 µM); lanes 5-15: p + FeSO4 + increasing concentrations of dmit: 0.1, 1, 10, 100, 250, 





Figure 3.8. Gel electrophoresis images of [Fe(EDTA)]2--mediated DNA damage inhibition by A) N,N’-
dimethylimidazole selone (dmise) and B) N,N’-dimethylimidazole thione (dmit) in MES buffer (10 mM, 
pH 6). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + 
S/Se compound (dmise = 6000 or dmit = 2000 μM) + H2O2; lane 4: p + [Fe(EDTA)]2- (400 µM) + H2O2 (50 
µM); lanes 5+: p + [Fe(EDTA)]2- + increasing concentrations of compound: A) 1, 10, 50, 100, 200, 500, 
1200, 1500, 2000, 4000, and 6000 μM dmise, respectively, and B) 0.1, 1, 10, 100,  250,  500, 750, 1000, 
1500, and 2000 μM dmit, respectively.   
 
 
Figure 3.9. Gel electrophoresis images of peroxynitrite (ONOO-)-mediated DNA damage inhibition by A) 
N,N’-dimethylimidazole selone (dmise) and B) N,N’-dimethylimidazole thione (dmit) in MOPS buffer (10 
mM, pH 6.8). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + NaNO2; 
lane 3: p + KNO3; lane 4: p + S/Se compound (1000 μM); lane 5: p + ONOO- (1450 µM); lanes 6-14: p + 
ONOO- + increasing concentrations of compounds: 0.01, 0.1, 1, 10, 100, 250, 500, 1000 and 2000 μM, 
respectively.   
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Table 3.2. Gel electrophoresis results for N,N’-dimethylimidazole selone (dmise) DNA damage assays with 
6 µM CuI and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition P Value 
1: plasmid DNA (p) 0 97.30 ± 0.79 2.70 ± 0.79 – – 
2: p + H2O2 0 97.10 ± 1.40 2.9 ± 1.40 – – 
3: p + H2O2 + dmise 2000 98.90 ± 0.96 1.10 ± 0.96 – – 
4: p + CuI  + H2O2 0 17.69 ± 6.64 82.31 ± 6.64 0 – 
5: p + CuI  + H2O2 + dmise  0.25 16.07 ± 1.19 83.92 ± 1.19 -1.44 ± 1.48 0.233 
6 0.5 1.29 ± 0.70 98.71 ± 0.70 -0.59 ± 0.74 0.301 
7 0.75 0.47 ± 0.44 99.53 ± 0.44 -1.15 ± 0.46 0.049 
8 0.9 21.59 ± 4.64 78.41 ± 4.64 9.90 ± 5.44 0.088 
9 1 13.73 ± 0.90 86.27 ± 0.90 12.55 ± 0.93 0.002 
10 2.5 18.59 ± 1.72 81.41 ± 1.72 17.57 ± 1.77 0.003 
11 5 39.18 ± 3.52 60.82 ± 3.52 38.94 ± 3.54 0.003 
12 7.5 40.46 ± 2.01 59.54 ± 2.01 40.17 ± 2.08 < 0.001 
13 10 49.38 ± 5.40 50.62 ± 5.40 39.95 ± 1.48 < 0.001 
14 50 51.43 ± 1.02 48.56 ± 1.02 44.32 ± 0.83 < 0.001 
15 100 46.25 ± 2.01 53.74 ± 2.01 42.65 ± 2.28 < 0.001 
16 200 50.77 ± 0.96 49.22 ± 0.96 47.78 ± 1.09 < 0.001 
17 300 59.80 ± 2.44 40.20 ± 2.44 51.97 ± 2.16 < 0.001 
18 400 56.55 ± 1.06 43.44 ± 1.06 54.31 ± 1.20 < 0.001 
19 600 72.35 ± 0.98 27.64 ± 0.98 72.20 ± 1.11 < 0.001 
20 800 88.10 ± 1.29 11.90 ± 1.29 88.20 ± 1.82 < 0.001 
21 1000 88.64 ± 1.71 11.35 ± 1.71 90.64 ± 1.93 < 0.001 
22 1200 95.22 ± 1.30 4.78 ± 1.30 97.23 ± 3.58 < 0.001 
23 1500 96.21 ± 1.01 3.79 ± 1.0 98.51 ± 0.93 < 0.001 
24 2000 98.01 ± 0.86 1.99 ± 0.86 100.77 ± 3.08 < 0.001 










Table 3.3. Gel electrophoresis results for N,N’-dimethylimidazole thione (dmit) DNA damage assays with 
6 µM CuI and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.50 ± 0.10 4.50 ± 0.10 – – 
2: p + H2O2 0 95.00 ± 0.20 5.00 ± 0.20 – – 
3: p + H2O2 + dmit 6000 98.90 ± 0.96 1.10 ± 0.96 – – 
4: p + CuI + H2O2 0 3.42 ± 2.85 96.58 ± 2.85 0 – 
5: p + CuI + H2O2 + dmit 0.1 6.47 ± 0.76 93.53 ± 0.76 3.10 ± 3.61 0.275 
6 1 4.19 ± 1.29 95.81 ± 1.29 0.73 ± 3.08 0.721 
7 10 4.52 ± 2.90 95.48 ± 2.90 1.10 ± 3.90 0.673 
8 50 14.37 ± 3.91 85.63 ± 3.91 5.34 ± 4.53 0.178 
9 100 9.66 ± 6.38 90.34 ± 6.38 6.57 ± 4.85 0.143 
10 250 20.15 ± 1.22 79.85 ± 1.22 12.03 ± 1.41 0.005 
11 500 10.51 ± 1.85 89.48 ± 1.85 10.51 ± 1.85 0.010 
12 1000 14.81 ± 2.31 85.18 ± 2.31 14.81 ± 2.31 0.008 
13 1500 46.78 ± 0.83 53.21 ± 0.83 46.78 ± 0.83 < 0.001 
14 2000 81.74 ± 1.60 18.25 ± 1.60 81.74 ± 1.60 < 0.001 
15 4000 99.91 ± 0.03 0.08 ± 0.03 99.91 ± 0.03 < 0.001 
16 6000 99.88 ± 0.07 0.11 ± 0.07 99.88 ± 0.07 < 0.001 
aData are reported as the average of three trials with calculated standard deviations. 
 
Table 3.4. Gel electrophoresis results for N,N’-dimethylimidazole selone (dmise) DNA damage assays with 





Supercoiled % Nicked 
% Damage 
Inhibition p value 
1: plasmid DNA (p) 0 97.75 ± 0.84 2.25 ± 0.84 – – 
2: p + H2O2 0 97.20 ± 1.53 2.80 ± 1.53 – – 
3: p + H2O2 + dmise 2000 96.71 ± 0.70 3.29 ±0.70 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 0.10 ± 0.21 99.86 ± 0.21 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + dmise 1 0.26 ± 0.14 99.74 ± 0.14 0.00 ± 0.06 1.000 
6 10 3.26 ± 1.13 96.74 ± 1.13 3.32 ± 1.16 0.038 
7 50 17.77 ± 1.27 82.22 ± 1.27 18.54 ± 1.33 0.002 
8 100 37.02 ± 1.61 62.98 ± 1.61 38.11 ± 1.65 < 0.001 
9 200 40.11 ± 3.00 59.88 ± 3.00 41.90 ± 3.14 < 0.001 
10 500 71.03 ± 2.28 28.97 ± 2.28 73.15 ± 2.35 < 0.001 
11 1200 88.14 ± 1.61 11.86 ± 1.61 90.77 ± 1.66 < 0.001 
12 1500 90.37 ± 1.26 9.62 ± 1.26 94.45 ± 1.32 < 0.001 
13 2000 93.24 ± 0.94 6.75 ± 0.94 97.45 ± 0.99 < 0.001 





Table 3.5. Gel electrophoresis results for N,N’-dimethylimidazole thione (dmit) DNA damage assays with 
50 µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.94 ± 0.62 1.06 ± 0.62 – – 
2: p + H2O2 0 98.66 ± 0.47 1.34 ± 0.47 – – 
3: p + dmit + H2O2 6000 96.71 ± 0.70 3.29 ± 0.70 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 0.28 ± 0.03 99.72 ± 0.03 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + dmit 0.1 0.36 ± 0.33 99.64 ± 0.33 0.07 ± 0.34 0.755 
6 1 0.31 ± 0.03 99.69 ± 0.03 0.03 ± 0.01 0.035 
7 10 0.27 ± 0.12 99.73 ± 0.12 -0.01 ± 0.09 0.865 
8 100 0.21 ± 0.15 99.79 ± 0.15 -0.07 ± 0.13 0.449 
9 1000 8.55 ± 0.45 91.45 ± 0.45 8.35 ± 0.45 < 0.001 
10 1500 31.52 ± 2.41 68.48 ± 2.41 33.35 ± 5.01 0.007 
11 2000 36.21 ± 2.93 67.79 ± 2.93 38.83 ± 2.17 0.001 
12 2500 36.37 ± 8.52 63.63 ± 8.52 42.07 ± 1.06 < 0.001 
13 3000 42.95 ± 1.07 57.05 ± 1.07 44.28 ± 0.88 < 0.001 
14 4000 53.65 ± 0.63 46.35 ± 0.63 55.99 ± 0.66 < 0.001 
15 6000 61.13 ± 2.96 38.87 ± 2.96 60.04 ± 1.11 < 0.001 































Table 3.6. Gel electrophoresis results for N,N’-dimethylimidazole selone (dmise) DNA damage assays with 





Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.03 ± 1.10 1.97 ± 1.10 – – 
2: p + H2O2 0 95.48 ± 0.49 4.52 ± 0.49 – – 
3: p + dmise + H2O2 6000 98.21 ± 1.81 1.79 ± 1.81 – – 
4: p + FeII + H2O2 0 4.40 ± 1.35 95.60 ± 1.35 0 – 
5: p + FeII + H2O2 + dmise 0.01 4.91 ± 3.24 95.09 ± 3.24 -1.78 ± 1.48 0.172 
6 0.2 5.85 ± 4.31 94.15 ± 4.31 -0.73 ± 3.01 0.715 
7 0.5 3.84 ± 0.88 96.15 ± 0.88 -2.00 ± 0.96 0.069 
8 0.75 6.55 ± 0.54 93.44 ± 0.54 0.94 ± 0.59 0.110 
9 1 9.05 ± 1.82 90.94 ± 1.82 3.64 ± 1.99 0.087 
10 2.5 41.56 ± 4.15 58.43 ± 4.15 39.03 ± 4.52 0.004 
11 5 67.86 ± 1.56 32.13 ± 1.56 67.64 ± 1.70 < 0.001 
12 7.5 74.03 ± 3.14 25.96 ± 3.14 74.46 ± 3.37 < 0.001 
13 10 62.86 ± 3.72 37.14 ± 3.72 63.08 ±2.12 < 0.001 
14 50 76.99 ± 1.83 23.01 ± 1.83 74.38 ± 2.44 < 0.001 
15 100 76.47 ± 0.66 23.53 ± 0.66 73.69 ± 3.47 < 0.001 
16 200 71.41 ± 1.86 28.58 ± 1.86 72.12 ± 1.96 < 0.001 
17 300 73.89 ± 1.74 26.10 ± 1.74 74.70 ± 1.84 < 0.001 
18 400 76.49 ± 2.17 23.50 ± 2.17 77.48 ± 2.29 < 0.001 
19 600 76.83 ± 0.82 23.17 ± 0.82 74.14 ± 3.33 < 0.001 
20 800 83.13 ± 4.27 16.86 ± 4.27 84.48 ± 4.50 < 0.001 
21 1000 84.21 ± 2.88 15.78 ± 2.88 86.04 ± 3.48 < 0.001 
22 1200 88.08 ± 1.10 11.92 ± 1.10 87.59 ± 4.33 < 0.001 
23 1500 87.35 ± 2.04 12.65 ± 2.04 86.91 ± 0.94 < 0.001 
24 2000 92.51 ± 1.96 7.48 ± 1.96 96.09 ± 2.38 < 0.001 
25 4000 94.66 ± 0.20 5.33 ± 0.20 96.56 ± 0.21 < 0.001 
26 6000 98.54 ± 1.28 1.45 ± 1.28 99.04 ± 1.58 < 0.001 










Table 3.7. Gel electrophoresis results for N,N’-dimethylimidazole thione (dmit) DNA damage assays with 
2 µM FeII and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.72 ± 1.07 1.28 ± 1.07 – – 
2: p + H2O2 0 98.91 ± 1.10 1.09 ± 1.10 – – 
3: p + dmit + H2O2 6000 98.09 ± 1.76 1.91 ± 1.76 – – 
4: p + FeII + H2O2 0 20.01 ± 0.90 79.98 ± 0.90 0 – 
5: p + FeII + H2O2 + dmit 0.1 33.73 ± 5.48 66.26 ± 5.48 5.21 ± 0.89 0.010 
6 1 38.98 ± 1.47 61.01 ± 1.47 24.67 ± 1.83 0.002 
7 10 51.29 ± 3.92 48.70 ± 3.92 40.03 ± 4.89 0.005 
8 100 60.99 ± 2.71 39.00 ± 2.71 52.12 ± 3.39 0.001 
9 250 60.45 ± 1.48 39.54 ± 1.48 51.30 ± 1.87 < 0.001 
10 500 72.59 ± 0.86 27.40 ± 0.86 66.64 ± 1.08 < 0.001 
11 1000 84.86 ± 1.67 15.13 ± 1.67 81.90 ± 2.09 < 0.001 
12 1500 81.85 ± 1.53 18.14 ± 1.53 78.34 ± 1.94 < 0.001 
13 2000 87.39 ± 3.33 12.60 ± 3.33 85.34 ± 4.21 < 0.001 
14 4000 89.19 ± 0.71 10.80 ± 0.71 87.74 ± 0.92 < 0.001 
15 6000 94.04 ± 1.08 5.95 ± 1.08 93.97 ± 1.39 < 0.001 
aData are reported as the average of three trials with calculated standard deviations. 
 
Table 3.8. Gel electrophoresis results for N,N’-dimethylimidazole selone (dmise) DNA damage assays with 





Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 
  
– – 
2: p + H2O2 0 
  
– – 
3: p + dmise + H2O2 6000 97.42 ± 2.00 2.58 ± 2.00 – – 
4: p + Fe(EDTA)2- + H2O2 0 16.08 ± 1.98 83.92 ± 1.98 0 – 
5: p + Fe(EDTA)2- + H2O2 + dmise 1 20.13 ± 0.52 79.87 ± 0.52 4.93 ± 2.57 0.080 
6 10 34.29 ± 4.43 65.71 ± 4.43 22.38 ± 3.90 0.010 
7 50 78.56 ± 1.47 21.44 ± 1.47 79.38 ± 1.73 < 0.001 
8 100 78.80 ± 2.09 21.20 ± 2.09 77.07 ± 2.60 < 0.001 
9 200 83.21 ± 3.52 16.79 ± 3.52 82.45 ±3.38 < 0.001 
10 500 86.41 ± 3.43 13.59 ± 3.43 86.40 ± 2.51 < 0.001 
11 1200 85.54 ± 1.95 14.46 ± 1.95 85.37 ± 2.47 < 0.001 
12 1500 86.66 ± 3.80 13.34 ± 3.80 86.69 ± 2.77 < 0.001 
13 2000 88.52 ± 1.72 11.48 ± 1.72 89.09 ± 1.59 < 0.001 
14 4000 94.41 ± 3.10 5.58 ± 3.10 93.87 ± 3.63 < 0.001 
15 6000 96.28 ± 1.45 3.71 ± 1.45 96.06 ± 1.69 < 0.001 




Table 3.9. Gel electrophoresis results for N,N’-dimethylimidazole thione (dmit) DNA damage assays with 
400 µM [Fe(EDTA)]2- and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 99.28 ± 0.63 0.71 ± 0.63 – – 
2: p + H2O2 0 98.66 ± 0.74 1.33 ± 0.74 – – 
3: p + dmit + H2O2 2000 99.40 ± 0.99 0.60 ± 0.99 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 10.80 ± 3.86 89.20 ± 3.86 0 – 
5: p + [Fe(EDTA)]2- + H2O2 + dmit 0.1 11.33 ± 3.54 88.67 ± 3.54 0.58 ± 0.35 0.103 
6 1 10.02 ± 3.32 89.98 ± 3.32 -0.92 ± 1.73 0.454 
7 10 12.01 ± 3.61 87.99 ± 3.61 1.35 ± 0.36 0.023 
8 100 17.49 ± 2.10 82.51 ± 2.10 7.51 ± 2.05 0.024 
9 250 46.10 ± 0.26 53.90 ± 0.26 41.04 ± 0.31 < 0.001 
10 500 66.62 ± 1.34 33.38 ± 1.34 64.93 ± 1.56 < 0.001 
11 750 78.94 ± 0.60 21.06 ± 0.60 79.27 ± 0.70 < 0.001 
12 1000 88.54 ± 1.16 11.46 ± 1.16 87.73 ± 0.59 < 0.001 
13 1500 95.94 ± 2.61 4.06 ± 2.61 99.06 ± 3.04 < 0.001 
14 2000 96.98 ± 0.61 3.02 ± 0.61 100.27 ± 0.71 < 0.001 
aData are reported as the average of three trials with calculated standard deviations. 
 
Table 3.10. Gel electrophoresis results for N,N’-dimethylimidazole selone (dmise) DNA damage assays 





Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.02 ± 2.45 3.98 ± 2.45 – – 
2: p + Na2NO2 0 95.17 ± 1.42 4.83 ± 1.42 – – 
3: p + KNO3 0 95.41 ± 1.15 4.59 ± 1.15 – – 
4: p + dmise 1000 94.04 ± 2.09 5.96 ± 2.09 – – 
5: p + ONOO- 0 15.59 ± 1.48 84.41 ± 1.48 0 – 
6: p + ONOO- + dmise 0.01 18.07 ± 1.04 81.93 ± 1.04 3.10 ± 0.51 0.009 
7 0.1 18.07 ± 1.04 81.93 ± 1.04 3.10 ± 0.51 0.009 
8 1 16.72 ± 1.63 83.28 ± 1.63 1.43 ± 0.29 0.013 
9 10 22.53 ± 0.35 77.47 ± 0.35 8.70 ± 1.51 0.010 
10 100 37.49 ± 0.91 62.51 ± 0.91 27.48 ± 1.77 < 0.001 
11 250 75.62 ± 1.55 24.37 ± 1.55 73.60 ± 2.02 < 0.001 
12 500 91.78 ± 1.23 8.22 ± 1.23 91.66 ± 1.53 < 0.001 
13 1000 90.05 ± 1.78 9.95 ± 1.78 93.58 ± 1.59 < 0.001 
14 2000 95.81 ± 0.42 4.19 ± 0.42 96.69 ± 0.53 < 0.001 





Table 3.11. Gel electrophoresis results for N,N’-dimethylimidazole thione (dmit) DNA damage assays with 





Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.57 ± 0.34 3.43 ± 0.34 – – 
2: p + Na2NO2 0 96.75 ± 0.66 3.25 ±0.66 – – 
3: p + KNO3 0 97.37 ± 0.30 2.63 ± 0.30 – – 
4: p + dmit 1000 96.60 ± 0.78 3.40 ± 0.78 – – 
5: p + ONOO- 0 17.70 ± 2.12 82.30 ± 2.12 0 – 
6: p + ONOO- + dmit 0.01 19.61 ± 0.62 80.38 ± 0.62 1.22 ± 0.79 0.116 
7 0.1 17.59 ± 1.75 82.41 ± 1.75 -0.15 ± 0.49 0.649 
8 1 19.13 ± 0.60 80.87 ± 0.60 1.73 ± 3.30 0.460 
9 10 32.15 ± 1.23 67.85 ± 1.23 18.26 ± 1.34 0.002 
10 100 39.89 ± 3.23 60.11 ± 3.23 28.13 ± 2.33 0.002 
11 250 56.91 ± 0.54 43.09 ± 0.54 49.23 ± 0.71 < 0.001 
12 500 84.58 ± 0.90 15.42 ± 0.90 84.98 ± 1.17 < 0.001 
13 1000 88.17 ± 1.06 11.83 ± 1.06 89.20 ± 1.68 < 0.001 
14 2000 89.91 ± 0.72 10.09 ± 0.72 91.85 ± 0.93 < 0.001 
aData are reported as the average of three trials with calculated standard deviations. 
 
 
Figure 3.10. Dose-response curves for the inhibition of oxidative DNA damage by N,N’-dimethylimidazole 
thione (dmit). A) Studies with CuI and [Cu(bipy)]+ were conducted in MOPS buffer (10 mM, pH 7) and B) 
Studies with FeII and [Fe(EDTA)]2- were conducted in MES buffer (10 mM, pH 6). Studies with ONOO- 
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IDENTIFYING CHEMICAL PROPERTIES THAT INFLUENCE THE DNA DAMAGE 
PREVENTION ABILITIES OF THIONES, SELONES, AND THEIR ANALOGS 
 
4.1. Introduction 
Antioxidant prevention of oxidative damage caused by reactive oxygen species 
(ROS) has resulted in increasing interest in determining how antioxidants can be used for 
the prevention or treatment of diseases caused by oxidative stress.1-5 For this reason 
sulfur and selenium compounds have been extensively studied for their antioxidant 
activity.6-13  
Initial interest in antioxidant selones, thiones, and their derivatives arose from the 
discovery of the naturally occurring thione amino acid, ergothioneine (ESH, Figure 4.1), 
found in concentrations 1-3 mM from in human plasma. ESH is a known ROS scavenger 
and effectively prevents CuI-mediated deoxyribose damage at a concentration of 1 mM.14-
19; whereas, selenoneine (Figure 4.1), has been reported in concentrations up to 9 nM in 
human blood.20 Although, very little is known about the antioxidant properties of 
selenoneine,21 studies have shown that it can protect myoglobin and hemoglobin from 
oxidation by iron ions under hypoxic conditions22,23 and act as a radical scavenger of 1,1-
diphenyl-2-picrylhydrazyl (DPPH).23 
Analogs of ergothioneine and selenoneine,N,N’-dimethylimidazole thione (dmit) 
and selone (dmise; Figure 4.1), prevent FeII, CuI-, and peroxynitrite-mediated oxidative 
DNA damage at low micromolar concentrations. Dmit and dmise were unique among 
sulfur and selenium antioxidants in that they not only prevent oxidative DNA damage 
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through multiple mechanisms, but that they more effectively prevent iron-mediated DNA 
damage than copper-mediated damage.  Their ability to prevent DNA damage when 
metal coordination was blocked by chelation, using [Fe(EDTA)]2- (EDTA = 
ethylenediaminetetraacetic acid) and [Cu(bipy)2]+ (bipy – 2,2’-bipyridyl) as the damaging 
metal species, suggested that metal coordination is necessary for activity at low 
micromolar concentrations, and DNA damage studies with peroxynitrite (ONOO–) 
confirmed that ROS scavenging is a major antioxidant mechanism at higher 
concentrations. In addition, oxidation studies conducted by Kimani et al.24 found that 
H2O2 reacted preferentially with CuI-bound dmise or dmit instead of CuI, thus preventing 
CuI oxidation and concomitant •OH generation (targeted scavenging).  
Concentrations of non-protein bound copper in human brain tissue have been 
measured between 1-1300 µM,25,26 and non-protein-bound iron concentrations have been 
reported between 1-30 µM in human cells.27-29 Under oxidative stress, the cellular 
pathways used to maintain metal homeostasis can be overwhelmed, leading to increased 
non-protein-bound FeII and CuI7,30-32 and overproduction of the damaging hydroxyl 
radical (•OH) via the Fenton (iron) and Fenton-like (copper) reactions (Reaction 1).33-35 
This catalytic metal-generated •OH formation results in oxidative DNA damage.8,30,32 
CuI/FeII + H2O2 → CuII/FeIII + –OH + •OH (1) 
Clinical trials with sulfur and selenium antioxidants have been of great interest, 
due to their potential to prevent cancer.7,36-38 However, clinical trials of selenium 
supplementation for prostate cancer prevention have concluded with mixed results. The 
Nutritional Prevention of Cancer trial (NPC) and Selenium and Vitamin E Cancer 
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Prevention Trial (SELECT) treated participants with selenium-enriched yeast and 
selenomethionine (200 µg/day), respectively. Results from the NPC trial revealed a 37% 
decrease in total cancer incidence, including a substantial reduction in prostate cancer,39 
yet the SELECT reported no significant effect of selenium supplementation on the 
prevention of prostate cancer.40-42 These conflicting trial results highlight the need to 
understand the antioxidant mechanisms for specific sulfur and selenium compounds at 
the chemical level before continuing with animal and clinical studies. 
The selected sulfur and selenium compounds in Figure 4.1 were investigated to 
determine if the multifunctional antioxidant activity observed for dmise and dmit was a 
universal trait for selones, thiones, and their derivatives, and to identify which 
mechanisms are primary in their DNA damage prevention ability. The compounds in 
Figure 4.1 were also chosen to identify specific relationships between chemical features 
and measured antioxidant activity.  
For this work, gel electrophoresis studies were used to assess the ability of the 
compounds in Figure 4.1 to prevent CuI- and FeII-mediated DNA damage and to identify 
the chemical properties (speciation, aromaticity, substituent functional groups, and 
denticity) that enhance inhibition of metal-mediated DNA damage. Mass spectrometry 
studies were also conducted to determine whether these sulfur and selenium compounds 
form complexes with CuI and FeII in aqueous solution. Similar DNA damage assays were 
conducted with peroxynitrite (ONOO–) as the damaging ROS source. Since no metal is 
required for peroxynitrite-mediated DNA damage, these studies determine the ROS 
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Figure 4.1. Sulfur and selenium compounds discussed in Chapter 4.  Potential metal-binding sites are 
highlighted in bold. 
performed to determine the ability of these compounds to readily undergo oxidation, an 
indication of ROS scavenging ability. This work is the first to explore the relationship 
between structure and DNA damage prevention ability of thiones, selones, and their 
analogs; and results from these studies will allow development of more effective selone 
and thione antioxidants for use as multifunctional drugs and supplements. The research 
presented in this Chapter was conducted in collaboration with of Prof. Daniel Rabinovich 
(University of North Carolina at Charlotte), who provided several selone and thione 
compounds for analysis, Prof. Sandra K. Wheeler  and undergraduate researcher Emily 
Kurfman (Furman University) who conducted ESI-MS studies on many sulfur and 
selenium compounds, and with Clemson undergraduate researcher Alyssa D. Rabon, who 
conducted some of the DNA damage assays with PTAS and PTASe. 
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4.2. Results and Discussion 
4.2.1. Copper(I)-mediated oxidative DNA damage prevention. Gel electrophoresis 
studies were used to investigate the thione- and selone-derived compounds in Figure 4.1 
for their ability to prevent CuI-mediated oxidative DNA damage. All experiments were 
conducted with 6 µM CuI at pH 7 to mimic physiological conditions. Figure 4.2 shows a 
representative gel showing copper-mediated DNA damage prevention by ESH. Hydrogen 
peroxide alone (50 µM; lane 2) does not cause oxidative DNA damage, nor does ESH 
combined with H2O2 (lane 3). Upon addition of H2O2 to CuI, more than 90% DNA 
damage is observed (lane 4). Subsequent addition of ESH shows a decrease in DNA 
damage with increasing ESH concentration (lanes 5-14); by 2000 µM, more than 95 % of 
the DNA damage is prevented. Figure 4.3 shows the best-fit sigmodial dose-response 
curve obtained from the DNA damage assays with ESH, and the concentration needed to 
inhibit 50 % of copper-mediated DNA damage (IC50 value) was calculated as 22.0 µM 
(Table 4.1). Using similar methods, IC50 values (Table 4.1) were also determined for the  
dithione, ebit  (31.9 µM), MetIm (102.3 µM), mpyMe (383.7 µM), and PTAS (1023 µM;  
 
Figure 4.2. Gel electrophoresis image of CuI-mediated DNA damage inhibition by ergothioneine (ESH) in 
MOPS buffer (10 mM, pH 7). Lane MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: 
p + H2O2 (50 µM); lane 3: p + ESH (2000 µM) + H2O2; lane 4: p + ascorbate (7.5 µM) + CuSO4 (6 µM) + 
H2O2; lanes 5-14: p + CuSO4 + ascorbate + H2O2 + increasing concentrations of ESH: 0.1, 1, 2, 5, 10, 50, 




Figure 4.3. Dose-response curve for CuI-mediated DNA damage inhibition versus ergothioneine 
concentration (µM). 
Figure 4.1; all gel images and IC50 plots are provided at the end of the Experimental 
Methods section in Figures 4.5 through 4.19). 
All of the sulfur-containing compounds investigated inhibit CuI-mediated DNA 
damage, in stark contrast to the lack of activity observed for many of the amino 
acid-derived sulfur compounds previously studied.7,9,10 Arranging the thione compounds 
from highest to lowest IC50 values, dmit < PTAS < mpyMe < MetIm < ebit < 2-MerIm < 
ESH, shows that these compounds cover a wide range of activities (IC50 values from 22-
1550 µM), indicating that structural or other properties play a significant role in 
enhancing antioxidant activity.  As methyl groups are removed from the imidazole ring, 
the antioxidant activity is enhanced by 70-fold from dimethylated dmit (IC50 = 1550 µM) 
to the mono-methylated MetIm (102 µM) to the non-methylated ESH and 2-MerIm (IC50 
= 22 µM).   The presence of the pyridine ring in mpyMe is not as effective as addition of a 
second thione in ebit or the amino acid group in ESH.  
Thione compounds with the lowest IC50 values have multiple potential metal- 
binding sites (shown in bold in Figure 4.1), suggesting that metal coordination ability  
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Table 4.1. IC50 valuesa for the prevention of DNA damage by sulfur and selenium compounds. 
Compound CuI IC50 (μM) FeII IC50 (µM) ONOO– IC50 (µM) 
Sulfur    
ESH 22.0 ± 0.1 5.78 ± 0.01 594 ± 5 
2-MerIm 22.06 ± 0.03 2.31 ± 0.01 417 ± 1 
Ebit 31.9 ± 0.1 88.3 ± 0.1  48 ± 6 % (100 µM) 
MetIm 102.3 ± 0.2 5.78 ± 0.07 378 ± 2 
MpyMe 383.7 ± 0.5 55 ± 2 % (1000 µM) ~289b 
PTAS 1023 ± 4 44 ± 4 % (1000 µM) 49 ± 2 % (1000 µM) 
Dmit 1550 ± 3c 89.1 ± 0.2 171.4 ± 0.2 
Selenium    
SepyMe 11.85 ± 0.01 44.66 ± 0.07 67.61 ± 0.08 
Ebis 13.09 ± 0.03 3.68 ± 0.01 71 ± 3 % (100 µM) 
PTASe 57.3 ± 0.2 52.4 ± 0.1 57.5 ± 0.2 
Dmise ~240b,c 3.2 ± 0.9 155.2 ± 0.1 
aIC50 is the concentration at which the compound inhibits 50%  DNA damage.  bEstimated values. 
cValues from reference 43. 
may contribute to DNA damage prevention for these compounds. The amino acid group 
in ESH increases activity more than the second thione in ebit and 70-fold over the 
monodentate dmit, but potential pyridine nitrogen coordination in mpyMe increases DNA 
damage prevention only 4-fold compared to dmit.43  Thus, the DNA damage prevention 
activities of the sulfur compounds investigated is heavily influenced by the secondary 
functional groups are present. 
 All the selone-derived compounds in Figure 4.1 inhibit CuI-mediated DNA 
damage. In contrast to the modest activity of the thione mpyMe, its selenium analog, 
sepyMe, is the most effective selone, inhibiting 50 % of CuI-mediated DNA damage at 
11.85 µM. Similarly, the IC50 values of ebis and PTASe are 13.09 µM and 57.3 µM, 
respectively. Again, potential metal binding sites influence antioxidant activity; the 
potentially bidentate diselone ebis, and the potentially bidentate pyridine-containing 
sepyMe both have similar IC50 values that are lower than the monodentate PTASe and 
dmise.43  Examining the effect of methyl substituents on the imidazole nitrogen atoms 
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was not possible, since removal of even one methyl group makes these selone compounds 
unstable to air oxidation.44  
 A comparison of the sulfur and selenium compounds reveals that the selenium 
compounds are substantially more effective at preventing CuI-mediated DNA damage 
than their sulfur analogs. SepyMe is ~30 times more effective than mpyMe, and PTASe is 
17 times more effective than its sulfur analog, PTAS. A similar trend was previously 
observed for selenoamino acid compounds when compared to their sulfur analogs.7,9,10  
4.2.2. FeII-mediated oxidative DNA damage prevention. A similar gel 
electrophoresis protocol was used to determine the ability of the compounds in Figure 4.1 
to prevent metal-mediated DNA damage caused by FeII/H2O2. All FeII experiments were 
conducted at pH 6, due to FeII insolubility at pH > 6.45-47 As with CuI DNA damage 
assays, all of the compounds investigated show the ability to prevent FeII-mediated DNA 
damage (gel images and IC50 plots are provided after the Experimental Methods section 
in Figures 4.5 and 4.19). This widespread ability to prevent FeII-mediated DNA damage 
was not observed with sulfur and selenium amino acid derivatives.7,9,10 This increased 
activity for preventing iron-mediated DNA damage over copper is unprecedented for 
sulfur and selenium antioxidants. In actuality, the majority of the sulfur amino acids 
investigated showed no ability to prevent FeII-mediated DNA damage. The ability of the 
sulfur and selenium compounds investigated in this Chapter to effectively inhibit FeII-
mediated DNA damage in addition to CuI-mediated DNA damage suggests that the 
antioxidant activity of these compounds can be tuned for various redox metals. 
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Under these conditions, 2-MerIm is the most effective antioxidant, inhibiting 50 
% of FeII-mediated DNA damage at 2.31 µM. Both ESH and MetIm also have very low 
IC50 values of 5.78 µM (Table 4.1). Ebit inhibits 50 % of FeII-mediated DNA damage at 
88.3 ± 0.1 µM, almost three times the concentration of its IC50 value for prevention of 
copper-mediated damage. Both mpyMe and PTAS only weakly inhibit iron-mediated 
DNA damage, preventing 55 ± 3 % and 44 ± 4 % DNA damage at 1000 µM, 
respectively. 
Selones and their analog compounds (Figure 4.1) also show significant ability to 
prevent iron-mediated DNA damage, with IC50 values ranging from 3-45 µM. The 
diselone ebis inhibits 50 % of FeII-mediated DNA damage at 3.68 µM. Ebis is 12 times 
more effective at preventing FeII-mediated DNA damage than sepyMe  (IC50 = 52.4 ± 0.1 
µM), indicating that the presence of two selone groups results in more effective 
antioxidant activity than one selone and one pyridine group. The non-selone PTASe (IC50 
= 44.66 µM) is the least effective selenium compound at preventing FeII-mediated DNA 
damage. 
In comparison to the sulfur compounds, the selenium compounds are substantially 
more effective than their sulfur analogs at preventing FeII-mediated DNA damage. Ebis is 
24 times more effective than ebit, and dmise is almost 28 times more effective than dmit 
at preventing irom-mediated damage. Once again, methylation is a significant factor in 
the prevention of iron-mediated DNA damage, since the non-methylated 2-MerIm has the 
lowest IC50 value, followed by the non-methylated ESH the mono-methylated MetIm, 
with the dimethylated dmit a distant fourth. Overall, these results suggest that the 
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presence of the imidazole-based thione or selone is stronger than the effects of the 
substituent functional groups, such as an amino acid tail, or denticity of the compounds. 
Interestingly, all mono-thione compounds have similar IC50 values compared to their 
dithione analogs, a trend also observed for the selone analogs. This similarity is not 
observed for prevention of CuI-mediated DNA damage, and indicates that the metal ion 
greatly affects the behavior of these antioxidants.  
4.2.3. Quantifying ROS scavenging using peroxynitrite (ONOO–)-mediated 
oxidative DNA damage. Gel electrophoresis experiments with peroxynitrite (ONOO–) as 
the DNA-damaging agent were conducted to investigate the ROS scavenging abilities of  
the sulfur and selenium compounds (Figure 4.1). Generation of ONOO– is metal-
independent and occurs biologically through the reaction of superoxide and nitric 
acid.48,49 Peroxynitrite directly damages biomolecules,50-55 including plasmid and 
eukaryotic DNA.56,57 At pH 6.8, ONOO– is protonated to peroxynitrous acid, which has 
half-life of 1 s, and rapidly decomposes into •OH and nitrogen dioxide (NO2•), leading to 
oxidative single-strand breaks in DNA similar to the Fenton and Fenton-like reactions 
(Reaction 1).58 For these experiments, a protocol similar to the FeII-mediated oxidative 
DNA damage studies was used, in which ONOO– (1450 µM) in MES buffer (10 mM, pH 
6.8) was substituted for FeII and H2O2. 
 All the investigated sulfur compounds prevent ONOO–-mediated DNA damage 
(Table 4.2), all gel images and IC50 plots are provided at the end of the Experimental 
Methods section in Figures 4.5 and 4.19), but at significantly higher concentrations than 
those required to prevent CuI- and FeII-mediated DNA damage. ESH, 2-MerIm, and 
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MetIm prevent 50 % of ONOO–-mediated DNA damage at 594 µM, 417 µM, and 378 
µM, respectively. To inhibit 50 % ONOO–-mediated DNA damage, ESH requires a 
concentration 27 times higher than that needed for similar prevention of CuI-mediated 
DNA damage. Similarly, 2-MerIm and MetIm require 19 and 4 times the concentrations 
needed to prevent 50 % of CuI-mediated damage, respectively, and 208 and 63 times the 
concentrations needed to prevent FeII-mediated DNA damage, respectively. At 1000 µM, 
PTAS inhibits 49 % of ONOO–-mediated DNA damage, similar to its activity observed 
with CuI and FeII. At the maximum concentration (100 µM), ebit inhibits only 48 % of 
ONOO–-mediated DNA damage, whereas lower concentrations are need for 50 % DNA 
damage prevention with CuI and FeII. 
All of the selenium compounds exhibit significantly more activity towards 
ONOO–-mediated DNA damage than their sulfur analogs (Table 4.2), similar to the 
trends for CuI and FeII DNA damage studies. The non-methylated and mono-methylated 
compounds, ESH, 2-MerIm, and MetIm all have close IC50 values, a trend previously 
Table 4.2. IC50 valuesa for the prevention of [Cu(bipy)2]+-, [Fe(EDTA)]2--, and ONOO–-
mediated DNA damage by the sulfur and selenium compounds. 
Compound [Cu(bipy)2]+ IC50 (μM) [Fe(EDTA)]2- IC50 (μM) 
Sulfur   
Dmit 3470 ± 5b 353.2 ± 0.4b 
Ebit 19 ± 1 % (100 µM) 35 ± 2 % (100 µM) 
MpyMe 63 ± 2 % (100 µM) 167.9 ± 0.2 
PTAS 19 ± 3 % (2000 µM)  13 ± 3 % (1000 µM) 
MetIm — 51.6 ± 0.1 
ESH — 238.2 ± 0.4 
2-MerIm — 139.9 ± 0.4 
Selenium   
Dmise 205.5 ± 0.4b 34.04 ± 0.07b 
Ebis 55 ± 2 % (100 µM) 38 ± 1 % (100 µM) 
SepyMe 14.13 ± 0.01 4.72 ± 0.01 
PTASe 2 ± 2 % (2000 µM)  57 ± 1 % (1000 µM) 
a IC50 is the concentration at which the compound inhibits 50%  DNA damage.  bValues 
from reference 43. 
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observed with prevention of FeII-mediated DNA damage. Both mpyMe and PTAS exhibit 
the least ability to prevent ONOO–-mediated DNA damage, similar to their activities 
towards labile CuI and FeII; however, unlike the metal-based studies, ebit is the most 
effective sulfur compound at preventing ONOO–-mediated DNA damage.  
Metal-mediated DNA damage prevention by the sulfur and selenium compounds 
in Figure 4.1 is typically observed at much lower concentrations than required to inhibit 
non-metal-mediated peroxynitrite damage, indicating that ROS scavenging is not the 
active antioxidant mechanism at lower, more biologically relevant concentrations of these 
compounds. Thus, the peroxynitrite DNA damage studies in addition to the metal-
mediated DNA damage results, confirm the ability of sulfur and selenium compounds to 
inhibit oxidative DNA damage through multiple pathways, not just ROS scavenging. 
4.2.4. The effect of metal coordination on the prevention of DNA damage. 
Previous studies have shown the importance of metal coordination for sulfur and 
selenium prevention of CuI-mediated DNA damage.7-13 To determine the significance 
metal coordination is to the DNA damage prevention abilities of the sulfur and selenium 
compounds investigated, experiments were conducted with [Cu(bipy)2]+ and H2O2, a 
combination that causes oxidative DNA damage, but where the CuI is chelated prior to 
antioxidant addition to prevent metal-antioxidant interactions.  Under these conditions, no 
DNA damage inhibition should be observed if copper coordination is necessary for 
antioxidant activity. 
Many of the sulfur and selenium compounds investigated show some ability to 
prevent oxidative DNA damage (Table 4.2) caused by [Cu(bipy)2]+ and H2O2, but most 
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only at high concentrations (1000 and 2000 µM). Only ESH, MetIm, 2-MerIm, and 
PTASe exhibit little to no activity under these conditions. Similar results were previously 
reported for dmit and dmise, with IC50 values of 3470 µM and 205 µM, respectively.43 It 
is not clear why ESH prevents no [Cu(bipy)2]+-mediated oxidative DNA damage, 
although this may be due to its amino acid functionality; the sulfur-containing amino 
acids previously studied also showed no ability to inhibit [Cu(bipy)2]+- mediated DNA 
damage.7,9,10  
Gel electrophoresis experiments were also conducted with [Fe(EDTA)]2- to 
investigate the extent that prior FeII chelation affects the antioxidant activity of the 
investigated sulfur and selenium compounds. Like [Cu(bipy)2]+, [Fe(EDTA)]2- reacts 
with H2O2 and generate DNA-damaging •OH,7,9,10 but EDTA fully coordinates the 
octahedral FeII ion and prevents sulfur and selenium antioxidant coordination to FeII.  
All of the investigated compounds show some ability to prevent [Fe(EDTA)]2--
mediated DNA damage (Table 4.2), with IC50 values between 4 and 353 µM. PTAS and 
PTASe at 1000 µM have maximum inhibition percentages of 13 % and 57 %, 
respectively, and ebit and ebis show 35 % and 38 % inhibition at 100 µM, respectively. 
Surprisingly, both mpyMe and sepyMe have lower IC50 values lower with [Fe(EDTA)]2- 
(Table 4.2) as compared to the studies with unchelated FeII, suggesting that ROS 
scavenging may be a more significant mechanism for mpyMe and sepyMe DNA damage 
inhibition. In contrast, MetIm, 2-MerIm, and ESH prevent [Fe(EDTA)]2--mediated DNA 
damage at substantially higher concentrations compared to their IC50 values for the 
prevention of FeII-mediated damage.  
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The dimethylated dmit is less effective at inhibiting [Fe(EDTA)]2–-mediated DNA 
damage than the mono-methylated MetIm and the non-methylated 2-MerIm, further 
indicating that removing methylation is critical to maximizing the antioxidant activity of 
thione compounds. Additionally, these results also indicate that metal coordination is the 
active mechanism at low concentrations of the compounds in Figure 4.2, and that a 
second mechanism, likely ROS scavenging, is active when [Fe(EDTA)]2- is used or at 
high concentrations of the investigated compounds.  
 Comparison between the [Cu(bipy)2]+ and [Fe(EDTA)]2- results reveals that most 
of the compounds investigated are more effective at preventing DNA damage caused by 
[Fe(EDTA)]2- than [Cu(bipy)2]+, with the exception of ebis and PTAS. Thus, antioxidant 
activity is affected by the metal species that causes the damage, not simply the ROS that 
is generated. It is likely that ROS scavenging is a primary mechanism for inhibition of 
this damage, since it is unlikely any of the compounds investigated can compete with 
bipy or EDTA for coordination sites of copper or iron; for example, the binding affinity 
of EDTA for FeII is 2 × 1014.59 Thus, these studies suggest that at biologically relevant, 
low concentrations of the investigated thione- and selone-containing compounds, metal 
coordination is the primary antioxidant mechanism, and at higher concentrations when 
the system is saturated with these compounds, ROS scavenging is a primary mechanism. 
Comparison of all the DNA damage inhibition results suggest that the metal complexes 
that cause oxidative DNA damage are just as important to the observed antioxidant 
activity as is the sulfur or selenium source.  
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 4.2.5. CuI and FeII coordination studies by mass spectrometry. MALDI-TOF mass 
spectrometry studies were conducted on the investigated sulfur and selenium antioxidants  
to determine their ability to coordinate CuI and FeII. Ebit, ebis, and mpyMe form only 1:1 
(CuI:ligand) complexes, sepyMe forms both 1:1 and 1:2 complexes with CuI, ESH forms 
only a 1:2 complex, and MetIm forms complexes with 1:2 and 1:3 ratios (Table 4.3). 
PTAS and PTASe exhibit no metal coordination under these conditions, although 
coordination complexes of these ligands with AgI and CoII are reported.60,61 
Since CuI typically prefers tetrahedral coordination geometry, it is likely that the 
compounds such as ESH, mpyMe, sepyMe, ebit, and ebis will bind CuI through multiple 
sites (Figure 4.1). ESH can bind through the thione sulfur as well as the carboxylate 
oxygen. Both mpyMe and sepyMe have been reported to coordinate CuI through the thione 
and selone, respectively, in addition to the pyridine nitrogen.62 Similarly, studies have 
reported the ability of dmit and dmise to coordinate CuI through the sulfur or selenium 
atoms, respectively.63,64 Although these studies confirm the ability of these sulfur and 
selenium compounds to bind CuI, they do not provide information on how copper binding 
Table 4.3. MALDI mass spectrometry data for the tested sulfur and selenium compounds. 
Compound m/z (Da) CuI : ligand m/z (Da) FeII : ligand 
Sulfur     
ESH 521a 1:2a 304b, 257 1:1 [FeII(ESH)(OH)]+, 1:2 
2-MerIm 263a, 365b 1:2a, 1:3a 332a 1:6a 
Ebit 317.6b 1:1b 348, 282a 1:1 [FeII(Ebit)(OH)(H2O)]+, 1:2a 
MetIm 292b, 427.2 1:2b, 1:3 332 1:6 
MpyMe 254 1:1 318 1:3 
PTAS — — — — 
Selenium     
SepyMe 303, 541, 562 1:1, 1:2a, 1:2  
[Cu(sepyMe)(H2O]+ 
267a, 386a 1:2a, 1:3a 
Ebis 413b 1:1b 426 1:1 [FeII(ebis)(OH)]+ 
PTASe — — — — 
 aCoordination observed in ESI studies. bCoordination observed in both MALDI and ESI. 
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results in the observed antioxidant activity. 
 Similar mass spectrometry studies conducted with FeII revealed the ability of 
these sulfur and selenium compounds to form FeII complexes in various ratios. Only  
PTAS and PTASe formed no complexes under these conditions. Ebis formed only a 1:1 
(FeII:ligand), ESH forms both 1:1 and 1:2 (FeII:ligand) complexes, and mpyMe only forms 
a 1:3 FeII complex, consistent with possible chelation. Ebit forms a 1:2 FeII complex, 
whereas sepyMe forms both 1:2 and 1:3 FeII complexes. Higher-order complexes were 
also observed for the monodentate compounds, in keeping with potentially octahedral FeII 
coordination, including both 1:4 and 1:6 complexes with MetIm  and a 1:6 complex with 
2-MerIm.  
 Since 6 µM CuI was used for the DNA damage studies, copper coordination is 
expected to occur between 6-24 µM for monodentate compounds, and between 3-12 µM 
for bidentate compounds. ESH, 2-MerIm, ebit, ebis, and sepyMe are among the most 
effective compounds at inhibiting copper-mediated DNA damage, with IC50 values 
within (or near) this range for copper coordination (Table 4.1). The similar activity 
between ESH and 2-MerIm, indicates that the non-methylated nitrogen atoms in 2-MerIm 
may provide some multidentate properties similar to ESH. Likewise, the similarity in 
activity of ebis and sepyMe may be due to bidentate copper binding. 
Since 2 µM FeII was used in these DNA damage experiments, coordination of FeII 
is expected to occur between 2-12 µM for the monodentate compounds, and 1-6 µM for 
bidentate compounds. ESH, MetIm, and 2-MerIm exhibit activity within this 1-6 µM 
coordination ratio window. Most notably, even compounds that show no metal binding 
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by mass spectrometry methods were found to significantly prevent copper-and iron-
mediated DNA damage, and even compounds with high IC50 values for prevention of 
metal-mediated DNA damage exhibit some ability to form metal complexes by mass 
spectrometry. Thus, these studies taken together show that metal coordination is 
necessary but not sufficient for antioxidant activity.  
4.2.6. Relationship between electrochemical properties and DNA damage 
prevention. Generation of •OH from H2O2 is a one-electron redox reaction, so if an 
antioxidant compound can undergo oxidation, ROS scavenging could occur. Cyclic 
voltammetry (CV) experiments were performed on the sulfur and selenium compounds to 
determine their electrochemical properties and their relationship to their antioxidant 
activities. Differential pulse voltammetry (DPV) experiments were simultaneously 
conducted to confirm weak waves observed in the CV experiments. All experiments were 
conducted in aqueous solution (10 mM MOPS buffer, pH 7.0) to mimic physiological 
conditions with potassium nitrate (0.1 M) as the supporting electrolyte. All potentials are 
reported relative to normal hydrogen electrode (NHE)  and are provided in Table 4.4. 
Table 4.4. Electrochemical potentials (versus NHE) of the tested sulfur and selenium compounds in 
MOPS buffer (10 mM, pH 7) with KNO3 (0.1 M) as the supporting electrolyte. 
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
Sulfur     
ESH 0.382a 0.655a 0.273b 0.518b 
2-MerIm 0.528 -0.275 0.803 0.126 
Ebit 0.590 0.507 0.083 0.548 
MetIm 0.625 -0.539 1.164 0.043 
MpyMe 0.534 0.650a 0.213b 0.726b 
PTAS — -0.612 — — 
Selenium     
SepyMe 0.272, 0.592 0.017, 0.647a 0.249, 0.131b 0.142, 0.581b 
Ebis 0.323 0.194 0.129 0.258 
PTASe — -0.164 — — 
aPotential from DPV scan. bCalculation performed with values obtained from DPV scan 
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The CV of mpyMe exhibits a single anodic wave at 0.534 V (Table 4.4 and Figure 
4A). In contrast, the DPV scans of mpyMe (data are provided in Figure 4.20 through 
Figure 4.22 at the end of the Experimental Methods section) reveal two redox couples; 
the first redox couple consists of an anodic wave at 0.650 V and a cathodic wave at 0.802 
V (E1/2 value of 0.726 V), and a second redox couple consisting of an anodic wave of 
0.954 V and a cathodic wave of 1.041 V (E1/2 value of 0.883 V). The more positive Epa 
values observed in the DPV compared to CV are a result of the different parameters used 
in these experiments.65,66 Similar studies with ESH, 2-MerIm, MetIm, and ebit revealed 
their ability to undergo both oxidation and reduction with E1/2 values of 0.518, 0.126, 
0.043, and 0.548 V respectively. The more positive E1/2 values for ESH, mpyMe, and ebit 
are likely attributed to their secondary functional groups (amino acid tail, pyridine ring, 
or second thione) compared to the lone thione of 2-MerIm and MetIm.   
In contrast to the trend observed for the CuI-mediated DNA damage studies, 
methylation of the imidazole nitrogens has less of an effect on the redox activity than 
denticity. Comparing E1/2 values of the investigated compounds reveals that the observed 
 
Figure 4.4. Cyclic voltammograms vs. NHE for A) mpyMe, and B) sepyMe. Samples are 1 mM  in MOPS 
buffer (10 mM, pH 7) with 0.1 M KNO3 as the supporting electrolyte. 
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trend is mpyMe (potentially bidentate) > ESH (no methylated nitrogens, and potentially 
bidentate) > ebit (potentially bidentate) > 2-MerIm (no methylated nitrogens) > MetIm 
one methylated nitrogen). PTAS only undergoes a single reduction and is not likely to be 
a highly effective ROS scavenger.  
 The selenium compound sepyMe exhibits two strong anodic waves in the cyclic 
voltammogram (Figure 4.4B; Epa values of 0.272 and 0.592 V) and a single cathodic 
wave at 0.017 V. In contrast, the DPV scans of sepyMe (provided in Figure 4.22 at the end 
of the Experimental Methods section) show two anodic waves (Epa values of 0.114 and 
0.647 V) and two cathodic waves (Epc values of 0.157 and 0.516 V), similar to results 
observed for mpyMe. The redox couple for sepyMe exhibits quasi-reversible behavior with 
and E1/2 value of 0.142 V and is highly susceptible to oxidation in aqueous solution. In 
contrast, the bidentate compound ebis only exhibits a single quasi-reversible couple with 
an E1/2 of 0.258 V. The more positive E1/2 value for sepyMe compared to ebis indicates 
that the selone-pyridine compounds is more prone to oxidation than a di-selone 
compound and that sepyMe may be a better ROS scavenger.  
Comparison of these electrochemical findings to results for ONOO–-mediated 
DNA damage reveals that compounds with more positive E1/2 values generally are more 
effective at preventing ONOO–-mediated DNA damage. In contrast, PTASe exhibits a 
single reductive wave (Epc= -0.164 V), similar to PTAS, indicating that ROS scavenging 
is not a likely mechanism for these two compounds. However, their ability to prevent 
ONOO–-mediated DNA damage suggests that the antioxidant mechanisms of PTASe and 
PTAS are likely different from those of the selone and thione compounds. 
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The monodentate thione and selone ligands dmit and dmise oxidize in aqueous 
solution when treated with H2O2 and ONOO–,44,64,67 and they have E1/2 values of 0.187 
and 0.125 V, respectively. The more positive shift in the E1/2 values for the sulfur and 
selenium compounds investigated in this Chapter compared to the values observed for 
dmise and dmit indicate that the potentially multidentate compounds are more readily 
oxidized than the monodentate sulfur and selenium compounds (including 2-MerIm and 
MetIm) and that this oxidation is readily accessible in aqueous solution. However, 
ONOO–-mediated DNA damage studies revealed that dmit was one of the most effective 
ROS scavengers of the sulfur compounds, and indicates that directly comparing 
electrochemical results with prevention of DNA damage by ROS scavenging is not 
always accurate.  
Additional electrochemical studies were conducted with CuI and FeII, focusing on 
the biological redox window of Fenton and Fenton-like reactions (-0.324 V < E1/2 < 0.460 
V). Pierre and Fontecave reported that when the potential for the FeIII/II (or CuII/I) couple 
is more positive than 0.460 V, H2O2 cannot oxidize FeII to FeIII (or CuI to CuII). Similarly, 
when the potential falls below -0.324 V, natural cellular reductants such as NADH are 
unable to reduce FeIII to FeII (or CuII to CuI).68 Thus, if these sulfur and selenium 
compounds shift the redox potential of FeIII/II (or CuII/I ) outside this window, metal-
mediated •OH formation may be effectively inhibited. For these studies, copper(II) sulfate 
or iron(II) sulfate was added to solutions of the sulfur and selenium prior to 
investigations. Copper studies were conducted in MOPS (10 mM, pH 7.0) to mimic 
biological conditions and for comparison to gel electrophoresis studies, whereas iron 
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studies were performed in MES buffer (10 mM, pH 6.0). All samples contained 
potassium nitrate (0.1 M) as the supporting electrolyte. Potentials are reported relative to 
normal hydrogen electrode (NHE) and are provided in Tables 4.5 and 4.6.  
Iron sulfate alone revealed an anodic wave at -0.037 V and a cathodic wave at 
-0.145 V, with an E1/2 of -0.091 V, attributed to the FeIII/II couple. A solution of FeII:ESH 
(1:6 molar ratio) exhibited an anodic wave at 0.017 V and a cathodic wave at -0.317 V 
with an E1/2 = -0.150 V for the same redox reaction. The significant negative shift of the 
cathodic wave indicative of FeIII reduction to FeII, indicates that ESH stabilizes the softer 
FeII oxidation state compared to the harder FeIII oxidation state. Similar results are 
observed with FeII:MetIm  (1:6), which exhibits a cathodic wave for FeIII/II at -0.205 V.  
Table 4.5. Electrochemical potentials (versus NHE) of the tested sulfur and selenium compounds and 
FeSO4 in MES buffer (10 mM, pH 6) with KNO3 (0.1 M) as the supporting electrolyte. 
 FeIII/II 
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
FeSO4 -0.037 -0.145 0.108 -0.091 
1:1 Fe:2-MerIm 0.222 -0.147 0.369 -0.037 
1:6 Fe:2-MerIm 0.120a -0.073a 0.193b 0.023b 
1:1 Fe:Ebit 0.220 -0.147 0.367 0.036 
1:1 Fe:Ebis 0.065a -0.128 0.193b -0.032b 
1:6 Fe:ESH 0.017 -0.317 0.334 -0.15 
1:1 Fe:MetIm -0.083 -0.195 0.112 -0.056 
1:6 Fe:MetIm -0.005 -0.205 0.200 -0.105 
aPotential from DPV scan. bCalculation performed with values obtained from DPV scan.  
 
Table 4.6. Electrochemical potentials (versus NHE) of the tested sulfur and selenium compounds and 
CuSO4 in MOPS buffer (10 mM, pH 7) with KNO3 (0.1 M) as the supporting electrolyte. 
 CuI/0 
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
CuSO4 — — — — 
1:1 Cu:2-MerIm 0.544 0.157 0.387 0.350 
1:4 Cu:2-MerIm 0.470 -0.395 0.865 0.037 
1:1 Cu:MetIm 0.590 0.194 0.396 0.392 
1:4 Cu:MetIm 0.516 -0.220 0.736 0.148 
1:1 Cu:Ebit 0.212, 0.599a, 0.811a 0.111, 0.525a 0.101 0.162 
1:1 Cu:Ebis 0.240, 0.525a 0.047 0.193 0.144 
1:4 Cu:ESH 0.321a,b -0.691, 0.169a,b — — 
aPotential from ligand. bPotential from DPV scan. 
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A 1:1 solution of MetIm:FeII exhibits a significant shift for the anodic wave of the FeIII/II 
couple (Epa = -0.083  V) compared to FeSO4, in addition to a negative shift of 0.050 V for 
the cathodic wave. High concentrations of ESH and 2-MerIm stabilize FeII more than 
FeIII, as indicated by the substantial negative E1/2 values for the FeII/III couple.  
In contrast, 2-MerIm has the opposite effect on the redox activity of iron. In the 
presence of 2-MerIm, the cathodic wave of the FeIII/II couple is not affected at low 
concentrations of 2-MerIm (-0.147 V, 1:1 molar ratio), but shifts positive when additional 
2-MerIm is added (-0.073 V, 1:6 molar ratio). The 1:1 molar ratio of 2-MerIm:Fe has an 
E1/2 of -0.037 V, whereas a 1:6 solution has a more positive E1/2 of 0.023 V, indicating 
that the FeII oxidation state is stabilized more with high concentrations of 2-MerIm. This 
is in agreement with DNA damage studies with FeII, which showed the ability to prevent 
> 75 % oxidative DNA damage by 10 µM. Studies with ebit (1:1 molar ratio) revealed a 
similar E1/2 of 0.036 V, indicating that ebit stabilizes FeII over FeIII.  Ebis with iron (1:1) 
exhibited a slightly less positive shift for the FeIII/II couple (E1/2 = -0.032 V), indicating 
that ebis is not as effective at stabilizing FeII compared to ebit.  
All of the compounds studied with copper only revealed signals for the CuI/0 
redox couple; the CuII/I redox couple is completely absent from all cyclic and differential 
pulse voltammograms. However, a negative shift is observed for the CuI/0 couple when 
high concentrations of 2-MerIm and Metlm are used, suggesting that CuI is favored over 
Cu0.  
The DNA damage prevention studies conducted in this Chapter reveal that more 
effectively preventing FeII-mediated DNA damage than CuI-mediated DNA damage is a 
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general behavior of selones and thiones, similar to results obtained for dmise and dmit 
(Chapter 3). These sulfur and selenium compounds also show significant ability to 
prevent DNA damage by [Fe(EDTA)]2-, [Cu(bipy)2]+, and ONOO–, indicating that 
compounds with C=S/Se and P=S/Se functional groups are the first characterized 
multifunctional sulfur and selenium compounds.  The relatively high concentrations 
required for activity with [Fe(EDTA)]2-, [Cu(bipy)2]+, and ONOO– compared to 
unchelated FeII and CuI indicates that metal coordination is the primary mechanism for 
antioxidant activity at low micromolar concentrations. In addition, activity is greatly 
affected by chemical structure, with the most effective properties: selenium versus sulfur 
> nitrogen methylation > denticity > potential aromaticity > S/Se speciation (C=S/Se 
versus P=S/Se). Electrochemical studies revealed the majority of these compounds 
readily undergo oxidation, in general agreement with the ROS scavenging ability 
observed with ONOO–-mediated DNA damage gels. Electrochemical studies with iron 
showed the ability of these sulfur and selenium compounds to stabilize FeII relative to 
FeIII, although their potentials remain within the electrochemical window for 
metal-generated hydroxyl radical, indicating that these compounds likely prevent metal-
mediated DNA damage by targeted scavenging rather than redox control. Thus, these 
studies have shown the first relationship between chemical structure and antioxidant 
activity, and a series of sulfur and selenium compounds that prevent oxidative DNA 





The gel electrophoresis studies presented in this Chapter confirm the that thiones 
and selones inhibit oxidative DNA damage via at least two separate mechanisms. In the 
CuI studies at low concentrations, metal coordination is the primary mechanism when the 
metal-to-ligand ratios are between 1:1 and 1:4 for the monodentate compounds or 
between 1:1 and 1:2 for potentially bidentate compounds (in gel electrophoresis studies). 
Similarly, metal coordination occurs with FeII, between the metal-to-ligand ratios of 1:1 
and 1:6 for the monodentate compounds, and 1:1 and 1:3 for potentially bidentate 
compounds (in gel electrophoresis studies). In contrast, ROS scavenging is likely the 
active mechanism once the solution is saturated by the thione and selone antioxidants.  
This conclusion is confirmed by the DNA damage prevention abilities observed for most 
of the compounds when bipy or EDTA is used to fully coordinate CuI or FeII, 
respectively, prior to antioxidant addition and from the lesser activities observed for 
peroxynitrite-mediated DNA damage inhibition.  
Methylation of the imidazole nitrogens has the most significant effect on the 
antioxidant properties of the sulfur compounds investigated, since the non-methylated 
compounds, ESH and 2-MerIm, most effectively prevent CuI- and FeII-mediated DNA 
damage. Although the mono-methylated MetIm is not the most effective antioxidant at 
inhibiting CuI-mediated damage, its ability to prevent FeII-mediated DNA damage is 
similar to ESH. Adding chelating capability generally increases the antioxidant activity of 
these compounds in preventing CuI-mediated oxidative DNA damage. In contrast, many 
of the bidentate compounds exhibited similar abilities to prevent FeII-mediated oxidative 
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DNA damage as their monodentate analogs. These results suggest that while denticity is 
important to activity, it is not consistent between metals, suggesting that these 
compounds can be tuned for specific metal ions. 
In the case of ESH, addition of the amino acid substituent to the thione results in 
behavior similar to that observed for selenomethione prevention of DNA damage by CuI 
and [Cu(bipy)2]+. Similarly, the presence of the pyridine functional group in mpyMe and 
sepyMe results in more effective inhibition of DNA damage by [Fe(EDTA)]2- and 
[Cu(bipy)2]+; however, having two thiones or selones in one compound (ebit and ebis) 
resulted in stronger activity in preventing DNA damage by both FeII and CuI. Thus, the 
identity of the secondary functional groups on the thione or selone compound has a 
drastic effect on the antioxidant activity. The presence of aromatic imidazole ring also 
increases the observed antioxidant ability, whereas PTAS and PTASe coordinate only 
through the P=S/Se bond required higher concentrations compared to the other 
compounds. Perhaps the largest contributor to antioxidant activity was the presence of 
selenium versus sulfur, since all of the selenium compounds are significantly more 
effective than their sulfur analogs at preventing oxidative DNA damage under all 
conditions.  
Not only are these compounds multifunctional antioxidants, similar to the 
previously reported dmise and dmit, but these results provide a glimpse as to how 
thiones, selones and their analogs might be tuned to maximize their antioxidant activity at 
biological concentrations. The significance of these studies also arises from the observed 
relationship between chemical structure and antioxidant activity, which has been difficult 
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to observe with the limited activity or number of tested compounds in previous studies. 
The information gained from this work has provided the groundwork for effective 
selection and synthesis of potent sulfur and selenium compounds for multifunctional 
antioxidant studies at biological concentrations. 
 
4.4. Experimental Methods 
Materials. Potassium nitrate was from Fisher. MOPS and MES were obtained 
from Alfa Aesar. PTAS, PTASe, mpyMe, and sepyMe were provided by Prof. Daniel 
Rabinovich (University of North Carolina at Charlotte). Ebit and ebis were synthesized 
according to previously published methods.69 NaCl (99.999%), glycerol, FeSO4 · 7H2O, 
2-MerIm, and bromophenol blue were all from Alfa Aesar. MetIm was purchased from 
Spectrum Chemical. Yeast extract, 30% H2O2, sodium EDTA, tryptone (peptone), CuSO4 
· 5H2O, and agarose were all from Fisher.  Glucose and ampicillin were from EMD.  
Ethidium bromide and agar were from Lancaster.  Ethanol (200 proof) and ascorbic acid 
were from Acros Organics.  Xylene cyanol FF was from J. T. Baker.  Tris hydrochloride 
and microcentrifuge tubes were from VWR.  A NANOpure Diamond water deionization 
system (Barnstead International) was used to prepare diH2O. Metal-free microcentrifuge 
tubes were prepared by washing the tubes in 1M HCl for ~1 hour, and then triple rinsing 
three times with diH2O.   
Plasmid transfection, amplification, and purification.  Plasmid DNA (pBSSK) 
was purified from DH1 E. coli competent cells using a 5 Prime PerfectPrepTM Spin Kit 
(250 count, Fisher).  Tris-EDTA buffer (pH 8.0) was used to elute the plasmid from the 
127 
spin columns.  Plasmid was dialyzed against 130 mM NaCl for 24 hours at 4°C to ensure 
all Tris-EDTA buffer and metal contaminates were removed, and plasmid concentration 
was determined by UV-vis spectroscopy at a wavelength of 260 nm.  Absorbance ratios 
of A250/A260 ≤ 0.95 and A260/A280 ≥ 1.8 were determined for DNA used in all 
experiments.  Plasmid purity was determined through digestion of plasmid (0.1 pmol) 
with Sac 1 and KpN1 in a mixture of NEB buffer and bovine serum albumin was 
conducted at 37°C for 90 minutes.  Comparison to an undigested plasmid sample and a 1 
kb molecular weight marker was conducted by gel electrophoresis. 
DNA damage gel electrophoresis experiments:  DiH2O, MOPS buffer (10 mM, 
pH 7.0), NaCl (130 mM), ethanol (100% metal free, 10 mM), CuSO4 · 5H2O (6000 nM), 
ascorbate (7500 nM), and the indicated concentrations of sulfur (or selenium) compounds 
were combined in an acid-washed microcentrifuge tube and allowed to stand for 5 min at 
room temperature. Plasmid (pBSSK, 0.1 pmol in 130 mmol NaCl) was then added to the 
reaction mixture and allowed to stand for 5 min at room temperature.  H2O2 (50 μM) was 
then added and allowed to react at room temperature for 30 min.  EDTA (50 μM) was 
added after 30 min to quench the reaction.  For FeII DNA damage experiments, FeSO4 ∙ 
7H2O (2 µM) and MES (10 mM, pH 6.0) were used in place of CuSO4, ascorbic acid, 
MOPS buffer. All concentrations mentioned are final concentrations in a 10 μL volume.  
All samples were loaded into a 1% agarose gel in a TAE running buffer (50X); damaged 
and undamaged plasmid was separated by electrophoresis (140 V for 30 min).  Gels were 
stained using ethidium bromide and imaged under UV light.  The amounts of nicked 
(damaged) and circular (undamaged) were analyzed using UViProMW (Jencons 
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Scientific Inc., 2007).  Intensity of circular plasmid was multiplied by 1.24, due to the 
poor binding ability of ethidium bromide to undamaged plasmid.7,9 Experiments using 
[Cu(bipy)2]2+ (50 µM) or [Fe(EDTA)]2- (400 µM) in the place of CuII and FeII were 
conducted using a similar procedure. For gels with [Cu(bipy)2]2+, 62.5 µM ascorbic acid 
was also added. 
Synthesis of peroxynitrite anion (ONOO-). Synthesis of peroxynitrite followed the 
method of Keith and Powell,70 resulting in the bright yellow-colored ONOO-. The 
concentration of ONOO- was calculated from its absorbance at 302 nm using an 
extinction coefficient of 1670 cm-1 mol-1 dm3.71 Samples of ONOO- were stored at -80°C 
for up to two weeks. 
Gel electrophoresis experiments with ONOO-. Selenium or sulfur compounds 
were combined with ethanol (10 mM, 100%), NaCl (130 mM), MOPS buffer (10 mM, 
pH 6.8), and plasmid DNA (pBSSK, 0.1 mmol in 130 mM NaCl) in an acid-washed 
microcentrifuge tube and allowed to stand for 5 min. Peroxynitrite (1450 µM) was added 
at 4°C, and the reaction was allowed to stand for an additional 5 min at room 
temperature. All concentrations indicated are the final concentrations in a 10 µL volume. 
After the 5 min incubation with ONOO-, loading dye (bromophenol blue) was added to 
obtain a final volume of 12 µL. All samples were loaded into a 1% agarose gel in TAE 
running buffer, and gel electrophoresis was conducted as previously stated. 
Calculating percent inhibition of DNA damage. The formula 1-[%N-%B]*100 
was used to calculate percent DNA damage inhibition; %N = percent of nicked DNA in 
the thione- or selone-containing lanes, and %B = the percent of nicked DNA in the 
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Cu+/H2O2 or Fe2+/H2O2 control lane. All percentages were corrected for residual nicked 
DNA prior to calculation. Results were obtained from an average of three trials, with 
indicated standard deviations. 
Mass spectrometry studies. MALDI mass spectrometry experiments were 
performed using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-
tert-butylphenyl)-2-methyl-2-propenyldiene (250.34 m/z) as the matrix. A 1:1 CuI:ligand 
sample was prepared by adding 300 µL of CuSO4 (900 µM) to 300 µL of ascorbic acid 
(900 µM) and allowed to incubate at room temperature for 5 min, followed by the 
addition of 300 µL of the sulfur or selenium compounds (900 µM). Similar samples with 
FeII were made by combining 300 µL of FeSO4 (900 µM) with 300 µL of the sulfur or 
selenium compounds, and 300 µL of deionized H2O. For higher ratio samples, the metal 
concentration remained the same (900 µM), with increased concentrations of the sulfur 
and selenium compounds (3600 µM for 1:4 ratios, and 5400 µM for 1:6 µM). ESI-MS 
studies were conducted on a Waters Alliance 2695 LC / Waters Micromass ZQ Mass 
Spectrometer by Emily Kurfman and Prof. Sandra K. Wheeler (Furman University). 
Experiments were conducted in diH2O and at the same concentration as MALDI studies.   
 Electrochemical studies.  Cyclic voltammetry (CV) and differential pulse 
voltammetry (DPV) experiments were conducted with a CH Electrochemical Analyzer 
(CH Instruments, Inc.). Studies were conducted in dry, degassed MOPS buffer (10 mM, 
pH 7.0) or MES buffer (10 mM, pH 6.0) with KNO3 (0.1 M) as a supporting electrolyte, 
respectively.  Final concentrations of all sulfur and selenium compounds absent of CuSO4 
or FeSO4 were 1 mM with a final volume of 9 mL. All samples were degassed for 10 
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minutes with N2 before each experiment. For metal studies, a solution of 1:1 metal-to-
ligand ratio was made by adding 3 mL of FeSO4 or CuSO4 (900 µM) to 3 mL of a sulfur 
or selenium compound (900 µM), then diluted with the respectively buffer (3 mL, 30 
mM). Final concentration of a 1:1 sample in 9 mL was 300 µM. A similar method was 
used to prepare 1:4 and 1:6 metal-to-ligand samples. All samples were degassed for 10 
minutes with N2 before each experiment. All CV experiments were conducted at 100 
mV/s.  A pulse amplitude of 0.080 V and a pulse width of 0.050 were used for all DPV 
experiments, in conjunction with a sample width of 0.045 and a pulse period of 0.200.   
Samples of each complex were cycled between -1.0 V and 1.0 V, using a glassy carbon 
working electrode, a Pt counter electrode, and a Ag/AgCl (+0.197 V vs. NHE72) 
reference electrode. All experiments were externally referenced to potassium ferricyanide 













Figure 4.5. Gel electrophoresis images of CuI-mediated DNA damage inhibition by A) 2-
mercaptoimidazole (2-MerIm), B) ethyl-bis(imidazole) thione (ebit), C) methimazole (MetIm), and D) (2-
mercapto-1-methyimidazolyl)pyridine thione (mpyMe) in MOPS buffer (10 mM, pH 7). Lane: MW = 1 kb 
molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + S/Se compound (2-MerIm 
= 1000, ebit = 100 μM, MetIm = 2000 µM, mpyMe = 1000 µM) + H2O2; lane 4: p + ascorbate (7.5 µM) + 
CuSO4 (6 μM) + H2O2 (50 µM); lanes 5+: p + CuSO4 + ascorbate + H2O2 + increasing concentrations of 
compound: A) 0.1, 1, 10, 100, and 1000 μM 2-MerIm, respectively, B) 0.1, 1, 5, 10, 25, 35, 40, 50, 75, 90, 
and 100 µM ebit, respectively, C) 0.1, 1, 2, 5, 10, 50, 100, 500, 1000, and 2000 µM MetIm, respectively, 
and D) 0.1, 1, 10, 25, 50, 75, 100, 250, 500, and 1000 µM mpyMe, respectively.   
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Figure 4.6. Gel electrophoresis images of CuI-mediated DNA damage inhibition by A) 1,3,5-triaza-7-
phospaadamantane sulfide (PTAS), B) (2-mercapto-1-methyimidazolyl)pyridine selone (sepyMe), C) ethyl-
bis(imidazole) selone (ebis), and D) 1,3,5-triaza-7-phospaadamantane selenide (PTASe) in MOPS buffer 
(10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; 
lane 3: p + S/Se compound (PTAS = 1500, sepyMe = 1000 μM, ebis = 100 µM, PTASe = 1000 µM) + H2O2; 
lane 4: p + ascorbate (7.5 µM) + CuSO4 (6 μM) + H2O2 (50 µM); lanes 5+: p + CuSO4 + ascorbate + H2O2 
+ increasing concentrations of compound: A) 0.1, 1, 10, 100, 250, 500, 1000, 1100 and 1500 μM PTAS, 
respectively, B) 0.1, 1, 10, 25, 50, 75, 100, 250, 500 and 1000 µM sepyMe, respectively, C) 0.1, 1, 5, 10, 25, 
40, 50, 75, 90, and 100 µM ebis, respectively, and D) 1, 5, 10, 50, 75, 100, 500, and 1000 µM PTASe, 
respectively.   
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Figure 4.7. Gel electrophoresis images of FeII-mediated DNA damage inhibition by A) ergothioneine 
(ESH), B) 2-mercaptoimidazole (2-MerIm), C) ethyl-bis(imidazole) thione (ebit),D) methimazole (MetIm), 
and E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe) in MES buffer (10 mM, pH 6). Lane: MW 
= 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + S/Se compound 
(ESH = 2000 µM, 2-MerIm = 1000, ebit = 100 μM, MetIm = 2000 µM, mpyMe = 1000 µM) + H2O2; lane 4: 
p + FeSO4 (2 μM) + H2O2 (50 µM); lanes 5+: p + FeSO4 + H2O2 + increasing concentrations of compound: 
A) 0.01, 0.1, 1, 10, 50, 100, 1000, 1500, and 2000 µM ESH, respectively, B) 0.1, 1, 10, 100, and 1000 μM 
2-MerIm, respectively, C) 0.1, 1, 10, 25, 50, 75, and 100 µM ebit, respectively, D) 0.1, 1, 5, 10, 50, 100, 




Figure 4.8. Gel electrophoresis images of FeII-mediated DNA damage inhibition by A) 1,3,5-triaza-7-
phospaadamantane sulfide (PTAS), B) (2-mercapto-1-methyimidazolyl)pyridine selone (sepyMe), C) ethyl-
bis(imidazole) selone (ebis), and D) 1,3,5-triaza-7-phospaadamantane selenide (PTASe) in MOPS buffer 
(10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; 
lane 3: p + S/Se compound (PTAS = 1500, sepyMe = 1000 μM, ebis = 100 µM, PTASe = 1000 µM) + H2O2; 
lane 4: p + FeSO4 (2 μM) + H2O2 (50 µM); lanes 5+: p + FeSO4 + H2O2 + increasing concentrations of 
compound: A) 0.1, 1, 10, 100, 250, 500, 1000, 1100 and 1500 μM PTAS, respectively, B) 0.1, 1, 10, 25, 
50, 75, 100, 250, 500 and 1000 µM sepyMe, respectively, C) 0.1, 0.2, 1, 2, 3, 8, 10, 25, 50, and 100 µM 
ebis, respectively, and D) 1, 5, 10, 50, 75, 100, 500, and 1000 µM PTASe, respectively. 
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Figure 4.9. Gel electrophoresis images of [Cu(bipy)2]+-mediated DNA damage inhibition by A) 
ergothioneine (ESH), B) 2-mercaptoimidazole (2-MerIm), C) ethyl-bis(imidazole) thione (ebit),D) 
methimazole (MetIm), and E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe) in MOPS buffer 
(10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; 
lane 3: p + S/Se compound (ESH = 2000 µM, 2-MerIm = 1000, ebit = 100 μM, MetIm = 2000 µM, mpyMe 
= 1000 µM) + H2O2; lane 4: p + [Cu(bipy)2]2+ (50 μM) + ascorbate (63 µM) + H2O2 (50 µM); lanes 5+: p + 
[Cu(bipy)2]2+ + ascorbate + H2O2 + increasing concentrations of compound: A) 0.01, 0.1, 1, 10, 50, 100, 
1000, 1500, and 2000 µM ESH, respectively, B) 0.1, 1, 10, 100, and 1000 μM 2-MerIm, respectively, C) 
0.1, 1, 10, 25, 50, 75, and 100 µM ebit, respectively, D) 0.1, 1, 5, 10, 50, 100, 500, 1000, and 2000 µM 
MetIm, respectively, and E) 0.1, 1, 10, 25, 50, 75, 100, 250, 500, and 1000 µM mpyMe, respectively. 
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Figure 4.10. Gel electrophoresis images of [Cu(bipy)2]+-mediated DNA damage inhibition by A) 1,3,5-
triaza-7-phospaadamantane sulfide (PTAS), B) (2-mercapto-1-methyimidazolyl)pyridine selone (sepyMe), 
C) ethyl-bis(imidazole) selone (ebis), and D) 1,3,5-triaza-7-phospaadamantane selenide (PTASe) in MOPS 
buffer (10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + 
H2O2; lane 3: p + S/Se compound (PTAS = 1500, SepyMe = 1000 μM, ebis = 100 µM, PTASe = 1000 µM) 
+ H2O2; lane 4: p + [Cu(bipy)2]2+ (50 μM) + ascorbate (63 µM) + H2O2 (50 µM); lanes 5+: p + 
[Cu(bipy)2]2+ + ascorbate + H2O2 + increasing concentrations of compound: A) 0.1, 1, 10, 100, 250, 500, 
1000, 1100 and 1500 μM PTAS, respectively, B) 0.1, 1, 10, 25, 50, 75, 100, 250, 500 and 1000 µM sepyMe, 
respectively, C) 0.1, 1, 5, 10, 25, 40, 50, 75, 90, and 100 µM ebis, respectively, and D) 1, 5, 10, 50, 75, 100, 
500, and 1000 µM PTASe, respectively.   
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Figure 4.11. Gel electrophoresis images of [Fe(EDTA)]2--mediated DNA damage inhibition by A) 
ergothioneine (ESH), B) 2-mercaptoimidazole (2-MerIm), C) ethyl-bis(imidazole) thione (ebit), D) 
methimazole (MetIm), and E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe) in MOPS buffer 
(10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; 
lane 3: p + S/Se compound (ESH = 2000 µM, 2-MerIm = 1000, ebit = 100 μM, MetIm = 2000 µM, mpyMe 
= 1000 µM) + H2O2; lane 4: p + [Fe(EDTA)]2- (400 μM) + H2O2 (50 µM); lanes 5+: p + [Fe(EDTA)]2- + 
H2O2 + increasing concentrations of compound: A) 0.01, 0.1, 1, 10, 50, 100, 1000, 1500, and 2000 µM 
ESH, respectively, B) 0.1, 1, 10, 100, and 1000 μM 2-MerIm, respectively, C) 0.1, 1, 10, 25, 50, 75, and 
100 µM ebit, respectively, D) 0.1, 1, 5, 10, 50, 100, 500, 1000, and 2000 µM MetIm, respectively, and E) 




Figure 4.12. Gel electrophoresis images of [Fe(EDTA)]2--mediated DNA damage inhibition by A) 1,3,5-
triaza-7-phospaadamantane sulfide (PTAS), B) (2-mercapto-1-methyimidazolyl)pyridine selone (sepyMe), 
C) ethyl-bis(imidazole) selone (ebis), and D) 1,3,5-triaza-7-phospaadamantane selenide (PTASe) in MOPS 
buffer (10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + 
H2O2; lane 3: p + S/Se compound (PTAS = 1500, sepyMe = 1000 μM, ebis = 100 µM, PTASe = 1000 µM) + 
H2O2; lane 4: p + [Fe(EDTA)]2- (400 μM) + H2O2 (50 µM); lanes 5+: p + [Fe(EDTA)]2- + H2O2 + 
increasing concentrations of compound: A) 0.1, 1, 10, 100, 250, 500, 1000, 1100 and 1500 μM PTAS, 
respectively, B) 0.1, 1, 10, 25, 50, 75, 100, 250, 500 and 1000 µM sepyMe, respectively, C) 0.1, 1, 5, 10, 25, 
40, 50, 75, 90, and 100 µM ebis, respectively, and D) 1, 5, 10, 50, 75, 100, 500, and 1000 µM PTASe, 




Figure 4.13. Gel electrophoresis images of peroxynitrite (ONOO-)-mediated DNA damage inhibition by A) 
ergothioneine (ESH), B) 2-mercaptoimidazole (2-MerIm), C) ethyl-bis(imidazole) thione (ebit),D) 
methimazole (MetIm), and E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe) in MOPS buffer 
(10 mM, pH 6.8). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + 
NaNO2; lane 3: p + KNO3; lane 4: p + S/Se compound (ESH = 2000 µM, 2-MerIm = 1000, ebit = 100 μM, 
MetIm = 2000 µM, mpyMe = 1000 µM); lane 5: p + ONOO- (1450 µM); lanes 6-14: p + ONOO- + 
increasing concentrations of compounds: A) 0.01, 0.1, 1, 10, 50, 100, 1000, 1500, and 2000 µM ESH, 
respectively, B) 0.1, 1, 10, 100, and 1000 μM 2-MerIm, respectively, C) 0.1, 1, 10, 25, 50, 75, and 100 µM 
ebit, respectively, D) 0.1, 1, 5, 10, 50, 100, 500, 1000, and 2000 µM MetIm, respectively, and E) 0.1, 1, 10, 
25, 50, 75, 100, 250, 500, and 1000 µM mpyMe, respectively. 
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Figure 4.14. Gel electrophoresis images of peroxynitrite (ONOO-)-mediated DNA damage inhibition by A) 
1,3,5-triaza-7-phospaadamantane sulfide (PTAS), B) (2-mercapto-1-methyimidazolyl)pyridine selone 
(sepyMe), C) ethyl-bis(imidazole) selone (ebis), and D) 1,3,5-triaza-7-phospaadamantane selenide (PTASe) 
in MOPS buffer (10 mM, pH 6.8). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); 
lane 2: p + NaNO2; lane 3: p + KNO3; lane 4: p + S/Se compound (PTAS = 1500, sepyMe = 1000 μM, ebis 
= 100 µM, PTASe = 1000 µM); lane 5: p + ONOO- (1450 µM); lanes 6-14: p + ONOO- + increasing 
concentrations of compounds: A) 0.1, 1, 10, 100, 250, 500, 1000, 1100 and 1500 μM PTAS, respectively, 
B) 0.1, 1, 10, 25, 50, 75, 100, 250, 500 and 1000 µM sepyMe, respectively, C) 0.1, 1, 5, 10, 25, 40, 50, 75, 
90, and 100 µM ebis, respectively, and D) 1, 5, 10, 50, 75, 100, 500, and 1000 µM PTASe, respectively.   
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Table 4.7. Gel electrophoresis results for ergothioneine (ESH) DNA damage assays with 6 µM CuI and 50 
µM H2O2.a 
Gel lane [ESH], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 93.25 ± 2.59 6.75 ± 2.59 – – 
2: p + H2O2 0 91.84 ± 2.80 8.16 ± 2.80 – – 
3: p + ESH + H2O2 2000 91.88 ± 3.56 8.12 ± 3.56 – – 
4: p + Cu+ + H2O2 0 7.82 ± 6.30 92.18 ± 6.30 0 – 
5: p + Cu+ + H2O2 + ESH 0.1 6.95 ± 4.07 93.05 ± 4.07 -1.15 ± 3.96 0.665 
6 1 6.34 ± 5.36 93.66 ± 5.36 -1.81 ± 1.31 0.139 
7 2 4.41 ± 6.12 95.59 ± 6.12 -4.39 ± 7.62 0.423 
8 5 18.00 ± 0.76 82.00 ± 0.76 6.12 ± 0.94 0.007 
9 10 40.31 ± 1.33 59.69 ± 1.33 33.66 ± 1.64 < 0.001 
10 50 67.90 ± 0.92 32.10 ± 0.92 71.49 ± 2.07 < 0.001 
11 100 82.56 ± 1.74 17.44 ± 1.74 89.05 ± 2.15 < 0.001 
12 500 87.38 ± 2.67 12.62 ± 2.67 94.79 ± 1.69 < 0.001 
13 1000 87.76 ± 1.55 12.24 ± 1.55 95.14 ± 1.78 < 0.001 
14 2000 88.87 ± 2.01 11.13 ± 2.01 96.49 ± 0.86 < 0.001 




Table 4.8. Gel electrophoresis results for 2-mercaptoimidazole (2-MerIm) DNA damage assays with 6 µM 
CuI and 50 µM H2O2.a 
Gel lane [2-MerIm], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.8 ± 1.2 5.2 ± 1.2 – – 
2: p + H2O2 0 94.2 ± 1.5 5.8 ± 1.5 – – 
3: p + 2-MerIm + H2O2 1000 94.7 ± 0.5 5.3 ± 0.5 – – 
4: p + Cu+ + H2O2 0 8.2 ± 1.9 91.8 ± 1.9 0 – 
5: p + Cu+ + H2O2 + 2-MerIm 0.1 8.4 ± 1.8 91.6 ± 1.8 0.15 ± 0.28 0.451 
6 1 8.7 ± 2.7 91.3 ± 2.7 0.56 ± 1.71 0.628 
7 10 35.5 ± 1.3 64.5 ± 1.3 31.69 ± 1.25 < 0.001 
8 100 73.8 ± 3.8 26.2 ± 3.8 76.32 ± 4.02 < 0.001 
9 1000 92.1 ± 3.6 7.9 ± 3.6 97.52 ± 2.58 < 0.001 












Table 4.9. Gel electrophoresis results for ethyl-bis(imidazole) thione (ebit) DNA damage assays with 6 µM 
CuI and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.85 ± 0.14 3.15 ± 0.14 – – 
2: p + H2O2 0 96.11 ± 0.30 3.89 ± 0.30 – – 
3: p + ebit + H2O2 100 97.11 ± 0.72 2.89 ± 0.72 – – 
4: p + Cu+ + H2O2 0 1.59 ± 2.06 98.41 ± 2.06 0 – 
5: p + Cu+ + H2O2 + ebit 0.1 2.10 ± 3.64 97.90 ± 3.64 0.57 ± 1.80 0.638 
6 1 1.58 ± 2.70 98.42 ± 2.70 -0.09 ± 4.55 0.976 
7 5 7.85 ± 3.28 92.15 ± 3.28 3.19 ± 3.67 0.271 
8 10 13.43 ± 2.22 86.57 ± 2.22 3.48 ± 2.57 0.144 
9 25 13.82 ± 1.17 86.18 ± 1.17 9.86 ± 1.31 0.006 
10 35 67.50 ± 0.82 32.50 ± 0.82 66.08 ± 0.95 < 0.001 
11 40 65.02 ± 2.30 34.98 ± 2.30 67.03 ± 2.57 < 0.001 
12 50 77.36 ± 2.88 22.64 ± 2.88 79.27 ± 2.96 < 0.001 
13 75 78.05 ± 1.21 21.95 ± 1.21 81.59 ± 1.35 < 0.001 
14 90 87.91 ± 1.09 12.09 ± 1.09 89.72 ± 1.26 < 0.001 
15 100 89.94 ± 2.78 10.06 ± 2.78 92.45 ± 2.46 < 0.001 




Table 4.10. Gel electrophoresis results for methimazole (MetIm) DNA damage assays with 6 µM CuI and 
50 µM H2O2.a 
Gel lane [MetIm], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.0 ± 0.3 5.0 ± 0.3 – – 
2: p + H2O2 0 95.2 ± 0.1 4.8 ± 0.1 – – 
3: p + MetIm + H2O2 2000 94.6 ± 0.8 5.4 ± 0.8 – – 
4: p + Cu+ + H2O2 0 4.9 ± 1.5 95.1 ± 1.5 0 – 
5: p + Cu+ + H2O2 + MetIm 0.1 1.4 ± 1.2 98.6 ± 1.2 -3.99 ± 2.80 0.132 
6 1 1.8 ± 0.6 98.2 ± 0.6 -3.54 ± 1.39 0.048 
7 2 1.8 ± 1.2 98.2 ± 1.2 -3.51 ± 2.58 0.143 
8 5 1.0 ± 1.0 99.0 ± 1.0 -4.45 ± 2.68 0.103 
9 10 4.0 ± 1.3 96.0 ± 1.3 -1.05 ± 2.49 0.541 
10 50 28.5 ± 2.0 71.5 ± 2.0 26.16 ± 1.02 < 0.001 
11 100 47.7 ± 1.2 50.3 ± 1.2 49.62 ± 0.75 < 0.001 
12 500 80.8 ± 2.6 19.2 ± 2.6 84.08 ± 2.57 < 0.001 
13 1000 84.9 ± 2.3 15.1 ± 2.3 88.63 ± 2.27 < 0.001 
14 2000 89.6 ± 1.8 10.4 ± 1.8 93.81 ± 1.78 < 0.001 






Table 4.11. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine thione (mpyMe) DNA 
damage assays with 6 µM CuI and 50 µM H2O2.a 
Gel lane  [mpyMe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.48 ± 0.38 3.52 ± 0.38 – – 
2: p + H2O2 0 95.92 ± 1.46 4.08 ± 1.46 – – 
3: p + mpyMe + H2O2 100 95.80 ± 0.45 4.20 ± 0.45 – – 
4: p + Cu+ + H2O2 0 15.29 ± 1.18 84.71 ± 1.18 0 – 
5: p + Cu+ + H2O2 + mpyMe 0.1 14.37 ± 0.45 85.63 ± 0.45 -1.17 ± 1.26 0.249 
6 1 16.65 ± 1.43 83.35 ± 1.43 1.69 ± 0.55 0.033 
7 10 16.34 ± 1.27 83.66 ± 1.27 1.30 ± 0.31 0.018 
8 25 13.85 ± 5.09 86.15 ± 5.09 8.09 ± 5.61 0.130 
9 50 29.91 ± 0.70 70.09 ± 0.70 18.12 ± 1.06 0.001 
10 75 21.26 ± 0.57 78.74 ± 0.57 16.26 ± 0.63 < 0.001 
11 100 42.39 ± 0.55 57.61 ± 0.55 33.61 ± 0.08 < 0.001 
12 250 33.31 ± 2.00 66.69 ± 2.00 28.74 ± 2.40 < 0.001 
13 500 63.50 ± 2.69 36.51 ± 2.69 62.81 ± 2.96 < 0.001 
14 1000 86.12 ± 0.87 13.87 ± 0.87 87.76 ± 0.95 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Table 4.12. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane sulfide (PTAS) DNA damage 
assays with 6 µM CuI and 50 µM H2O2.a 
Gel lane  [PTAS], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.69 ± 3.31 2.31 ± 3.31 – – 
2: p + H2O2 0 95.66 ± 0.38 4.34 ± 0.38 – – 
3: p + PTAS + H2O2 1000 97.62 ± 1.75 2.38 ± 1.75 – – 
4: p + Cu+ + H2O2 0 5.31 ± 2.75 94.69 ± 2.75 0 – 
5: p + Cu+ + H2O2 + PTAS 0.1 6.37 ± 3.55 93.63 ± 3.55 -0.84 ± 2.01 0.544 
6 1 10.56 ± 7.24 89.44 ± 7.24 -0.71 ± 3.05 0.726 
7 10 8.18 ± 7.61 91.82 ± 7.61 3.22 ± 5.42 0.412 
8 100 18.59 ± 0.89 81.41 ± 0.89 16.01 ± 0.98 0.001 
9 250 36.13 ± 3.34 63.87 ± 3.34 13.76 ± 5.14 0.043 
10 500 40.41 ± 2.55 59.59 ± 2.55 20.36 ± 3.93 0.012 
11 1000 43.99 ± 2.02 56.01 ± 2.02 43.95 ± 2.22 < 0.001 
12 1100 73.53 ± 3.55 26.47 ± 3.55 71.36 ± 5.47 0.002 
13 1500 96.16 ± 0.67 3.84 ± 0.67 101.31 ± 0.74 < 0.001 









Table 4.13. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine selone (sepyMe) DNA 
damage assays with 6 µM CuI and 50 µM H2O2.a 
Gel lane  [sepyMe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.76 ± 1.74 4.24 ± 1.74 – – 
2: p + H2O2 0 96.71 ± 1.76 3.29 ± 1.76 – – 
3: p + sepyMe + H2O2 100 95.92 ± 0.66 4.08 ± 0.66 – – 
4: p + Cu+ + H2O2 0 7.04 ± 4.12 92.96 ± 4.12 0 – 
5: p + Cu+ + H2O2 + sepyMe 0.1 10.02 ± 3.98 89.98 ± 3.98 3.34 ± 1.09 0.034 
6 1 12.72 ± 1.70 87.28 ± 1.70 6.27 ± 2.33 0.043 
7 10 53.61 ± 3.64 46.39 ± 3.64 51.86 ± 5.99 0.004 
8 25 63.61 ± 1.42 36.38 ± 1.42 66.56 ± 1.51 < 0.001 
9 50 66.92 ± 0.08 33.08 ± 0.08 66.75 ± 1.85 < 0.001 
10 75 75.95 ± 0.87 24.05 ± 0.87 79.66 ± 0.92 < 0.001 
11 100 78.52 ± 2.35 21.48 ± 2.35 79.81 ± 3.38 < 0.001 
12 250 90.14 ± 0.41 9.86 ± 0.41 94.72 ± 0.43 < 0.001 
13 500 92.50 ± 0.73 7.45 ± 0.73 97.28 ± 0.78 < 0.001 
14 1000 95.55 ± 0.65 4.44 ± 0.65 100.48 ± 0.69 < 0.001 




Table 4.14. Gel electrophoresis results for ethyl-bis(imidazole) selone (ebis) DNA damage assays with 6 
µM Cu+ and 50 µM H2O2.a 
Gel lane  [ebis], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.54 ± 0.16 2.46 ± 0.16 – – 
2: p + H2O2 0 95.63 ± 0.85 4.37 ± 0.85 – – 
3: p + ebis + H2O2 100 98.05 ± 1.71 1.95 ± 1.71 – – 
4: p + Cu+ + H2O2 0 1.49 ± 1.14 98.51 ± 1.14 0 – 
5: p + Cu+ + H2O2 + ebis 0.1 0.34 ± 0.54 99.66 ± 0.54 -1.19 ± 1.08 0.196 
6 1 3.87 ± 2.98 96.13 ± 2.98 2.45 ± 2.00 0.168 
7 5 20.56 ± 4.74 79.44 ± 4.74 16.82 ± 5.28 0.031 
8 10 40.50 ± 3.18 59.50 ± 3.18 40.43 ± 4.08 0.003 
9 25 72.03 ± 3.23 27.97 ± 3.23 74.15 ± 3.60 < 0.001 
10 40 78.64 ± 0.65 21.36 ± 0.65 81.52 ± 0.72 < 0.001 
11 50 94.93 ± 1.95 5.07 ± 1.95 95.88 ± 0.86 < 0.001 
12 75 84.20 ± 1.91 15.80 ± 1.91 96.57 ± 0.70 < 0.001 
13 90 89.16 ± 4.32 10.84 ± 4.32 93.24 ± 4.82 < 0.001 
14 100 95.18 ± 0.82 4.82 ± 0.82 97.04 ± 2.41 < 0.001 







Table 4.15. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane selenide (PTASe) DNA 
damage assays with 6 µM CuI and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.34 ± 0.79 2.66 ± 0.79 – – 
2: p + H2O2 0 98.56 ± 1.17 1.44 ± 1.17 – – 
4: p + PTASe + H2O2 1000 98.20 ± 1.45 1.80 ± 1.45 – – 
5: p + Cu+  + H2O2 0 4.47± 5.65 95.53 ± 5.65 0 – 
6: p + Cu+  + H2O2 + PTASe  1 0.91 ± 1.16 99.09 ± 1.16 -4.13 ± 7.30 0.430 
7 5 13.74 ± 2.84 86.26 ± 2.84 3.89 ± 3.32 0.179 
8 10 20.85 ± 11.13 79.15 ± 11.13 12.21 ± 13.01 0.245 
9 50 21.01 ± 1.12 78.99 ± 1.12 12.39 ± 1.31 0.004 
10 75 68.87 ± 7.86 31.13 ±7.86 72.41 ± 8.78 0.004 
11 100 95.25 ± 2.38 4.75 ± 2.38 96.92 ± 1.67 < 0.001 
12 500 93.13 ± 2.01 6.87 ± 2.01 96.74 ± 2.35 < 0.001 
13 1000 91.28 ± 0.34 8.72 ± 0.34 94.57± 0.39 < 0.001 




Table 4.16. Gel electrophoresis results for ergothioneine (ESH) DNA damage assays with 2 µM FeII and 
50 µM H2O2.a 
Gel lane  [ESH], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 88.25 ± 1.71 11.75 ± 1.71 – – 
2: p + H2O2 0 84.42 ± 1.37 15.58 ± 1.37 – – 
3: p + ESH + H2O2 1000 88.80 ± 1.00 11.20 ± 1.00 – – 
4: p + Fe2+ + H2O2 0 20.50 ± 2.29 79.50 ± 2.29 0 – 
5: p + Fe2+ + H2O2 + ESH 0.01 20.89 ± 2.91 79.11 ± 2.91 -0.80 ± 4.59 0.791 
6 0.1 21.37 ± 1.89 78.63 ± 1.89 -0.05 ± 2.97 0.979 
7 1 29.54 ± 0.61 70.46 ± 0.61 14.06 ± 3.93 0.025 
8 10 61.59 ± 2.13 38.41 ± 2.13 64.36 ± 2.81 < 0.001 
9 50 72.14 ± 0.21 27.85 ± 0.21 80.00 ± 0.33 < 0.001 
10 100 73.22 ± 1.42 26.78 ± 1.42 82.52 ± 1.16 < 0.001 
11 1000 76.12 ± 1.53 23.88 ± 1.53 87.00 ± 0.79 < 0.001 
12 1500 81.40 ± 1.31 18.61 ± 1.31 94.56 ± 2.06 < 0.001 
13 2000 81.56 ± 0.67 18.44 ± 0.67 94.84 ± 1.06 < 0.001 











Table 4.17. Gel electrophoresis results for 2-mercaptoimidazole (2-MerIm) DNA damage assays with 2 
µM Fe2+ and 50 µM H2O2.a 
Gel lane  [2-MerIm], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.4 ± 0.4 5.6 ± 0.4 – – 
2: p + H2O2 0 94.1 ± 0.6 5.9 ± 0.6 – – 
3: p + 2-MerIm + H2O2 1000 94.8 ± 1.1 5.2 ± 1.1 – – 
4: p + Fe2+ + H2O2 0 13.9 ± 1.9 86.1 ± 1.9 0 – 
5: p + Fe2+ + H2O2 + 2-MerIm 0.1 17.1 ± 0.8 82.9 ± 0.8 4.01 ± 3.28 0.168 
6 1 39.6 ± 4.3 60.3 ± 4.3 32.19 ± 3.92 0.005 
7 10 75.6 ± 2.9 24.4 ± 2.9 76.94 ± 4.25 0.001 
8 100 88.2 ± 2.6 11.8 ± 2.6 92.66 ± 3.89 < 0.001 
9 1000 91.5 ± 1.1 8.5 ± 1.1 96.77 ± 1.97 < 0.001 




Table 4.18. Gel electrophoresis results for ethyl-bis(imidazole) thione (ebit) DNA damage assays with 2 
µM Fe2+ and 50 µM H2O2.a 
Gel lane  [ebit], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.77 ± 0.90 1.23 ± 0.90 – – 
2: p + H2O2 0 98.75 ± 0.77 1.25 ± 0.77 – – 
3: p + ebit + H2O2 100 98.98 ± 0.45 1.02 ± 0.45 – – 
4: p + Fe2+ + H2O2 0 15.13 ± 1.47 84.87 ± 1.47 0 – 
5: p + Fe2+ + H2O2 + ebit 0.1 12.60 ± 2.04 87.40 ± 2.04 -3.08 ± 4.20 0.332 
6 1 14.44 ± 1.70 85.56 ± 1.70 -0.82 ± 0.25 0.030 
7 10 32.95 ± 0.66 67.05 ± 0.66 21.21 ± 2.03 0.003 
8 25 33.54 ± 1.09 66.45 ± 1.09 30.49 ± 1.18 < 0.001 
9 50 42.77 ± 1.04 57.23 ± 1.04 32.96 ± 0.36 < 0.001 
10 75 39.47 ± 2.17 60.53 ± 2.17 36.91 ± 2.35 < 0.001 
11 100 69.45 ± 1.74 30.55 ± 1.74 64.76 ± 2.23 < 0.001 













Table 4.19. Gel electrophoresis results for methimazole (MetIm) DNA damage assays with 2 µM Fe2+ and 
50 µM H2O2.a 
Gel lane  [MetIm], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.16 ± 0.50 5.84 ± 0.50 – – 
2: p + H2O2 0 83.81 ± 1.76 6.19 ± 1.76 – – 
3: p + MetIm + H2O2 1000 93.77 ± 1.24 6.23 ± 1.24 – – 
4: p + Fe2+ + H2O2 0 7.86 ± 5.53 92.14 ± 5.53 0 – 
5: p + Fe2+ + H2O2 + MetIm 0.1 9.77 ± 5.67 90.23 ± 5.67 2.40 ± 5.54 0.531 
6 1 8.49 ± 4.11 91.51 ± 4.11 0.75 ± 2.01 0.584 
7 5 36.55 ± 1.18 63.45 ± 1.18 17.03 ± 1.75 0.003 
8 10 50.54 ± 0.97 49.46 ± 0.97 56.08 ± 3.16 0.001 
9 50 76.65 ± 1.72 23.35 ± 1.72 76.19 ± 2.54 < 0.001 
10 100 76.63 ± 1.22 23.37 ± 1.22 90.46 ± 2.40 < 0.001 
11 500 88.50 ± 2.73 11.48 ± 2.73 93.70 ± 4.03 < 0.001 
12 1000 82.68 ± 1.89 17.32 ± 1.89 98.37 ± 4.34 < 0.001 
13 2000 91.40 ± 0.64 8.57 ± 0.64 98.00 ± 0.94 < 0.001 





Table 4.20. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine thione (mpyMe) DNA 
damage assays with 2 µM Fe2+ and 50 µM H2O2.a 
Gel lane  [mpyMe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.38 ± 0.41 3.62 ± 0.41 – – 
2: p + H2O2 0 96.25 ± 1.47 3.75 ± 1.47 – – 
3: p + mpyMe + H2O2 100 95.87 ± 0.62 4.13 ± 0.62 – – 
4: p + Fe2+ + H2O2 0 16.39 ± 2.23 83.61 ± 2.23 0 – 
5: p + Fe2+ + H2O2 + mpyMe 0.1 21.01 ± 6.08 78.99 ± 6.08 5.85 ± 5.56 0.210 
6 1 19.47 ± 1.91 80.53 ± 1.91 3.86 ± 1.21 0.031 
7 10 22.92 ± 2.68 77.08 ± 2.68 8.18 ± 0.96 0.004 
8 25 11.28 ± 1.51 88.72 ± 1.51 8.26 ± 1.67 0.013 
9 50 23.50 ± 1.86 76.50 ± 1.86 8.90 ± 0.87 0.003 
10 75 26.09 ± 2.44 73.91 ± 2.44 24.59 ± 2.69 0.004 
11 100 41.04 ± 2.05 58.96 ± 2.05 30.84 ± 1.73 0.001 
12 250 44.28 ± 1.33 55.72 ± 1.33 44.65 ± 1.46 < 0.001 
13 500 54.60 ± 1.25 45.37 ± 1.25 56.08 ± 1.38 < 0.001 
14 1000 53.98 ± 2.25 46.02 ± 2.25 55.36 ± 2.49 < 0.001 







Table 4.21. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane sulfide (PTAS) DNA damage 
assays with 2 µM Fe2+ and 50 µM H2O2.a 
Gel lane  [PTAS], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.45 ± 1.59 3.55 ± 1.59 – – 
2: p + H2O2 0 95.32 ± 1.92 4.68 ± 1.92 – – 
3: p + PTAS + H2O2 1000 95.39 ± 3.01 4.61 ± 3.01 – – 
4: p + Fe2+ + H2O2 0 17.71 ± 2.20 82.29 ± 2.20 0 – 
5: p + Fe2+ + H2O2 + PTAS 0.01 6.64 ± 1.05 93.36 ± 1.05 -0.94 ± 1.16 0.295 
6 0.1 19.30 ± 4.59 80.70 ± 4.59 2.02 ± 4.69 0.533 
7 1 24.48 ± 3.84 75.52 ± 3.84 8.81 ± 2.98 0.036 
8 10 30.68 ± 4.14 69.32 ± 4.14 16.77 ± 3.39 0.013 
9 100 47.18 ± 2.76 52.82 ± 2.76 37.92 ± 4.94 0.005 
10 1000 52.00 ± 3.86 48.00 ± 3.86 44.15 ± 4.05 0.003 




Table 4.22. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine selone (sepyMe) DNA 
damage assays with 2 µM Fe2+ and 50 µM H2O2.a 
Gel lane [sepyMe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.78 ± 0.52 4.22 ± 0.52 – – 
2: p + H2O2 0 96.58 ± 0.59 3.42 ± 0.59 – – 
3: p + sepyMe + H2O2 100 97.01 ± 0.40 2.99 ± 0.40 – – 
4: p + Fe2+ + H2O2 0 19.09 ± 0.65 80.91 ± 0.65 0 – 
5: p + Fe2+ + H2O2 +sepyMe 0.1 22.75 ± 1.51 77.25 ± 1.51 4.69 ± 2.70 0.095 
6 1 22.99 ± 2.01 77.01 ± 2.01 5.05 ± 1.84 0.042 
7 10 43.26 ± 1.06 56.74 ± 1.06 31.17 ± 1.54 < 0.001 
8 25 55.17 ± 1.76 44.83 ± 1.76 46.19 ± 2.23 < 0.001 
9 50 57.76 ± 2.03 42.24 ± 2.03 49.91 ± 2.45 < 0.001 
10 75 58.64 ± 2.50 41.36 ± 2.50 50.57 ± 3.16 < 0.001 
11 100 61.17 ± 3.05 38.83 ± 3.05 54.33 ± 3.83 < 0.001 
12 250 64.57 ± 0.23 35.43 ± 0.23 58.07 ± 0.29 < 0.001 
13 500 61.80 ± 1.86 38.15 ± 1.86 54.63 ± 2.35 < 0.001 
14 1000 66.29 ± 1.70 33.71 ± 1.70 60.24 ± 2.15 < 0.001 












Table 4.23. Gel electrophoresis results for ethyl-bis(imidazole) selone (ebis) DNA damage assays with 2 
µM Fe2+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.02 ± 1.48 1.98 ± 1.48 – – 
2: p + H2O2 0 96.65 ± 0.29 3.35 ± 0.29 – – 
3: p + ebis + H2O2 100 98.94 ± 1.20 1.06 ± 1.20 – – 
4: p + Fe2+ + H2O2 0 22.44 ± 8.48 77.56 ± 8.48 0 – 
5: p + Fe2+ + H2O2 + ebis 0.1 21.94 ± 11.46 78.06 ± 11.46 -0.37 ± 4.81 0.906 
6 0.2 14.58 ± 1.00 85.42 ± 1.00 3.34 ± 1.17 0.039 
7 1 41.84 ± 6.87 58.16 ± 6.87 25.42 ± 1.13 < 0.001 
8 2 39.10 ± 2.63 60.90 ± 2.63 31.76 ± 3.05 0.003 
9 3 51.58 ± 3.69 48.41 ± 3.69 42.96 ± 4.78 0.004 
10 8 73.85 ± 3.65 26.15 ± 3.65 71.77 ± 4.73 0.001 
11 10 90.30 ± 3.36 9.70 ± 3.36 88.41 ± 4.40 < 0.001 
12 25 86.96 ± 1.11 13.04 ± 1.11 87.23 ± 1.29 < 0.001 
13 50 94.72 ± 3.72 5.28 ± 3.72 94.47 ± 3.17 < 0.001 
14 100 94.89 ± 2.78 5.11 ± 2.78 94.72 ± 1.96 < 0.001 




Table 4.24. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane selenide (PTASe) DNA 
damage assays with 2 µM Fe2+ and 50 µM H2O2.a 
Gel lane  [PTASe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.90 ± 1.34 2.10 ± 1.34 – – 
2: p + H2O2 0 97.69 ± 0.70 2.31 ± 0.70 – – 
4: p + PTASe + H2O2 1000 98.63 ± 0.03 1.37 ± 0.03 – – 
5: p + Fe2+  + H2O2 0 20.24 ± 3.01 79.76 ± 3.01 0 – 
6: p + Fe2+  + H2O2 + PTASe  0.01 23.84 ± 1.48 76.16 ± 1.48 -2.84 ± 2.11 0.145 
7 0.1 24.28 ± 3.82 75.72 ± 3.82 5.23 ± 1.25 0.019 
8 1 30.62 ± 5.06 69.38 ± 5.06 13.45 ± 3.30 0.019 
9 10 41.59 ± 4.60 58.41 ± 4.60 27.55 ± 4.95 0.011 
10 50 40.38 ± 2.37 59.62 ± 2.37 20.81 ± 3.38 0.009 
11 100 83.66 ± 1.40 16.34 ± 1.40 81.88 ± 1.62 < 0.001 
12 1000 83.26 ± 1.85 16.74 ± 1.85 81.36 ± 2.38 < 0.001 









Table 4.25. Gel electrophoresis results for ergothioneine (ESH) DNA damage assays with 50 µM 
[Cu(bipy)2]+ and 50 µM H2O2.a 
Gel lane  [ESH], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.03 ± 0.85 5.97 ± 0.85 – – 
2: p + H2O2 0 93.42 ± 1.33 6.58 ± 1.33 – – 
3: p + ESH + H2O2 2000 94.61 ± 0.48 5.39 ± 0.48 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 2.74 ± 1.48 97.26 ± 1.48 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + ESH 0.1 1.45 ± 1.10 98.55 ± 1.10 -1.42 ± 0.46 0.033 
6 1 2.20 ± 1.43 97.80 ± 1.43 -0.60 ± 1.92 0.642 
7 2 1.64 ± 1.01 98.36 ± 1.01 -1.21 ± 1.32 0.253 
8 5 1.54 ± 1.18 98.46 ± 1.18 -1.32 ± 1.65 0.300 
9 10 2.47 ± 2.20 97.53 ± 2.20 -0.30 ± 1.37 0.741 
10 50 1.66 ± 1.21 98.34 ± 1.21 -1.19 ± 1.45 0.291 
11 100 1.61 ± 1.80 98.39 ± 1.80 -1.24 ± 3.04 0.553 
12 500 4.06 ± 1.61 95.94 ± 1.61 1.45 ± 2.50 0.421 
13 1000 1.75 ± 1.04 98.25 ± 1.04 -1.09 ± 1.08 0.222 
14 2000 2.59 ± 1.15 97.41 ± 1.15 -0.16 ± 2.11 0.905 





Table 4.26. Gel electrophoresis results for 2-mercaptoimidazole (2-MerIm) DNA damage assays with 50 
µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.8 ± 0.5 5.2 ± 0.5 – – 
2: p + H2O2 0 94.6 ± 1.3 5.4 ± 1.3 – – 
3: p + 2-MerIm + H2O2 1000 94.7 ± 0.6 5.3 ± 0.6 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 7.4 ± 2.0 92.6 ± 2.0 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + 2-
MerIm 0.1 7.5 ± 2.6 92.6 ± 2.6 0.20 ± 1.45 0.833 
6 1 13.6 ± 1.0 86.4 ± 1.0 7.15 ± 1.38 0.122 
7 2 6.0 ± 0.5 94.0 ± 0.5 3.40 ± 0.58 0.009 
8 5 11.7 ± 1.2 88.3 ± 1.2 9.77 ± 1.37 0.006 
9 10 13.4 ± 2.4 86.6 ± 2.4 6.90 ± 1.55 0.016 
10 50 8.1 ± 2.9 91.9 ± 2.9 5.69 ± 3.25 0.094 
11 100 15.5 ± 2.2 84.5 ± 2.2 9.29 ± 1.44 0.008 
12 500 1.0 ± 0.2 99.0 ± 0.2 
-2.25 ± 
0.23 0.003 
13 1000 5.4 ± 1.8 94.6 ± 1.8 2.70 ± 2.09 0.249 











Table 4.27. Gel electrophoresis results for ethyl-bis(imidazole) thione (ebit) DNA damage assays with 50 
µM [Cu(bipy)2]+ and 50 µM H2O2.a 
Gel lane  [ebit], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.52 ± 1.01 2.48 ± 1.01 – – 
2: p + H2O2 0 94.78 ± 1.89 5.22 ± 1.89 – – 
3: p + ebit + H2O2 100 95.36 ± 0.28 4.64 ± 0.28 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 11.27 ± 7.72 88.73 ± 7.72 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + ebit 0.1 15.01 ± 6.04 84.99 ± 6.04 4.38 ± 1.78 0.051 
6 1 20.85 ± 11.79 79.15 ± 11.79 11.80 ± 6.53 0.089 
7 10 24.61 ± 6.40 75.39 ± 6.40 15.96 ± 2.03 0.005 
8 25 23.65 ± 3.22 76.34 ± 3.22 11.93 ± 4.02 0.036 
9 50 22.08 ± 8.31 77.92 ± 8.31 13.01 ± 2.21 0.009 
10 75 28.55 ± 0.06 71.45 ± 0.06 18.04 ± 0.08 < 0.001 
11 100 26.82 ± 5.89 73.18 ± 5.89 18.58 ± 0.83 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Table 4.28. Gel electrophoresis results for methimazole (MetIm) DNA damage assays with 50 µM 
[Cu(bipy)2]+ and 50 µM H2O2.a 
Gel lane  [MetIm], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.9 ± 1.0 5.1 ± 1.0 – – 
2: p + H2O2 0 94.1 ± 0.5 5.9 ± 0.5 – – 
3: p + MetIm + H2O2 2000 94.6 ± 1.0 5.4 ± 1.0 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 3.8 ± 3.9 96.2 ± 3.9 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + MetIm 0.1 1.6 ± 0.5 98.4 ± 0.5 -2.57 ± 4.07 0.388 
6 1 4.4 ± 2.9 95.6 ± 2.9 0.64 ± 2.16 0.659 
7 2 2.5 ± 2.6 97.5 ± 2.6 -1.47 ± 1.51 0.234 
8 5 4.9 ± 4.0 95.1 ± 4.0 1.22 ± 2.45 0.479 
9 10 4.1 ± 3.0 95.8 ± 3.0 0.29 ± 3.98 0.911 
10 50 6.9 ± 1.1 93.1 ± 1.1 3.39 ± 3.30 0.217 
11 100 4.9 ± 3.4 95.1 ± 3.4 1.16 ± 3.77 0.647 
12 500 1.7 ± 0.2 98.3 ± 0.2 -2.44 ± 4.31 0.430 
13 1000 3.5 ± 2.7 96.5 ± 2.7 -0.56 ± 6.97 0.902 
14 2000 4.6 ± 3.3 95.4 ± 3.3 0.73 ± 7.09 0.875 











Table 4.29. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine thione (mpyMe) DNA 
damage assays with 50 µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.16 ± 1.67 2.84 ± 1.67 – – 
2: p + H2O2 0 96.93 ± 1.57 3.07 ± 1.57 – – 
3: p + mpyMe + H2O2 1000 96.87 ± 1.48 3.13 ± 1.48 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 8.46 ± 1.22 91.54 ± 1.22 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + mpyMe 0.1 3.81 ± 1.38 96.19 ± 1.38 -5.28 ± 1.60 0.029 
6 1 4.21 ± 1.83 95.79 ± 1.83 -4.82 ± 1.69 0.039 
7 5 1.9 ± 1.0 98.0 ± 1.0 1.61 ± 1.09  0.125 
8 10 11.99 ± 0.37 88.01 ± 0.37 3.99 ± 1.26 0.032 
9 50 0.36 ± 0.57 99.64 ± 0.57 2.70 ± 4.56 0.413 
10 100 16.41 ± 1.16 83.59 ± 1.16 8.96 ± 2.15 0.019 
11 500 38.96 ± 0.52 61.04 ± 0.52 41.79 ± 0.56 < 0.001 
13 1000 63.97 ± 2.38 36.03 ± 2.38 62.72 ± 1.86 < 0.001 




Table 4.30. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane sulfide (PTAS) DNA damage 
assays with 50 µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.47 ± 0.81 4.53 ± 0.81 – – 
2: p + H2O2 0 95.45 ± 0.53 4.55 ± 0.53 – – 
3: p + PTAS + H2O2 2000 95.90 ± 0.85 4.10 ± 0.85 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 8.62 ± 1.87 91.38 ± 1.87 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + PTAS 0.01 4.21 ± 3.30 95.79 ± 3.30 1.70 ± 3.54 0.493 
6 0.1 7.44 ± 2.63 92.56 ± 2.63 -1.39 ± 3.92 0.602 
7 1 8.08 ± 2.83 91.92 ± 2.83 -0.64 ± 3.82 0.799 
8 10 5.48 ± 2.79 94.52 ± 2.79 -3.60 ± 1.23 0.037 
9 50 6.00 ± 3.79 94.00 ± 3.79 5.63 ± 2.99 0.082 
10 100 16.99 ± 10.39 83.01 ± 10.39 9.69 ± 10.96 0.265 
11 1000 19.83 ± 2.91 80.17 ± 2.91 12.87 ± 4.39 0.037 
12 2000 20.33 ± 2.95 79.67 ± 2.95 18.97 ± 3.16 0.009 











Table 4.31. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl) pyridine selone (sepyMe) DNA 
damage assays with 50 µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.56 ± 1.57 2.44 ± 1.57 – – 
2: p + H2O2 0 97.69 ± 1.80 2.31 ± 1.80 – – 
3: p + sepyMe + H2O2 1000 96.39 ± 0.52 3.61 ± 0.52 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 9.14 ± 1.43 90.86 ± 1.43 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + sepyMe 0.1 7.99 ± 1.49 92.01 ± 1.49 -1.31 ± 0.92 0.132 
6 1 7.84 ± 1.53 92.16 ± 1.53 -1.48 ± 1.00 0.124 
7 10 41.74 ± 2.54 58.26 ± 2.54 36.80 ± 2.19 0.001 
8 100 91.89 ± 1.96 8.11 ± 1.96 93.46 ± 1.38 < 0.001 
9 1000 96.79 ± 2.33 3.21 ± 2.33 98.97 ± 0.65 < 0.001 




Table 4.32. Gel electrophoresis results for ethyl-bis(imidazole) selone (ebis) DNA damage assays with 50 
µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 99.13 ± 1.05 0.87 ± 1.05 – – 
2: p + H2O2 0 99.67 ± 0.23 0.33 ± 0.23 – – 
3: p + ebis + H2O2 100 99.24 ± 0.84 0.76 ± 0.84 – – 
4: p + [Cu(bipy)2]+ + H2O2 0 1.30 ± 1.72 98.70 ± 1.72 0 – 
5: p + [Cu(bipy)2]+ + H2O2 + ebis 0.1 1.61 ± 1.61 98.39 ± 1.61 0.31 ± 0.47 0.372 
6 1 0.23 ± 0.29 99.77 ± 0.29 -1.12 ± 1.91 0.417 
7 10 10.68 ± 11.30 89.32 ± 11.30 9.51 ± 11.73 0.295 
8 50 39.78 ± 2.93 60.22 ± 2.93 39.24 ± 3.54 0.003 
9 100 56.34 ± 2.08 43.66 ± 2.08 56.15 ± 2.43 < 0.001 




















Table 4.33. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane selenide (PTASe) DNA 
damage assays with 50 µM [Cu(bipy)2]+ and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.91 ± 0.20 4.09 ± 0.20 – – 
2: p + H2O2 0 95.75 ± 0.95 4.25 ± 0.95 – – 
3: p + H2O2 + PTASe 1000 93.46 ± 1.53 6.54 ± 1.53 – – 
4: p + Cu+ + H2O2 0 8.26 ± 1.46 91.74 ± 1.46 0 – 
5: p + Cu+ + H2O2 + PTASe 0.01 2.88 ± 2.41 97.12 ± 2.41 0.67 ± 2.73 0.712 
6 0.1 8.24 ± 1.34 91.76 ± 1.34 -0.03 ± 0.44 0.917 
7 1 7.19 ± 4.37 92.81 ± 4.37 -1.22 ± 3.34 0.592 
8 10 6.24 ± 4.78 93.76 ± 4.78 -2.29 ± 3.81 0.410 
9 50 2.82 ± 2.42 97.18 ± 2.42 2.16 ± 0.77 0.040 
10 100 5.05 ± 3.25 94.95 ± 3.25 -3.65 ± 2.02 0.089 
11 1000 5.90 ± 2.43 94.10 ± 2.43 -2.72 ± 4.10 0.369 
12 2000 4.36 ± 1.40 95.64 ± 1.40 2.35 ± 1.59 0.125 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Table 4.34. Gel electrophoresis results for ergothioneine (ESH) DNA damage assays with 400 µM 
[Fe(EDTA)]2- and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 91.78 ± 1.13 8.22 ± 1.13 – – 
2: p + H2O2 0 89.95 ± 1.94 10.05 ± 1.94 – – 
3: p + ESH + H2O2 2000 91.71 ± 1.15 8.29 ± 1.15 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 16.44 ± 4.06 83.56 ± 4.06 0 – 
5: p + [Fe(EDTA)]2- + H2O2 + ESH 0.1 16.23 ± 2.39 83.77 ± 2.39 -0.35 ± 2.46 0.828 
6 1 17.64 ± 3.51 82.36 ± 3.51 1.60 ± 0.67 0.054 
7 2 20.89 ± 4.14 79.11 ± 4.14 6.05 ± 0.56 0.003 
8 5 19.85 ± 3.60 80.15 ± 3.60 4.63 ± 0.73 0.008 
9 10 21.68 ± 1.39 78.32 ± 1.39 7.01 ± 3.27 0.065 
10 50 25.05 ± 5.23 74.95 ± 5.23 11.79 ± 2.35 0.013 
11 100 30.52 ± 0.76 69.48 ± 0.76 19.05 ± 3.66 0.012 
12 500 60.49 ± 2.36 39.51 ± 2.36 59.82 ± 2.97 < 0.001 
13 1000 67.73 ± 2.62 32.27 ± 2.62 69.72 ± 1.59 < 0.001 
14 2000 71.46 ± 2.32 28.54 ± 2.32 74.82 ± 1.04 < 0.001 











Table 4.35. Gel electrophoresis results for 2-mercaptoimidazole (2-MerIm) DNA damage assays with 400 
µM [Fe(EDTA)]2- and 50 µM H2O2.a 




Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.0 ± 1.4 5.0 ± 1.4 – – 
2: p + H2O2 0 94.4 ± 0.7 5.6 ± 0.7 – – 
3: p + 2-MerIm + H2O2 1000 94.6 ± 0.4 5.4 ± 0.4 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 17.1 ± 1.9 82.9 ± 1.9 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ 2-MerIm 0.1 20.7 ± 3.2 79.3 ± 3.2 4.72 ± 2.90 0.106 
6 1 26.8 ± 0.5 73.2 ± 0.5 12.58 ± 1.59 0.005 
7 10 34.0 ± 7.5 66.0 ± 7.5 21.75 ± 11.29 0.079 
8 100 51.5 ± 2.5 48.5 ± 2.5 44.54 ± 2.19 < 0.001 
9 1000 87.8 ± 0.2 12.2 ± 0.2 91.49 ± 0.99 < 0.001 




Table 4.36. Gel electrophoresis results for ethyl-bis(imidazole) thione (ebit) DNA damage assays with 400 
µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[ebit], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 97.78 ± 0.12 2.22 ± 0.12 – – 
2: p + H2O2 0 97.61 ± 2.11 2.39 ± 2.11 – – 
3: p + ebit + H2O2 100 96.84 ± 0.09 3.16 ± 0.09 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 19.02 ± 2.63 80.98 ± 2.63 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ ebit 0.1 23.17 ± 3.18 76.83 ± 3.18 5.32 ± 1.53 0.026 
6 1 28.39 ± 3.85 71.61 ± 3.85 11.94 ± 2.88 0.019 
7 10 31.63 ± 1.35 68.37 ± 1.35 16.02 ± 0.76 < 0.001 
8 25 40.35 ± 0.64 59.65 ± 0.64 21.26 ± 0.09 < 0.001 
9 50 39.69 ± 2.13 60.31 ± 2.13 26.30 ± 1.04 < 0.001 
10 75 45.70 ± 1.58 54.30 ± 1.58 28.59 ± 2.16 0.002 
11 100 46.74 ± 2.38 53.26 ± 2.38 35.34 ± 2.44 0.001 
















Table 4.37. Gel electrophoresis results for methimazole (MetIm) DNA damage assays with 400 µM 
[Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[MetIm], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 93.76 ± 0.32 6.24 ± 0.32 – – 
2: p + H2O2 0 85.41 ± 2.81 14.59 ± 2.81 – – 
3: p + MetIm + H2O2 2000 93.93 ± 0.97 6.07 ± 0.97 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 22.99 ± 1.31 77.01 ± 1.31 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ MetIm 0.1 23.40 ± 2.63 76.60 ± 2.63 0.70 ± 3.17 0.739 
6 1 25.34 ± 2.76 74.66 ± 2.76 3.86 ± 4.60 0.283 
7 2 34.12 ± 0.71 65.88 ± 0.71 18.22 ± 0.97 < 0.001 
8 5 40.05 ± 1.98 59.95 ± 1.98 26.31 ± 2.70 0.005 
9 10 47.87 ± 0.70 52.13 ± 0.70 39.91 ± 3.50 0.002 
10 50 54.62 ± 2.83 45.38 ± 2.83 46.18 ± 3.86 0.002 
11 100 61.15 ± 1.25 38.85 ± 1.25 61.18 ± 3.95 0.001 
12 500 79.90 ± 0.65 20.05 ± 0.65 80.73 ± 0.89 < 0.001 
13 1000 82.05 ± 2.59 17.95 ± 2.59 94.63 ± 2.38 < 0.001 
14 2000 91.69 ± 1.47 8.31 ± 1.47 96.74 ± 2.00 < 0.001 




Table 4.38. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine thione (mpyMe) DNA 
damage assays with 400 µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[mpyMe], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.86 ± 1.98 4.14 ± 1.98 – – 
2: p + H2O2 0 93.77 ± 2.65 6.23 ± 2.65 – – 
3: p + mpyMe + H2O2 1000 96.63 ± 1.89 3.37 ± 1.89 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 12.40 ± 2.37 87.60 ± 2.37 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ mpyMe 0.1 14.38 ± 1.14 85.62 ± 1.14 2.38 ± 1.47 0.107 
6 1 16.93 ± 1.66 83.07 ± 1.66 5.53 ± 1.34 0.019 
7 10 24.05 ± 1.28 75.95 ± 1.28 14.17 ± 3.72 0.022 
8 100 41.70 ± 1.87 58.30 ± 1.87 36.07 ± 1.69 < 0.001 
9 1000 90.49 ± 0.71 9.51 ± 0.71 96.05 ± 2.20 < 0.001 













Table 4.39. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane sulfide (PTAS) DNA damage 
assays with 400 µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[PTAS], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.90 ± 0.23 5.10 ± 0.23 – – 
2: p + H2O2 0 91.67 ± 1.29 8.33 ± 1.29 – – 
3: p + PTAS + H2O2 2000 91.60 ± 0.45 8.40 ± 0.45 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 25.33 ± 1.54 74.67 ± 1.54 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ PTAS 0.01 18.46 ± 1.89 81.53 ± 1.89 -0.71 ± 2.54 0.676 
6 0.1 25.63 ± 2.27 74.37 ± 2.27 0.48 ± 1.13 0.538 
7 1 28.39 ± 2.24 71.61 ± 2.24 4.63 ± 1.29 0.025 
8 10 32.29 ± 2.08 67.71 ± 2.08 10.52 ± 1.12 0.004 
9 50 36.14 ± 0.85 63.86 ± 0.85 23.08 ± 1.15 < 0.001 
10 100 36.82 ± 0.69 63.18 ± 0.69 17.27 ± 2.36 0.006 
11 1000 33.68 ± 1.31 66.32 ± 1.31 12.53 ± 2.46 0.013 
12 2000 9.67 ± 2.37 90.33 ± 2.37 -12.56 ± 3.19 0.021 




Table 4.40. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine selone (sepyMe) DNA 
damage assays with 400 µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane # 
[sepyMe], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 96.75 ± 1.26 3.25 ± 1.26 – – 
2: p + H2O2 0 92.68 ± 0.54 7.32 ± 0.54 – – 
3: p + sepyMe + H2O2 1000 97.27 ± 0.57 2.73 ± 0.57 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 12.74 ± 0.86 87.26 ± 0.86 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ sepyMe 0.1 13.95 ± 1.83 86.05 ± 1.83 -1.31 ± 0.92 0.132 
6 1 20.17 ± 1.56 79.83 ± 1.56 -1.48 ± 1.00 0.124 
7 10 72.21 ± 1.17 27.79 ± 1.17 36.80 ± 2.19 0.001 
8 100 89.73 ± 1.70 10.27 ± 1.70 93.46 ± 1.38 < 0.001 
9 1000 91.24 ± 1.77 8.76 ± 1.77 99.00 ± 0.65 < 0.001 














Table 4.41. Gel electrophoresis results for ethyl-bis(imidazole) selone (ebis) DNA damage assays with 400 
µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[ebis], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 98.06 ± 1.79 1.94 ± 1.79 – – 
2: p + H2O2 0 96.57 ± 1.15 3.43 ± 1.15 – – 
3: p + ebis + H2O2 100 98.19 ± 1.00 1.81 ± 1.00 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 3.71 ± 2.17 96.29 ± 2.17 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ ebis 0.1 4.73 ± 1.37 95.27 ± 1.37 1.05 ± 3.50 0.520 
6 1 7.36 ± 0.75 92.64 ± 0.75 3.84 ± 3.04 0.160 
7 10 8.89 ± 1.98 91.11 ± 1.98 5.48 ± 1.12 0.014 
8 25 22.22 ± 1.76 77.78 ± 1.76 9.84 ± 2.19 0.016 
9 50 14.57 ± 1.75 85.43 ± 1.75 11.48 ± 3.13 0.024 
10 75 25.65 ± 2.82 74.35 ± 2.82 14.11 ± 3.50 0.020 
11 100 17.26 ± 3.42 82.74 ± 3.42 14.31 ± 5.31 0.043 




Table 4.42. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane selenide (PTASe) DNA 
damage assays with 400 µM [Fe(EDTA)]2- and 50 µM H2O2.a 
Gel lane  
[PTASe], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.97 ± 0.32 4.03 ± 0.32 – – 
2: p + H2O2 0 91.98 ± 1.93 8.02 ± 1.93 – – 
3: p + PTASe + H2O2 1000 95.27 ± 0.86 4.73 ± 0.86 – – 
4: p + [Fe(EDTA)]2- + H2O2 0 22.29 ± 1.90 77.71 ± 1.90 0 – 
5: p + [Fe(EDTA)]2- + H2O2 
+ PTASe 0.01 18.46 ± 1.89 81.53 ± 1.89 -0.71 ± 2.54 0.676 
6 0.1 20.73 ± 1.98 79.27 ± 1.98 -2.23 ± 3.42 0.376 
7 1 31.74 ± 2.45 68.26 ± 2.45 13.46 ± 3.82 0.026 
8 10 37.21 ± 0.79 62.79 ± 0.79 21.35 ± 2.90 0.006 
9 50 36.14 ± 0.85 63.86 ± 0.85 23.08 ± 1.15 < 0.001 
10 100 51.28 ± 1.10 48.72 ± 1.10 41.61 ± 1.22 < 0.001 
11 1000 62.03 ± 1.96 37.97 ± 1.96 57.04 ± 1.27 < 0.001 
12 2000 9.67 ± 2.37 90.33 ± 2.37 -12.56 ± 3.19 0.021 











Table 4.43. Gel electrophoresis results for ergothioneine (ESH) DNA damage assays with 1450 µM 
ONOO-.a 
Gel lane  
[ESH], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 91.91 ± 0.22 8.09 ± 0.22 – – 
2: p + Na2NO2 0 91.17 ± 0.35 8.83 ± 0.35 – – 
3: p + KNO3 0 91.33 ± 1.21 8.67 ± 1.21 – – 
4: p + ESH 1000 90.59 ± 0.95 9.41 ± 0.95 – – 
5: p + ONOO- 0 25.31 ± 5.37 74.69 ± 5.37 0 – 
6: p + ONOO- + ESH 0.1 24.57 ± 2.60 75.43 ± 2.60 -1.36 ± 4.81 0.673 
7 1 24.58 ± 1.68 75.42 ± 1.68 -1.41 ± 6.08 0.727 
8 5 25.49 ± 3.48 74.51 ± 3.48 0.13 ± 2.89 0.945 
9 10 26.02 ± 5.79 73.98 ± 5.79 1.12 ± 0.72 0.114 
10 25 30.85 ± 5.14 69.15 ± 5.14 8.43 ± 0.37 < 0.001 
11 50 31.66 ± 5.98 68.34 ± 5.98 9.71 ± 1.81 0.011 
12 100 40.95 ± 4.50 59.05 ± 4.50 23.76 ± 0.66 < 0.001 
13 250 44.84 ± 1.57 55.16 ± 1.57 29.48 ± 3.63 0.005 
14 500 54.04 ± 3.57 45.96 ± 3.57 43.63 ± 1.78 < 0.001 
15 750 68.03 ± 1.78 31.97 ± 1.78 64.05 ± 2.34 < 0.001 
16 1000 75.89 ± 2.73 24.11 ± 2.73 76.50 ± 6.08 0.002 
17 2000 93.22 ± 1.41 6.77 ± 1.41 97.21 ± 1.85 < 0.001 




Table 4.44. Gel electrophoresis results for 2-mercaptoimidazole (2-MerIm) DNA damage assays with 1450 
µM ONOO-.a 
Gel lane  
[2-MerIm], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.0 ± 2.0 6.0 ± 2.0 – – 
2: p + Na2NO2 0 93.1 ± 1.3 6.9 ± 1.3 – – 
3: p + KNO3 0 92.6 ± 1.0 7.4 ± 1.0 – – 
4: p + ESH 2000 91.8 ± 0.6 8.2 ± 0.6 – – 
5: p + ONOO- 0 27.4 ± 0.5 72.6 ± 0.5 0 – 
6: p + ONOO- + 2-MerIm 0.1 26.9 ± 0.4 73.1 ± 0.4 -0.74 ± 1.43 0.465 
7 1 30.2 ± 1.1 69.8 ± 1.1 4.34 ± 1.55 0.039 
8 2 28.8 ± 0.4 71.2 ± 0.4 2.19 ± 1.09 0.073 
9 5 34.4 ± 6.9 65.6 ± 6.9 10.54 ± 10.03 0.210 
10 10 33.9 ± 1.4 66.1 ± 1.4 9.88 ± 1.48 0.007 
11 50 35.4 ± 0.6 64.6 ± 0.6 12.15 ± 0.39 < 0.001 
12 100 41.2 ± 1.8 58.8 ± 1.8 20.98 ± 3.34 0.008 
13 500 59.2 ± 1.2 41.8 ± 1.2 46.89 ± 2.74 0.001 
14 1000 85.5 ± 1.7 14.5 ± 1.7 88.39 ± 2.15 < 0.001 
15 2000 86.6 ± 0.7 13.4 ± 0.7 90.12 ± 2.73 < 0.001 




Table 4.45. Gel electrophoresis results for ethyl-bis(imidazole) thione (ebit) DNA damage assays with 
1450 µM ONOO-.a 
Gel lane  [ebit], μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.54 ± 0.83 4.46 ± 0.83 – – 
2: p + Na2NO2 0 94.84 ± 0.79 5.16 ± 0.79 – – 
3: p + KNO3 0 95.24 ± 0.70 4.76 ± 0.70 – – 
4: p + ebit 100 95.99 ± 0.98 4.01 ± 0.98 – – 
5: p + ONOO- 0 23.82 ± 2.66 76.18 ± 2.66 0 – 
6: p + ONOO- + ebit 0.1 42.12 ± 19.30 57.88 ± 19.30 26.18 ± 25.89 0.222 
7 1 36.81 ± 14.89 63.19 ± 14.89 18.37 ± 20.76 0.265 
8 10 45.77 ± 3.71 54.23 ± 3.71 30.99 ± 2.98 0.003 
9 50 49.25 ± 1.58 50.75 ± 1.58 35.81 ± 0.51 < 0.001 
10 100 57.72 ± 4.43 42.28 ± 4.43 47.72 ± 6.27 0.006 




Table 4.46. Gel electrophoresis results for methimazole (MetIm) DNA damage assays with 1450 µM 
ONOO-.a 
Gel lane  
[MetIm], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 93.16 ± 0.77 6.84 ± 0.77 – – 
2: p + Na2NO2 0 93.10 ± 0.59 6.90 ± 0.59 – – 
3: p + KNO3 0 92.62 ± 1.08 7.38 ± 1.08 – – 
4: p + MetIm 1000 91.06 ± 1.13 8.94 ± 1.13 – – 
5: p + ONOO- 0 23.39 ± 1.18 76.61 ± 1.18 0 – 
6: p + ONOO- + MetIm 0.1 24.13 ± 3.90 75.87 ± 3.90 0.99 ± 7.02 0.830 
7 1 25.96 ± 2.05 74.04 ± 2.05 3.66 ± 4.38 0.285 
8 5 30.76 ± 0.59 69.24 ± 0.59 10.57 ± 1.16 0.004 
9 10 34.01 ± 5.99 65.99 ± 5.99 15.25 ± 7.61 0.074 
10 25 38.76 ± 3.78 61.24 ± 3.78 21.98 ± 6.53 0.028 
11 75 35.76 ± 1.70 64.24 ± 1.70 17.77 ± 1.51 0.002 
12 100 35.89 ± 1.50 64.11 ± 1.50 17.92 ± 1.79 0.003 
13 250 49.92 ± 2.77 50.08 ± 2.77 38.08 ± 2.76 0.002 
14 500 61.71 ± 1.99 38.29 ± 1.99 54.99 ± 1.94 < 0.001 
15 750 76.31 ± 1.66 23.69 ± 1.66 75.93 ± 2.04 < 0.001 
16 1000 83.65 ± 1.45 16.35 ± 1.45 86.46 ± 2.58 < 0.001 










Table 4.47. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine thione (mpyMe) DNA 
damage assays with 1450 µM ONOO-.a 
Gel lane  
[mpyMe], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 92.85 ± 0.98 7.15 ± 0.98 – – 
2: p + Na2NO2 0 92.71 ± 1.73 7.29 ± 1.73 – – 
3: p + KNO3 0 92.20 ± 2.64 7.80 ± 2.64 – – 
4: p + MpyMe 1000 92.97 ± 0.53 7.03 ± 0.53 – – 
5: p + ONOO- 0 21.95 ± 3.67 78.05 ± 3.67 0 – 
6: p + ONOO- + mpyMe 0.1 26.84 ± 2.45 73.16 ± 2.45 6.73 ± 7.87 0.277 
7 1 26.44 ± 3.32 73.56 ± 3.32 6.34 ± 0.31 < 0.001 
8 10 40.17 ± 2.47 59.83 ± 2.47 25.69 ± 1.95 0.002 
9 100 42.74 ± 3.08 57.26 ± 3.08 29.22 ± 5.45 0.011 
10 1000 77.93 ± 2.23 22.07 ± 2.23 79.11 ± 0.54 < 0.001 




Table 4.48. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane sulfide (PTAS) DNA damage 
assays with 1450 µM ONOO-.a 
Gel lane  
[PTAS], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 94.63 ± 1.22 5.37 ± 1.22 – – 
2: p + Na2NO2 0 95.90 ± 0.84 4.10 ± 0.84 – – 
3: p + KNO3 0 95.28 ± 1.42 4.72 ± 1.42 – – 
4: p + PTAS 1000 95.12 ± 0.89 4.88 ± 0.89 – – 
5: p + ONOO- 0 28.13 ± 6.93 71.87 ± 6.93 0 – 
6: p + ONOO- + PTAS 0.1 27.13 ± 7.69 72.87 ± 7.69 -1.44 ± 4.34 0.623 
7 1 29.41 ± 7.68 70.59 ± 7.68 1.97 ± 1.40 0.135 
8 10 32.53 ± 8.11 67.47 ± 8.11 6.65 ± 2.48 0.043 
9 100 43.73 ± 4.83 56.27 ± 4.83 22.96 ± 1.07 < 0.001 
10 1000 61.65 ± 2.92 38.35 ± 2.92 49.38 ± 1.80 < 0.001 


















Table 4.49. Gel electrophoresis results for (2-mercapto-1-methylimidazolyl)pyridine selone (sepyMe) DNA 
damage assays with 1450 µM ONOO-.a 
Gel lane  [sepyMe], μM 
% 
Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 92.30 ± 1.14 7.70 ± 1.14 – – 
2: p + Na2NO2 0 91.65 ± 2.33 8.35 ± 2.33 – – 
3: p + KNO3 0 93.52 ± 1.04 6.48 ± 1.04 – – 
4: p + sepyMe 1000 93.02 ± 1.01 6.98 ± 1.01 – – 
5: p + ONOO- 0 22.85 ± 5.14 77.15 ± 5.14 0 – 
6: p + ONOO- + sepyMe 0.1 24.20 ± 3.38 75.80 ± 3.38 1.80 ± 2.32 0.311 
7 1 24.39 ± 5.60 75.61 ± 5.60 2.27 ± 2.82 0.298 
8 10 31.25 ± 3.22 68.75 ± 3.22 12.10 ± 2.18 0.011 
9 100 63.59 ± 3.73 36.41 ± 3.73 59.47 ± 4.78 0.002 
10 1000 86.48 ± 1.23 13.52 ± 1.23 92.56 ± 1.68 < 0.001 




Table 4.50. Gel electrophoresis results for ethyl-bis(imidazole) selone (ebis) DNA damage assays with 
1450 µM ONOO-.a 
Gel lane  
[ebis], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 95.04 ± 1.67 4.96 ± 1.67 – – 
2: p + Na2NO2 0 95.85 ± 0.19 4.15 ± 0.19 – – 
3: p + KNO3 0 95.05 ± 1.07 4.95 ± 1.07 – – 
4: p + ebis 100 94.93 ± 0.58 5.07 ± 0.58 – – 
5: p + ONOO- 0 24.84 ± 2.99 75.16 ± 2.99 0 – 
6: p + ONOO- + ebis 0.1 27.65 ± 6.95 72.35 ± 6.95 4.06 ± 7.03 0.422 
7 1 26.95 ± 3.42 73.05 ± 3.42 2.99 ± 0.81 0.024 
8 10 45.48 ± 4.82 54.52 ± 4.82 29.16 ± 3.66 0.005 
9 50 50.92 ± 1.99 49.08 ± 1.99 36.68 ± 3.08 0.002 
10 100 75.67 ± 2.40 24.33 ± 2.40 71.58 ± 3.22 < 0.001 

















Table 4.51. Gel electrophoresis results for 1,3,5-triaza-7-phosphaadmantane selenide (PTASe) DNA 
damage assays with 1450 µM ONOO-.a 
Gel lane  
[PTASe], 
μM % Supercoiled % Nicked 
% Damage 
Inhibition p Value 
1: plasmid DNA (p) 0 93.77 ± 1.22 6.23 ± 1.22 – – 
2: p + Na2NO2 0 95.20 ± 1.46 4.80 ± 1.46 – – 
3: p + KNO3 0 94.43 ± 0.70 5.57 ± 0.70 – – 
4: p + PTASe 1000 93.99 ± 1.81 6.01 ± 1.81 – – 
5: p + ONOO- 0 26.73 ± 2.77 73.27 ± 2.77 0 – 
6: p + ONOO- + PTASe 0.1 25.60 ± 1.56 74.40 ± 1.56 -1.73 ± 2.06 0.283 
7 1 28.60 ± 4.60 71.40 ± 4.60 2.84 ± 3.50 0.295 
8 10 34.12 ± 3.90 65.88 ± 3.90 10.88 ± 3.64 0.036 
9 100 58.26 ± 6.92 41.74 ± 6.92 45.63 ± 11.34 0.020 
10 1000 81.01 ± 1.42 18.99 ± 1.42 79.23 ± 2.19 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
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Figure 4.15. Dose-response curves for the prevention of CuI-mediated DNA damage by A) 2-mercaptoimidazole (2-MerIm), B) ethyl-bis(imidazole) 
thione (ebit), C) methimazole (MetIm), D) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe), E) 1,3,5-triaza-7-phospaadamantane sulfide 




Figure 4.16. Dose-response curves for the prevention of FeI-mediated DNA damage by A) ergothioneine (ESH), B) 2-mercaptoimidazole (2-MerIm), C) 
ethyl-bis(imidazole) thione (ebit), D) methimazole (MetIm), E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe), F) 1,3,5-triaza-7-




Figure 4.17. Dose-response curves for the prevention of [Cu(bipy)2]+-mediated DNA damage by A) ergothioneine (ESH), B) 2-mercaptoimidazole (2-
MerIm), C) ethyl-bis(imidazole) thione (ebit), D) methimazole (MetIm), E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe), F) 1,3,5-triaza-7-




Figure 4.18. Dose-response curves for the prevention of [Fe(EDTA)]2--mediated DNA damage by A) ergothioneine (ESH), B) 2-mercaptoimidazole (2-
MerIm), C) ethyl-bis(imidazole) thione (ebit), D) methimazole (MetIm), E) (2-mercapto-1-methyimidazolyl)pyridine thione (mpyMe), F) 1,3,5-triaza-7-




Figure 4.19. Dose-response curves for the prevention of peroxynitrite (ONOO–)-mediated DNA damage by A) ergothioneine (ESH), B) 2-
mercaptoimidazole (2-MerIm), C) ethyl-bis(imidazole) thione (ebit), D) methimazole (MetIm), E) (2-mercapto-1-methyimidazolyl)pyridine thione 
(mpyMe), F) 1,3,5-triaza-7-phospaadamantane sulfide (PTAS), G) (2-mercapto-1-methyimidazolyl)pyridine selone (sepyMe), H) ethyl-bis(imidazole) 




Figure 4.20. Cyclic voltammograms for A) ergothioneine, B) 2-mercaptoimazole, C) ethyl-bis(imidazole) 
thione, D) methimazole, and E)1,3,5-triaza-7-phosphaadamantane sulfide in MOPS buffer (10 mM, pH 
=7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Compounds (1 mM) were cycled between -




Figure 4.21. Cyclic voltammograms for A) ethyl-bis(imidazole) selone and B) 1,3,5-Triaza-7-
phosphaadamantane sulfide in MOPS buffer (10 mM, pH =7.0) containing KNO3 (10 mM) as a supporting 





Figure 4.22. Differential pulse voltammetry scans for A) negative scan of ergothioneine, B) positive scan of ergothioneine, C) negative scan of (2-
mercapto-1-methyimidazolyl)pyridine thione (MpyMe), D) positive scan of (2-mercapto-1-methyimidazolyl)pyridine thione (MpyMe), E) negative scan of 
(2-mercapto-1-methyimidazolyl)pyridine selone (SepyMe), and F) (2-mercapto-1-methyimidazolyl)pyridine selone (SepyMe) in MOPS buffer (10 mM, 
pH 7.0) containing KNO3 (10 mM) as a supporting electrolyte.  Compounds (1 mM) were cycled between -1000 mV and 1000 mV vs. NHE, a pulse 




Figure 4.23. Cyclic voltammograms for A) 1:1 Fe:2-mercaptoimidazole, B) 1:6 Fe:2-mercaptoimidazole, 
C) 1:1 Fe:methimazole, and D) 1:6 Fe:methimazole in MES buffer (10 mM, pH 6.0) containing KNO3 (10 
mM) as a supporting electrolyte.  All solutions were cycled between -1000 mV and 1000 mV vs. NHE at a 




Figure 4.24. Cyclic voltammograms for A) 1:6 Fe:ergothioneine, B) 1:1 Fe:ethyl-bis(imidazole) thione, 
and C) 1:1 Fe: ethyl-bis(imidazole) selone in MES buffer (10 mM, pH 6.0) containing KNO3 (10 mM) as a 






Figure 4.25. Differential pulse voltammetry scans for A) negative scan of 1:1 Fe:ethyl-bis(imidazole) 
selone, B) positive scan of 1:1 Fe:ethyl-bis(imidazole) selone, C) negative scan of 1:6 Fe:2-
mercaptoimidazole, and D) positive scan of 1:6 Fe:2-mercaptoimidazole in MES buffer (10 mM, pH 6.0) 
containing KNO3 (10 mM) as a supporting electrolyte.  Compounds were cycled between -1000 mV and 




Figure 4.26. Differential pulse voltammetry scans for A) negative scan of 1:1 Fe:methimazole, B) positive 
scan of 1:1 Fe:methimazole, C) negative scan of 1:6 Fe:methimazole, and D) positive scan of 1:6 
Fe:methimazole in MES buffer (10 mM, pH 6.0) containing KNO3 (10 mM) as a supporting electrolyte.  
Compounds were cycled between -1000 mV and 1000 mV vs. NHE, using a pulse width of 0.100, a sample 














Figure 4.27. Cyclic voltammograms for A) 1:1 Cu:2-mercaptoimidazole, B) 1:4 Cu:2-mercaptoimidazole, 
C) 1:1 Cu:methimazole, and D) 1:4 Cu:methimazole in MES buffer (10 mM, pH 6.0) containing KNO3 (10 
mM) as a supporting electrolyte.  All solutions were cycled between -1000 mV and 1000 mV vs. NHE at a 




Figure 4.28. Cyclic voltammograms for A) 1:4 Cu:ergothioneine, B) 1:1 Cu:ethyl-bis(imidazole) thione, 
and C) 1:1 Cu:ethyl-bis(imidazole) selone in MES buffer (10 mM, pH =6.0) containing KNO3 (10 mM) as 




Figure 4.29. Differential pulse voltammetry scans for A) negative scan of 1:4 Cu:ergothioneine, and B) 
positive scan of 1:4 Cu:ergothioneine in MOPS buffer (10 mM, pH 7.0) containing KNO3 (10 mM) as a 
supporting electrolyte.  Compounds were cycled between -1000 mV and 1000 mV vs. NHE, using a pulse 
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INVESTIGATIONS INTO THE FUNCTIONS OF CLOTRIMAZOLE AND 
PSEUDOEPHEDRINE-DERIVATIVE METAL COMPLEXES: ELECTROCHEMICAL 
AND COPPER OXIDATIVE DNA DAMAGE STUDIES  
 
5.1. Introduction 
 A vast amount of research has been focused on the use of organometallic and 
inorganic metal complexes as drugs for the treatment of cancer, largely due to the success 
of cisplatin.1-3 However, there are numerous non-metal-containing drugs such as 
clotrimazole and pseudoephedrine that possess metal binding sites, and yet the effect of 
metal coordination on their function has been relatively unexplored. This is of particular 
concern since redox-active transition metals such as FeII and CuI can generate damaging 
hydroxyl radical (•OH) when exposed to hydrogen peroxide via the Fenton and Fenton-
like reactions, respectively.4-6  
 Clotrimazole (Figure 5.1) is an antifungal agent and calmodulin antagonist,7,8 and 
it can reduce the viability of MCF-7 human breast cancer cells by inducing detachment of 
6-phosphofructo-1-kinase, aldolase, and glycolytic enzymes from the cytoskeleton.9 
Penso and Beitner reported similar activity in LL/2 Lewis lung carcinoma cells and CT-
26 colon adenocarcinoma cells.10 Clotrimazole can also deplete intracellular CaII 
concentrations in acute lymphoblastic leukemia cells, resulting in apoptosis.11 Since 
clotrimazole contains metal-coordinating atoms, metal binding and generation of •OH or 

























Figure 5.1. Structures of clotrimazole (clotri) and chiral pseudoephedrine derivatives N-[2-hydroxy-1(R)-
methyl-2(R)-phenylethyl]-N-methylglycine [R,R(-)(H2cpse)], N-[2-hydroxy-1(S)-methyl-2(S)-phenylethyl]-
N-methylglycine [S,S(-)(H2cpse)], and N-[2-hydroxy-1(S)-methyl-2(R)-phenylethyl]-N-methylglycine 
[S,R(-)(H2ceph)].  Metal coordinating atoms in each ligand are highlighted in bold type. 
In vitro studies with clotrimazole (clotri) determined that its cytotoxic properties 
were substantially enhanced upon addition of CdCl2 or PbCl2.12 This synergistic 
advantage was also observed with ZnCl2, with the added benefit of faster apoptosis 
induction.13 Previous studies by Barba-Behrens et al. reported the successful synthesis, 
identification, and cytotoxic properties of CuII, CoII, ZnII, and NiII clotri complexes with 
HeLa (cervix-uterine), PC3 (prostate), and HCT-15 (colon) carcinoma cells.14 However, 
no studies have focused on understanding the mechanisms behind the cytotoxic activity 
of these novel metal-clotri complexes.  
Pseudoephedrine (Figure 5.1) is commonly used as a nasal decongestant, 
stimulant,15 or an antitussive drug.16,17 Yet, little is known about how its function may be 
altered in the presence of biological transition metals.   Thus, copper complexes of 
pseudoephedrine derivatives (Figure 5.1) were studied for their electrochemical 
properties and ability to promote oxidative DNA damage. These derivatives have a 
carboxylic-acid-containing substituent bound to the nitrogen, thus providing a possible 
third coordination site in addition to the hydroxyl oxygen and nitrogen.18  
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Electrochemical studies were conducted on [Cu(clotri)3(NO3)][NO3]•2H2O, 
Cu3(R,R(-)-cpse)3 and Cu3(S,S(+)-cpse)3 to determine their potential ability to readily 
undergo oxidation and reduction within the redox window of Fenton-like reactions. Gel 
electrophoresis studies were conducted on these CuII complexes to assess their ability to 
generate the hydroxyl radical (•OH) when hydrogen peroxide is added, resulting in DNA 
damage. Since DNA contains the cellular genetic map, significant DNA damage may 
result in harmful mutations, leading to the onset of various diseases. If these complexes 
promote •OH generation then it is possible that they can cause cellular oxidative damage 
leading to apoptosis.  Studies with clotrimazole and pseudoephedrine derivatives and 
their metal complexes were performed in collaboration with Dr. Noráh Barba-Behrens 
(Universidad Nacional Autónoma de México). The work on the clotrimazole and its 
metal complexes presented in this Chapter soon will be submitted for publication in a 
special issue of Dalton Transactions focusing on DNA-binding metal complexes 
(Betanzos-Lara, S.; Chmel, N. P.; Zimmerman, M. T.; Barrón-Sosa, L. R.; Garino, C.; 
Salassa, L.; Rodger, A., Brumaghim, J.; Gracia-Mora, I.; Barba-Behrens, N. “Redox-
active and DNA-binding coordination complexes of clotrimazole,” Dalton Trans., 
manuscript in preparation).  
 
5.2. Results and Discussion 
5.2.1. Electrochemical studies of clotrimazole-metal complexes. Cyclic 
voltammetry (CV) experiments were conducted on the clotri complexes of ZnII, CoII, and 


























aPotentials from the clotri ligand. bPotentials from the CoII/0 couple. cPotentials from the CoIII/II couple. dPotentials from the CuI/0 couple. 
ePotentials from the CuII/I couple.
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
Zn(clotri)2Cl2 — — — — 
Zn(clotri)2Br2 1.021a 0.591a 0.435a 0.806a 
[Zn(clotri)3(NO3)][NO3]•5H2O — — — — 
Co(clotri)2Cl2 -0.238b, 0.997c, 1.206a — — — 
Co(clotri)2Br2 -0.038b, 0.648c, 0.948a -1.612b, 0.376c 1.574b, 0.272c -0.825b, 0.512c 
Co(clotri)3(NO3)2 -0.296b -1.669b 1.373b -0.982b 
Cu(clotri)2Cl2•5H2O -0.512d, -0.082e -1.192d, -0.379e 0.680d, 0.297e -0.852d, -0.239e 
Cu(clotri)2Br2•5H2O -0.479d, 0.018e, 0.962a -1.407d, -0.297e, 0.614a 0.928d, 0.279e, 0.348a -0.943d, -0.139e, 0.788a 
[Cu(clotri)3NO3][NO3]•2H2O -0.441d, 0.117e, 0.693a -1.603d, -0.141e, 0.338a 1.162d, 0.258e, 0.355a -1.022d, -0.012e, 0.515a 
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Figure 5.2. Cyclic voltammograms vs. NHE for A) clotrimazole, B) [Zn(clotri)2Cl2], C) [Zn(clotri)2Br2], 
and D) [Zn(clotri)3NO3]. Samples are 1 mM in acetonitrile with 0.1 M TBAPF6 as the supporting 
electrolyte. 
performed in acetonitrile unless otherwise specified, and all potentials are normalized to  
the normal hydrogen electrode (NHE). Electrochemical studies of the clotri ligand show 
that this ligand is redox-inactive within the investigated window (Figure 5.2A). 
The cyclic voltammograms for Zn(clotri)2Cl2 and [Zn(clotri)3(NO3)][NO3] 
(Figures 5.2A and 5.2C) show no electrochemical activity. In contrast, studies of the 
analogous Zn(clotri)2Br2 complexshow a cathodic wave at 1.021 V and an anodic wave at 
0.591 V (Figure 5.2 B), with an E1/2 value of 0.806 V. This redox couple is attributed to 
the clotri ligand, in agreement with previous studies involving metal coordinated histidine 
and imidazole-derived ligands.19,20  
However, Nair and Ray21 reported a Zn(furfural-histidine)2 complex with N2O2 
coordination where the voltammogram exhibited an irreversible two-electron cathodic  
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Figure 5.3. Cyclic voltammograms vs. NHE for A) Co(clotri)2Cl2, B) Co(clotri)2Br2, and C) 
Co(clotri)3(NO3)2. Samples are 1 mM in acetonitrile with 0.1 M TBAPF6 as the supporting electrolyte. 
wave at -0.900 V for the ZnII to Zn0 reduction. In contrast the clotri ligand only has a 
single N atom of the histidine ring capable of coordination, with no O coordination sites. 
Additionally, the [Zn(clotri)3(NO3)][NO3] complex contains a third clotri ligand, 
compared to the two clotri ligands in the chloride or bromide complexes, and binding of 
this additional clotri ligand may also shift the ZnII/0 redox couple outside the investigated 
window. 
Cyclic voltammetric studies of Co(clotri)2Cl2 (Figure 5.3A) show an anodic wave 
at 1.206 V, indicating oxidation of the clotri ligand, and anodic waves at 0.977 V and 
-0.238 V that represent the oxidation of CoII to CoIII and Co0 to CoII, respectively. 
Differential pulse voltammetry (DPV) studies (Figures 5.4A and 5.4B) confirm both 




Figure 5.4. Differential pulse voltammetry vs. NHE for A) Co(clotri)2Cl2 positive scan, B) Co(clotri)2Cl2 
negative scan, C) Co(clotri)2Br2 positive scan, and D) Co(clotri)2Br2 negative scan. Samples are 1 mM in 
acetonitrile with 0.1 M TBAPF6 as the supporting electrolyte. 
Electrochemical studies of the bromide complex, Co(clotri)2Br2, reveal both 
CoIII/II and CoII/0 redox couples, in addition to oxidation of the clotri ligand (Figure 5.3B). 
The quasi-reversible CoII/0 redox couple with a cathodic wave at -1.612 V and an anodic 
wave at -0.038 V has an E1/2 value of -0.825 V. The CoIII/II redox couple has an E1/2 value 
of 0.512 V, and the oxidation of the clotri ligand occurs at 0.948 V. DPV studies (Figures 
5.4C and 5.4D) confirm the reduction of the clotri ligand in addition to the CoIII/II and 
CoII/0 redox couples for this bromide complex. The cyclic voltammogram for the nitrate 
complex, Co(clotri)3(NO3)2, exhibits only the CoII/0 redox couple (E1/2 = -0.982 V), 
whereas DPV studies also show waves for the CoIII/II couple and the clotri ligand (Figures 
5.5A and 5.5B).  
A comparison of the anodic waves for the CoII/3Ioxidation of Co(clotri)2Cl2 and  
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Figure 5.5. Differential pulse voltammetry vs. NHE for A) Co(clotri)3(NO3)2 positive scan and B) 
Co(clotri)3(NO3)2 negative scan. Samples are 1 mM in acetonitrile with 0.1 M TBAPF6 as the supporting 
electrolyte. 
Co(clotri)2Br2 reveals that the chloride complex more readily undergoes oxidation to hard 
CoIII relative to borderline CoII compared to the bromide complex, as expected by hard- 
soft acid-base theory. These electrochemical results therefore demonstrate that the halide 
ligand significantly affects the electrochemical properties of the cobalt center.  
Araujo et al.19 reported a conjugated bis(imino)pyridine ligand (2,6-bis[1-(4-R-
phenylimino)ethyl]pyridine) with 3N donors and two coordinated chlorides (or bromides) 
bound to a CoII center, and observed a one-electron CoIII/II redox couple by cyclic 
voltammetry. Their studies revealed a more negative E1/2 value for the CoIII/II redox 
couple (E1/2 value of 0.153 V), compared to the Co(clotri)2Br2 complex, consistent with 
our results indicating that the clotri ligand stabilizes the higher oxidation states of cobalt. 
Electrochemical studies were also conducted on analogous clotri-CuII complexes. 
In acetonitrile, Cu(clotri)2Cl2 (Figure 5.6A) exhibits both quasi-reversible CuII/I and CuI/0 
redox couples with E1/2 values of -0.239 V and -0.852 V, respectively. However, these 
potentials are weaker than expected due to precipitation observed after the initial scan. In 
contrast, the Cu(clotri)2Br2 complex (Figure 5.6B) clearly shows CuII/I and Cu0/I redox 
couples in addition to redox activity of the clotri ligand. The cathodic wave at -1.407 V  
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Figure 5.6. Cyclic voltammograms vs. NHE for A) Cu (clotri)2Cl2•5H2O, B) Cu(clotri)2Br2•5H2O, and C) 
[Cu(clotri)3NO3][NO3]. Samples are 1 mM in acetonitrile with 0.1 M TBAPF6 as the supporting electrolyte. 
and the anodic wave at -0.479 V form the quasi-reversible CuI/0 redox couple for the 
bromide complex, with an E1/2 value of -1.022 V.  The sharp shape of the anodic wave at 
-0.479 V is characteristic of Cu0 to CuI oxidation due to the copper stripping from the 
carbon working electrode.22 The anodic wave around 0.190 V and the cathodic wave 
around 0.620 V are attributed to possible formation of an electrochemically active 
acetonitrile complex upon clotri dissociation. The quasi-reversible CuII/I and clotri redox 
couples have E1/2 values of -0.139 V, and 0.788 V, respectively.  
 The [Cu(clotri)3(NO3)][NO3] complex exhibits a strong quasi-reversible redox 
couple for the CuI/0 couple (E1/2 = -1.022), and two weaker quasi-reversible redox couples 
for both the CuII/I and clotri couples (E1/2 values of -0.012 V and 0.515 V, respectively). It 
has the most positive E1/2 value for the CuII/I redox couple (-0.012 V), followed by the 
bromide and chloride complexes (E1/2 values of -0.139 V and -0.239 V, respectively),  
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Figure 5.7. Cyclic voltammograms of A) [Cu(clotri)2Cl2] and B) [Cu(clotri)2Br2]. Samples are 1 mM in 
dichloromethane with 0.1 M TBAPF6 as the supporting electrolyte. 
indicating that the hard chloride ligands stabilize borderline CuII relative to the soft CuI. 
Interestingly, the [Cu(clotri)3(NO3)][NO3] complex containing a hard nitrate ligand 
stabilizes soft CuI relative to the borderline CuII ion. Thus, the three clotri ligands present 
in the nitrate complex have a greater influence on the electrochemical properties of the 
CuII center than the halide ligands.  
Additional studies were conducted on both the Cu(clotri)2Cl2 and Cu(clotri)2Br2 
complexes in dichloromethane, since both remain in solution over the course of the 
electrochemical experiments using this solvent. Neither of these complexes exhibits the 
CuI/0 redox couple in CH2Cl2. Under these conditions, Cu(clotri)2Cl2 has a significant 
redox wave at the positive end of the voltammogram (Figure 5.7), consistent with a 
clotri-based redox couple (E1/2 value of 1.002 V; Table 5.2). In comparison, 
Cu(clotri)2Br2 exhibits both the clotri and CuII/I redox couples (Figure 5.7B; E1/2 values of 
1.057 V and 0.768 V, respectively). 
Table 5.2. Electrochemical potentials (versus NHE) of the complexes investigated in dichloromethane. 
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
Cu(clotri)2Cl2•5H2O 1.034b 0.970\b 0.064b 1.002b 
Cu(clotri)2Br2•5H2O 0.703a, 1.070b 0.834a, 1.044b 0.131a, 0.026b 0.768a, 1.057b 
aPotentials of the CuII/I couple. bPotentials of the clotri ligand. 
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  Studies by Neelakantan et al.20 found the anodic wave for oxidation of CuI to CuII 
for a CuII-pyridoxine-imidazole complex (with 2O and 1N donor ligands, respectively) 
appears around 0.503 V (versus NHE). Miyamoto et al.23 also found that coordination to 
tri(2-pyridylthio)methyl, a tridentate imidazole ligand, caused CuI/II oxidation to occur 
around 0.480 V when CuII was coordinated to either bromide or chloride. However, this 
anodic wave is observed over the range of -0.082 V to 0.117 V for the CuII-clotri 
complexes. The negative shifts of these anodic waves for the CuII-clotri complexes 
compared to the CuII-pyridoxine-imidazole complex and tri(2-pyridylthio)methyl 
complexes indicate that additional imidazole-based ligand coordination stabilizes higher 
copper oxidation states. Our results indicate that the borderline clotri ligand has a 
stronger effect than the anionic halide or nitro ligands on the electrochemical potential of 
CuII, since addition of a third clotri ligand stabilizes CuII relative to CuI. When only two 
clotri ligands are present, in the case of the Cu(clotri)2Br2 complex, the E1/2 value is 
shifted more positively, favoring CuI relative to CuII.   
5.2.2. Electrochemical studies of chiral pseudophedrine derivatives. 
Electrochemical studies were performed on chiral H2cpse ligands (Figure 5.1), the four 
mononuclear CuII complexes, and the two trinuclear CuII complexes listed in Table 5.3. 
Pseudophedrine derivatives and metal complexes were synthesized and characterized by 
the Barba-Behrens group.18 All experiments were conducted in degassed methanol due to 
limited solubility of both the ligands and their copper complexes in other solvents.  
Cyclic voltammograms of (+)S,S-H2cpse, (-)R,S-H2cpse, and (+)S,R-H2cpse all 
exhibit a single irreversible oxidation wave (Figure 5.8) with Epa values of 0.926, 0.871,  
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Figure 5.8. Cyclic voltammograms vs. NHE for the ligands A) (+)S,S-H2cpse, B) (-)R,S-H2cpse, and C) 
(+)S,R-H2cpse. Samples are 1 mM in methanol with 0.1 M tetrabutylammonium hexafluorophosphate as 
the supporting electrolyte. 
and 0.831 V, respectively.  This difference of almost 100 mV for oxidations of these 
chiral ligands is significant, and it would be informative to also test the (-)R,R-H2cpse 
ligand to determine its oxidation potential, although samples of this ligand were not 
available from our collaborator.  Few articles investigate the electrochemical activity of 
chiral metal complexes with N and O donor ligands,24,25 and no reports specifically 
discuss the electrochemical activity of the unbound chiral compounds. 
Cpse and ceph ligands have the same structure, but Barba-Behrens et al.26 
reported that the ceph ligands can show bidentate coordination to CuII, binding through 
only the nitrogen and the carboxylate oxygen atoms (Figure 5.1).18  Oxidation waves for 
the ligand are only observed for the Cu(S,S(-)Hcpse)2 and Cu(R,S(-)Hcpse)2 complexes. 
There is no change for the ligand potential in the S,S complex compared to the unbound 
S,S(+)H2cpse, but a positive shift of 0.135 V is observed for coordinated R,S(-)H2cpse in 
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the R,S complex. The quasi-reversible CuII/I redox couples for Cu(S,S(+)Hcpse)2 and 
Cu(R,R(-)Hcpse)2 are similar (E1/2 of -0.520  and -0.524 V, respectively; Figure 5.9); 
however, the quasi-reversible CuI/0 couples vary by 0.047 V (E1/2 values of -0.095 and 
-0.142 V, respectively). Thus, the oxidation waves for the CuII/I and CuI/0 redox couples 
of Cu(R,S(-)Hceph)2 are shifted more positively than the oxidation waves observed for 
the diastereomeric Cu(S,S(+)Hcpse)2 and Cu(R,R(-)Hcpse)2 complexes (Table 5.3), 
resulting in more positive E1/2 values for both copper redox couples of Cu(R,S(-)Hceph)2.  
In contrast, Cu(S,R(+)Hceph)2 only shows a CuI/0 redox couple with similar Epc 
and E1/2 values to those observed for its diasteromer Cu(R,S(-)Hceph)2 (Table 5.3).  The 
diastereomers Cu(R,R(-)Hcpse)2 and Cu(S,S(+)Hcpse)2 differ by -0.047 V for the CuII/I 
redox couple. Comparison to Cu(R,S(-)Hceph)2, reveals a shift in the CuII/I E1/2 value of 
+0.039 V compared to Cu(S,S(+)Hcpse)2, and +0.086 V compared to Cu(R,R(-)Hcpse)2. 
These significant shifts indicate that ligand chirality affects the electrochemical properties 
of the coordinated CuII and that H2ceph stabilizes CuI over CuII relative to the H2cpse 
ligands. 
Niklas et al.27 reported only the CuII/I redox couple for chiral and achiral 
derivatives of [bis(picolyl)amino]acylglycine ethyl ester and [bis(picolyl)amino]-
acylphenylalanine methyl ester complexes of CuII, complexes with square pyramidal or 
distorted octahedral geometry and N3O coordination; additional ligands such as 
acetonitrile, oxygen, and chloride aid in stabilizing these geometries. These studies were 
conducted under similar conditions to our studies (in methanol with 0.1 M 











Table 5.3. Electrochemical potentials (versus NHE) from cyclic voltammetry studies of the tested complexes in methanol. 
Compound Epa (V) Epc (V) ΔE (V) E1/2 (V) 
(+)S,S-H2cpse 0.926 — — — 
(-)R,S-H2cpse 0.871 — — — 
(+)S,R-H2cpse 0.831 — — — 
Cu(S,S(+)Hcpse)2 0.075a, 0.264b, 0.926 -1.115a, -0.454b 1.040a, 0.718b -0.520a, -0.095b 
Cu(R,R(-)Hcpse)2 0.075a, 0.178b -1.124a, -0.461b 1.049a, 0.639b -0.524a, -0.142b 
Cu(R,S(-)Hceph)2 0.075a, 0.264b, 0.966 -0.918a, -0.375b 0.843a, 0.639b -0.413a, -0.056b 
Cu(S,R(+)Hceph)2 0.098a -0.903a 0.805a -0.402a 
Cu3(S,S(+)-cpse)3 0.145a, 0.414b -1.399a, -0.982a, -0.430b 1.254a, 0.837a, 0.844b -0.627a, -0.415a, -0.008b 




Figure 5.9. Cyclic voltammograms vs. NHE for A) Cu(S,S(+)Hcpse)2, B) Cu(R,R(-)Hcpse)2, C) Cu(R,S(-
)Hceph)2 and D) Cu(S,R(+)Hceph)2. Samples are 1 mM in methanol with 0.1 M tetrabutylammonium 
hexafluorophosphate as the supporting electrolyte. 
normal hydrogen electrode), but with a smaller electrochemical window of -0.4 to 0.2 V. 
No electrochemical data were reported for the uncoordinated ligands, and no observed 
redox waves in the copper complex voltammograms were assigned to either ligand. The 
CuII/I E1/2 values reported for the complexes by Niklas et al. are between -0.16 V and 
-0.10 V,27 and are relatively similar to the E1/2 values determined for the CuII/I couples of 
Cu(S,S(+)Hcpse)2 and Cu(R,R(-)Hcpse)2 (E1/2 values of -0.142 and -0.095 V, 
respectively). The significant shift observed for the CuII/I redox couple (between -0.104 V 
and -0.044 V) E1/2 value of Cu(R,S(-)Hcpse)2 compared to the complexes reported by 
Niklas et al. is likely attributed to the presence of the borderline nitrogen donor pyridines 
in the [bis(picolyl)amino]acylglycine ethyl ester and [bis(picolyl)amino]-
acylphenylalanine methyl ester for stabilizing CuII substantially more than CuI. The 
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absence of a visible CuII/I redox couple for Cu(S,R(+)Hceph)2 is surprising, since the 
geometry and CuII coordination is the same as in Cu(R,S(+)Hceph)2; thus, chirality must 
be a significant factor in the electrochemical potentials of these mononuclear copper 
complexes.  
Similar electrochemical studies were conducted on the trinuclear copper 
complexes Cu3(S,S(+)-cpse)3 and Cu3(R,R(-)-cpse)3 (Figure 5.10), in which the H2cpse  
ligands are doubly deprotonated.18 No ligand-based oxidative waves are observed in the 
voltammograms of these trinuclear complexes. The voltammogram of Cu3(S,S(+)-cpse)3 
exhibits three reductive waves but only two oxidative waves. The two reductive waves at 
-1.399 and -0.952 V are attributed to the reduction of CuI to Cu0, similar in shape to the 
CuI/0 reductive wave observed for the mononuclear copper complexes (Figure 5.9). The  
third reductive wave at -0.430 V is attributed to the reduction of CuII to CuI. The 
oxidative wave at 0.145 V is attributed to the oxidation of Cu0 to CuI, and the wave at 
0.414 V is attributed to the oxidation of CuI to CuII; however, the Cu0/I oxidative wave is  
 
Figure 5.10. Cyclic voltammograms vs. NHE for A) Cu3(S,S(+)-cpse)3] and B) Cu3(R,R(-)-cpse)3. Samples 
are 1 mM in methanol with 0.1 M tetrabutylammonium hexafluorophosphate as the supporting electrolyte. 
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broader than expected, suggesting that all three CuII centers are not chemically 
equivalent.  
Two reductive waves are observed in the voltammogram of Cu3(R,R(-)-cpse)3, but 
Cu3(R,R(-)-cpse)3 exhibits a single broad oxidative wave at 0.193 V, caused by the 
overlapping of the CuI stripping and CuII oxidation waves. Comparison of the CuI/0 E1/2 
values of Cu(S,S(+)Hcpse)2 and Cu(R,R(-)Hcpse)2 to their respective trinuclear copper 
complexes reveal a shift of -0.127 V for the CuI/0 E1/2 value of Cu3(S,S(+)-cpse)3 and of 
-0.040 V for Cu3(R,R(-)-cpse)3. Previous studies with of a trinuclear CuII complex with 
tetradenate aromatic ligands (three nitrogen and one oxygen donor atoms) showed three 
oxidative waves for each of the three CuII/I redox couples.28 However, these studies did 
not reveal redox activity for the CuI/0 couple, and did not identify any waves attributed to 
ligand electrochemistry. Our studies with these trinuclear complexes suggest that the 
three CuII centers behave differently and that the overall effect of ligand chirality on the 
redox activity of the CuII centers is significant. Cu(R,S(-)Hceph)2 exhibits the largest shift 
in the CuII/I redox couple compared to Cu(S,S(+)Hcpse)2 and Cu(R,R(-)Hcpse)2 and only 
differs from the H2cpse ligands through chirality.   
5.2.3. DNA damage studies. Gel electrophoresis studies were performed on three 
CuII complexes listed in Table 5.4 to determine their ability to promote oxidative DNA 
damage caused by CuI/H2O2 (pH 7). Due to their limited aqueous solubility, these 
complexes were first dissolved in ethanol (5 mL) and then diluted with water (20 mL) for 
these studies (200 µM final concentration). In all cases, ascorbic acid (1.25 equiv) was 
added to the CuII complexes to reduce the copper to radical-generating CuI. 
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Table 5.4. Effective concentration (EC50) values for DNA damage and electrochemical potentials (versus 
NHE) of the complexes in methanol. 
Compound EC50 (µM) E1/2 (V) 
[Cu(clotri)3(NO3)][NO3]•2H2O 10.47 ± 0.01 -0.515a, -0.012b 
Cu3(S,S(+)-cpse)3 15.14 ± 0.02 -0.627a, -0.415a, -0.008b 
Cu3(R,R(-)-cpse)3 21.72 ± 0.03 -0.564a, -0.383a 
aCuI/0 potential. bCuII/I potential. 
DNA damage caused by increasing concentrations of [Cu(clotri)3(NO3)][NO3] 
and ascorbic acid with H2O2 is shown in Figure 5.11. Lane 2 shows that hydrogen 
peroxide alone does not result in DNA damage, but reducing CuII to form CuI in the 
presence of H2O2 results in DNA damage (lane 3).  
Upon adding increasing concentrations of [Cu(clotri)3(NO3)][NO3], DNA damage 
is significantly increased, with ~90 % DNA damage at 50 µM. Clotri alone shows no 
ability to damage DNA at these concentrations (data not shown) or over the 30 min 
reaction time. This is not surprising, since previous studies have shown clotrimazole 
reduces the viability of human breast cancer cell line (MCF-7) in both dose- and 
time-dependent responses (EC50 of 89 ± 5 µM at 90 ± 7 min).9  Likewise, Barba-Behrens 
et al. reported EC50 values between 12-52 µM for clotri toxicity in HeLa (cervix-uterine), 
PC3 (prostate), and HCT-15 (colon) cancer cell lines after treatment for 24 h.14 Figure 
5.12A shows a best-fit dose-response curve for DNA damage by  
 
Figure 5.11. Gel electrophoresis image of CuI-mediated DNA damage by [Cu(clotri)3(NO3)][NO3]•2H2O in 
MOPS buffer (10 mM, pH 7). Lane: MW = 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 
2: p + H2O2; lane 3: p + compound + H2O2; lane 4: p + ascorbate (AA, 7.5 μM) + CuSO4 (6 μM) + H2O2 
(50 µM); lanes 5-9: p + increasing compound concentration + AA + H2O2: 1 (lane 5), 5 (lane 6), 10 (lane 
7), 25 (lane 8), and 50 µM (lane 9) [Cu(clotri)3(NO3)][NO3]•2H2O, respectively. 
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[Cu(clotri)3(NO3)][NO3], resulting in a calculated concentration required to promote 50% 
DNA damage (EC50) of 10.47 ± 0.01 µM.  
Similar studies were conducted with Cu3(R,R(-)-cpse)3 and Cu3(S,S(+)-cpse)3, to 
determine their ability to promote DNA damage; EC50 plots for these complexes are 
shown in Figure 5.12.  Cu3(R,R(-)-cpse)3 and Cu3(S,S(+)-cpse)3 promote DNA damage 
with EC50 values of 21.72 ± 0.03 µM and 15.14 ± 0.02 µM, respectively (Table 5.4). The 
only difference between these two complexes is the chirality of the coordinated H2cpse 
ligands, yet they have statistically different EC50 values. Thus, chirality plays asignificant 
role in the DNA damaging ability of these copper complexes. 
The obtained DNA damage results correlate well with previously published 
growth inhibition data for these complexes in HeLa (cervical-uterine), PC3 (prostate),  
 
Figure 5.12. Dose-response curves for  DNA damage by  A) [Cu(clotri)3(NO3)][NO3], B) 
Cu3(R,R(-)-cpse)3, and C) Cu3(S,S(+)-cpse)3.  
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and HCT-15 (colon) cancer cell lines.14 CuII compounds [Cu(clotri)2Cl2] and 
[Cu(clotri)3(NO3)][NO3] exhibit generally lower IC50 values (3.2-8.2 µM) compared with 
CoII complex [Co(clotri)2Cl2] and [Co(clotri)3(NO3)2] (IC50 values of 7.0-27.0 µM), 
suggesting that DNA interactions might be the cause of these compounds’ cytotoxicity. 
Electrochemical results also correlate with the reported cytotoxicity, since 
[Cu(clotri)2Cl2], [Cu(clotri)2Br2], and [Cu(clotri)3(NO3)][NO3] were the most cytotoxic 
clotri complexes,14 and these CuII complexes readily undergo reduction to CuI (CuII/I 
potentials of -0.239 to -0.012 V) at biologically attainable potentials.  Cellular CuI is 
known to generate hydroxyl radical that causes DNA damage and death,29 and this 
reaction primarily occurs in biological systems if the metal redox potentials are between 
−0.324 to 0.460 V.30 The less electrochemically accessible CoIII/II potentials (0.512 V for 
the cobalt chloride complex and only an oxidation potential of 0.977 V for the cobalt 
bromide complex) lie outside the biological window for hydroxyl radical generation, so 
these complexes are less likely to cause cellular damage by ROS generation. 
Unsurprisingly, the redox inactive ZnII complexes were found to be the least cytotoxic.31 
Correlation of the cellular toxicity results with the electrochemical redox potentials for 
these complexes suggest that some of these compounds may cause cell death by 
generating reactive oxygen species.  
Cu3(S,S(+)-cpse)3 has slightly more negative E1/2 values for the CuII/I redox couple 
compared to [Cu(clotri)3(NO3)][NO3] (Table 5.4), indicating that CuII is favored more 
upon coordination by the H2cpse ligand. When this complex is reduced by ascorbic acid, 
the resulting CuI species should be more susceptible to oxidation by H2O2, resulting in 
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greater hydroxyl radical formation and oxidative DNA damage. The E1/2 value for the 
CuII/I couple for [Cu(clotri)3(NO3)][NO3] and Cu3(S,S(+)-cpse)3 falls within the biological 
electrochemical window for the Fenton-like reaction (-0.324 V < E1/2 < 0.460 V),30 as 
would be expected from the observed DNA damage. Given the degree of DNA damage 
observed at relatively low concentrations of these copper complexes, it is likely that 
copper-mediated oxidative DNA damage plays a significant role in their cytotoxicity. 
 
5.3. Conclusions 
 We have shown that clotrimazole when bound to transition metals CoII and CuII 
exhibits the ability to stabilize the higher (harder) oxidation state of the respective metals 
over the lower (softer) oxidation state. Gel studies with labile clotri in the presence of 
H2O2 did not result in oxidative damage to plasmid DNA within the 30 min reaction 
window, and is in agreement with previous studies that found the cytotoxic ability of 
clotri was both dose- and time-dependent. However, [Cu(clotri)3(NO3)][NO3] treated 
with ascorbic acid and H2O2 resulted in significant oxidative DNA damage at low 
concentrations, suggesting that the cytotoxic ability of clotri is amplified in the presence 
of copper, and is primarily dose-dependent. 
 In contrast, the electrochemical studies with chiral pseudophedrine analogs favor 
CuI over CuII, whereas previous studies have shown that similar ligands with borderline 
nitrogen donor pyridines favor CuII. This preference of the CuI oxidation state is likely 
due to the absence of aromatic nitrogen binding sites in the pseudophedrine analogs. 
DNA damage studies revealed the ability of Cu3(R,R(-)-cpse)3 and Cu3(S,S(+)-cpse)3 to 
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promote oxidative damage at low concentrations, exhibiting 50% effective concentrations 
between 10-24 µM.  
 This work has provided evidence that drugs with metal coordination sites promote 
oxidative damage in a dose-dependent manner when a redox active metal is present. In 
addition, the potential of the CuI/II couple for these complexes fall within the biological 
window for •OH generation, suggesting that their cytotoxic properties may be due in part 
to ROS generation. 
  
5.4. Materials and Methods 
Materials. Potassium nitrate was from Fisher. MOPS was obtained from Alfa 
Aesar. All compounds clotrimazole and pseudoephedrine-derived compounds were 
provided by Dr. Noráh Barba-Behrens (Universidad Nacional Autónoma de México).  
Acetonitrile was obtained from BDH. Tetrabutylammonium hexafluorophosphate 
(TBAPF6) was obtained from Alfa Aesar and was purified by recrystallizing in a 3:1 
mixture of ethanol:deionized water. Plasmid DNA (pBSSK) was purified from DH1 E. 
coli competent cells using a 5 Prime PerfectPrepTM Spin Kit (250 count, Fisher). NaCl 
(99.999%), glycerol, and bromophenol blue were all from Alfa Aesar.  Yeast extract, 
30% H2O2, sodium EDTA, tryptone (peptone), CuSO4·5H2O, agarose, and 
dichoromethane were all from Fisher.  Glucose and ampicillin were from EMD.  
Ethidium bromide and agar were from Lancaster.  Ethanol (200 proof) and ascorbic acid 
were from Acros Organics.  Xylene cyanol FF was from J. T. Baker.  Tris hydrochloride 
and microcentrifuge tubes were from VWR.  A NANOpure Diamond water deionization 
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system (Barnstead Internationl, Dubuque, IA) was used to prepare deionized H2O 
(diH2O). Degassed diH2O was prepared by bubbling with N2 gas for at least 4 h.  Metal-
free microcentrifuge tubes were prepared by washing the tubes in 1 M HCl for ~1 h, and 
then triple rinsing three times with diH2O.  
Electrochemical Studies.  Cyclic voltammetry (CV) and differential pulse 
voltammetry (DPV) experiments were conducted with a CH Electrochemical Analyzer 
(CH Instruments, Inc.) in dry, degassed acetonitrile (or dichloromethane) with TBAPF6 
(0.1 M) as a supporting electrolyte.  Final concentrations of all compounds were 1 mM, 
with a final volume of 5 mL. All samples were degassed for 10 min with N2 before each 
experiment. CV experiments were conducted with a scan rate of 100 mV/s.  DPV 
experiments were conducted on all samples and confirmed all waves observed in the 
cyclic voltammograms. A pulse amplitude of 0.020 V and a pulse width of 0.050 were 
used for all DPV experiments, in conjunction with a sample width of 0.020 and a pulse 
period of 0.100.   Samples of each complex were cycled between -1.6 V and 1.6 V using 
a glassy carbon working electrode, a Pt counter electrode, and a Ag/AgCl (+0.197 V vs. 
NHE32) reference electrode. All acetonitrile and dichloromethane experiments were 
externally referenced to ferrocene (0.593 V vs. Ag/AgCl33).  
Plasmid transfection, amplification, and purification. Tris-EDTA buffer (pH 
8.01) was used to elude the plasmid from the spin columns.  Plasmid was dialyzed 
against 130 mM NaCl for 24 h at 4°C to ensure all Tris-EDTA buffer and metal 
contaminates were removed.  Plasmid concentration at 260 nm and absorbance ratios of 
A250/A260 ≤ 0.95 and A260/A280 ≥ 1.8 were determined via UV-vis for DNA used in all 
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experiments.  Plasmid purity was determined through digestion (0.1 pmol) with Sac 1 and 
KpN1 in a mixture of NEB buffer and bovine serum albumin was conducted at 37°C for 
90 min.  Comparison to an undigested plasmid sample and a 1 kb molecular weight 
marker was performed using gel electrophoresis. 
DNA damage gel electrophoresis experiments.  Deionized H2O, MOPS buffer (10 
mM, pH 7.39), NaCl (130 mM), ethanol (0.02-0.86 M), ascorbate (7.5-62.5 µM), and the 
indicated concentrations of the CuII complexes (1-50 µM)  were combined in a 
microcentrifuge tube and allowed to stand for 5 min at room temperature. Plasmid 
(pBSSK; 0.1 pmol in 130 mmol NaCl solution) was then added to the reaction mixture 
and allowed to stand for 5 min at room temperature. Hydrogen peroxide (50 μM) was 
added and allowed to react at room temperature for 30 min, and then EDTA (50 μM) was 
added to quench the reaction.  All given concentrations were final concentrations in a 10 
μL volume.  Samples were loaded into a 1% agarose gel in TAE running buffer; and 
damaged and undamaged plasmid DNA was separated by electrophoresis (140 V for 30 
min).  Gels were then stained using ethidium bromide and imaged under UV light.  The 
amounts of nicked (damaged) and circular (undamaged) DNA were quantified using 
UViProMW (Jencons Scientific Inc., 2007).  The intensity of the circular plasmid band 
was multiplied by 1.24, due to the different binding abilities of ethidium bromide to 
supercoiled and nicked plasmid DNA.34,35  
Calculating percent inhibition of DNA damage. The formula 1-[%N-%B]*100 
was used to calculate percent DNA damage inhibition; %N = percent of nicked DNA in 
lanes 6 and higher, and %B = the percent of nicked DNA in the CuI/H2O2 or FeII/H2O2 
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control lane (lane 5). All percentages were corrected for residual nicked DNA (lane 2) 
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DNA DAMAGE PREVENTION ABILITIES OF MULTIFUNCTIONAL SELENIUM 
AND SULFUR COMPOUNDS AND THE ROLE OF REDOX-ACTIVE METALS IN 
THE BIOLOGICAL ACTIVITY OF CLOTRIMAZOLE AND PSEUDOEPHEDRINE-
DERIVED COMPOUNDS 
 
6.1. Conclusions  
The primary cause of DNA damage under oxidative stress conditions is metal-
mediated formation of •OH from H2O2 reduction,1-3 and this damage is an underlying 
cause of many chronic diseases.4-8 Both metal ions and ROS are required for cellular 
functions, so cells have many mechanisms to maintain metal and ROS homeostasis. 
During oxidative stress, however, levels of ROS can rise faster than cellular antioxidants 
can scavenge them. Oxidative damage can quickly spiral out of control when metal-
chelating proteins are damaged, releasing redox-active metals such as FeII and CuI.9-11 
Interest in endogenous and exogenous sulfur and selenium antioxidants arose from their 
natural roles in maintaining cellular homeostasis, previously observed anticancer 
properties, the biological abundance of sulfur- and selenium-containing amino acids, and 
their ability to treat and prevent many chronic diseases.12,13 
Previous studies determined that sulfur- and selenium-containing amino acids and 
their derivatives more effectively prevent CuI-mediated DNA damage than FeII-mediated 
DNA damage, and demonstrated that copper coordination is necessary, but not sufficient, 
for their observed antioxidant activity.14-18 Electrochemical studies of these sulfur and 
selenium antioxidants revealed that the majority of the selenium compounds are readily 
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oxidized, an indication of potential ROS scavenging properties, but only two of the sulfur 
compounds exhibited any redox behavior (Chapter 2) under the conditions used. Since 
DNA damage prevention is observed for sulfur compounds that are redox-inactive and 
not all redox-active selenium compounds prevent DNA damage, metal binding rather 
than ROS scavenging was determined to be the primary mechanism for sulfur selenium 
antioxidant prevention of metal-mediated DNA damage. 
Due to the promising antioxidant behavior quantified for sulfur- and selenium-
containing amino acids, the abilities of N,N’-dimethylimazole thione (dmit) and selone 
(dmise) to prevent metal-mediated DNA damage were also investigated. These thione 
and selone compounds are similar to the antithyroid drug methimazole and the naturally 
occuring thione- and selone-containing amino acids ergothioneine and selenoneine. Dmit 
and dmise inhibit CuI-mediated DNA damage (IC50 = 1550 µM and ~240 µM, 
respectively; Chapter 3), but in contrast to all other sulfur and selenium antioxidants 
tested for prevention of metal-mediated DNA damage,  dmit and dmise are more potent 
inhibitors of FeII-mediated DNA damage (IC50 = 89.1 µM and 3.2 µM, respectively; 
Chapter 3). Additional mass spectrometry studies confirmed their ability to coordinate 
both CuI and FeII. Interest in these two compounds was further peaked upon observing 
prevention of oxidative damage when their ability to bind CuI or FeII was removed by 
using [Cu(bipy)2]+ and [Fe(EDTA)]2- to generate DNA-damaging hydroxyl radical, 
suggesting that these antioxidants can effectively scavenge •OH in addition to binding 
copper and iron to prevent DNA damage. This idea was reinforced by the fact that dmit 
prevents peroxynitrite (ONOO–)-mediated DNA damage under metal-free conditions, 
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albeit at higher concentrations (> 100 µM). Similar to previous DNA damage prevention 
studies, the selenium-containing dmise was more effective than the sulfur-containing 
dmit at preventing DNA damage from all sources. Thus, the research described in 
Chapter 3 has identified the first multifunctional sulfur and selenium antioxidants that 
prevent metal-mediated DNA damage by metal coordination at very low micromolar 
concentrations and by ROS scavenging at concentrations over 100 µM. 
Since dmit and dmise prevent DNA damage by multiple antioxidant mechanisms, 
further studies were conducted on structurally similar compounds to determine: 1) if they 
possess similar multifunctional antioxidant properties, 2) if they have similar antioxidant 
mechanisms (metal coordination, targeted scavenging of ROS, etc.) for DNA damage 
prevention, and, 3) if there are relationships between structure and antioxidant activity. In 
contrast to the sulfur and selenium amino acid compounds,14-16 every sulfur and selenium 
compound studied in Chapter 4 prevents both CuI- and FeII-mediated DNA damage with 
IC50 values ranging from 12-1023 µM and 2.3-1000 µM, respectively. Additionally, the 
majority of these compounds, with the exception of ethyl-bis(imidazole) thione and (2-
mercapto-1-methylimidazolyl) pyridine thione, more effectively prevent DNA damage by 
FeII than by CuI ;. As observed for dmit and dmise in Chapter 3, antioxidant behavior is 
also observed for these thione and selone compounds when [Cu(bipy)2]+, [Fe(EDTA)]2-, 
and ONOO– cause the DNA damage but at substantially higher concentrations compared 
to DNA damage from CuI and FeII. Therefore, the thione, selone and related compounds 
investigated in Chapter 4 utilize multiple mechanisms to prevent oxidative DNA damage.  
Comparing results from the sulfur-containing compounds from Chapter 4, it is 
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evident that methylation of the imidazole nitrogens plays a significant role in DNA 
damage prevention, since the non-methylated ergothioneine and 2-mercaptoimazole have 
the lowest IC50 values with both CuI and FeII, followed by the mono-methylated 
methimazole and ergothioneine. Nitrogen methylation accounts for an average 5-fold 
increase in activity for compounds with no methylation compared to mono-methylated 
compounds and an average 15-fold increase in activity compared to di-methylated 
compounds. The potentially aromatic thiones 2-MerIm and MetIm are active at 
concentrations 12 times lower than the non-aromatic sulfide PTAS for inhibition of both 
copper- and iron-mediated DNA damage. The largest contributor to thione antioxidant 
activity is denticity; compounds that possess more than one possible metal binding site 
typically require concentrations 48-fold less than compounds with only one metal binding 
site. Denticity also has a significant impact on selenium antioxidant prevention of CuI-
mediated DNA damage, followed by selenium functional group (C=Se or P=Se; 
accounting for an approximately 4-fold difference in activity). As is typical,14-18 the 
selenium-containing compounds were 6-to-27-fold more effective than analogous sulfur-
containing compounds at preventing metal-mediated DNA damage. 
Mass spectrometry studies revealed that the majority of the compounds form 
complexes with CuI and FeII, supporting the relationship between metal coordination and 
DNA damage prevention (Chapter 4). Electrochemical studies revealed that many of 
these compounds are readily oxidized, indicative of ROS scavenging capabilities. When 
CuI or FeII is added to solutions of these antioxidants, most were found to stabilize CuII 
and FeII relative to CuI and FeIII, but the CuII/I and FeIII/II potentials in the presence of 
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these antioxidants fall within the redox window of the biological Fenton and Fenton-like 
reactions, suggesting that thione- and selone-metal binding to prevent metal redox 
cycling is not a major mechanism for antioxidant activity. The primary antioxidant 
mechanism at very low micromolar concentrations is through metal coordination 
(targeted scavenging), whereas ROS scavenging is active at high concentrations. These 
are the first studies that have observed multifunctional sulfur and selenium compounds 
capable of preventing multiple types of metal- and nonmetal-mediated DNA damage.  
The most exciting breakthrough from this work is the determination of a 
relationship between chemical structure and antioxidant activity, which has been difficult 
to observe in previous research due to the limited structural diversity of the antioxidants 
studied. The most pertinent chemical properties observed in this work are nitrogen 
methylation > denticity > aromaticity > S/Se speciation, and these results will allow 
researchers to develop compounds of interest that are highly potent inhibitors of oxidative 
damage, instead of the time consuming process of investigating compounds one by one. 
Since many of the sulfur and selenium compounds discussed in Chapters 3 and 4 are 
analogs of both natural and pharmaceutical compounds, this work will also allow 
effective development and execution of animal and clinical trials for prevention and 
treatment of diseases caused by oxidative stress. 
Similar to sulfur and selenium antioxidant activity, interactions of redox-active 
biological metal ions with known drugs and anticancer agents is not well explored. In 
Chapter 5, electrochemical studies of clotrimazole, an antifungal agent, with CuII/I and 
CoII/I showed that the higher oxidation state is stabilized more than the lower oxidation 
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state upon clotrimazole coordination. In addition, DNA damage studies with 
[Cu(clotri)3(NO3)][NO3] ∙ 2H2O revealed that the CuII center is readily reduced by 
ascorbic acid, and when treated with H2O2, can generate DNA damaging •OH. These 
results support previous studies that clotrimazole-metal complexes kill cancer cells19,20 
and suggest that the observed cytotoxic activity may be due to apoptosis caused by 
cellular DNA damage.  
Pseudophedrine is a stimulant and antitussive drug that can potentially coordinate 
metal ions. Studies of pseudoephedrine-derived CuII complexes (Chapter 5) revealed their 
ability to stabilize CuI relative to CuII, likely due to these ligands’ lack of aromatic 
nitrogen binding sites. Little is known about interactions of pseudoephedrine and 
redox-active metals, but DNA damage studies conducted on Cu3(R,R(-)-cpse)3 and 
Cu3(S,S(+)-cpse)3 revealed their ability to generate •OH, resulting in effective 
concentrations for 50% oxidative DNA damage between 10-24 µM. These studies of 
clotrimazole and pseudoephedrine-derived metal complexes illustrated how redox-active 
metal binding can amplify known cytotoxic properties (clotrimazole), or result in 
unexpected cytotoxic properties (pseudoephedrine). This information is crucial for the 
future development of effective cytotoxic metal complexes as antifungal and anticancer 
agents and for the development of drugs that have minimum adverse reactions in the 
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